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ABSTRACT 
Introduction: XCR1 is a chemokine receptor that is activated by the chemokine 
lymphotactin (hLtn) and has been shown to play an important role in oral squamous cell 
carcinoma (OSCC) and a few other cancers. hLtn is a metamorphic protein which 
interconverts between two distinct protein conformations in physiological conditions, 
where one has the canonical chemokine fold while the other forms a dimer. Due to the 
complexity, the mechanism of action and precise role of each hLtn conformation in 
context of cancer is unknown. 
Aim: Examine the role of XCR1 and its ligand hLtn in OSCC as well as understanding 
the function of different hLtn conformations in the disease. 
Methods: Immunohistochemistry was performed on primary and metastatic OSCC 
tissue sections. Autocrine regulation of XCR1 by hLtn of oral cancer cell lines (OCCL) 
was investigated using qPCR and flow cytometry. Additionally, the role of tumour 
microenvironment on XCR1 expression was also investigated using an indirect co-
culture of fibroblasts (inactive, stimulated, cancer-associated and senescent) with OCCL. 
Recombinant hLtn variants were designed, produced and purified. The activity of the 
variants was determined using intracellular calcium flux and functional assays including 
proliferation, adhesion (collagen I and IV, and fibronectin) and cell migration/chemotaxis 
assays to study the effect of bioengineered hLtn variants on OCCL. 
Results: XCR1 and hLtn expression was seen in basal epithelial cells in normal oral 
mucosa ex vivo and both were upregulated in primary and metastatic carcinoma. 
Exposure of OCCL (H357 and SCC4) to hLtn in vitro cause a decrease in XCR1 
expression. Conditioned media from cancer-associated fibroblasts but not 
myofibroblasts upregulated the expression of XCR1 and hLtn mRNA in OCCL. 
Interestingly, senescent fibroblasts downregulate the expression of XCR1 and hLtn in 
SCC4 cells. hLtn CC3 mutant, with the canonical chemokine fold was highly functional 
and facilitated proliferation and migration through XCR1. The W55D mutant dimer 
caused minimal cell proliferation suggesting possible receptor dimerization. 
Conclusions: These findings confirm that XCR1 and hLtn are expressed in both primary 
and metastatic OSCC ex vivo. XCR1 expression regulation by its ligand hLtn and 
crosstalk with fibroblasts are novel findings suggesting a close association with tumour 
microenvironment. A novel method was used to produce and purify hLtn variants which 
stimulated OCCL proliferation, adhesion and migration. These discoveries confirm and 
build upon previous studies and suggest that the hLtn/XCR1 axis may have a bigger role 
in OSCC biology than originally envisaged.
CHAPTER 1 
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CHAPTER 1: LITERATURE REVIEW 
1.1 Oral Cancer 
Cancer usually involves mutation of normal cells because of DNA damage. In 
normal cells, mutation or damage to the DNA is detected and the cell programmed to 
undergo apoptosis or cell death. In case of cancer cells, the damage or mutations are 
irreversible leading to uncontrolled division and proliferation through alteration of normal 
survival signals. 
Oral cancer accounted for 3% of all cancer cases in 2015 in the United Kingdom 
and 2% of cancer death in 2016 (Cancer Research UK, accessed 2018), an increase of 
1% from 2012 data. It has a higher incidence in developing countries due to a wider 
range of risk factors (de Camargo Cancela et al., 2010). Oral cancer has a poor 
prognosis as it usually diagnosed at a late stage (Warnakulasuriya, 2009). The incidence 
of oral and oropharyngeal cancer is highest in East Asia, South Asia and Southeast Asia 
(Warnakulasuriya, 2009). 
The precise cause or pathogenesis of oral cancer is not completely understood. 
Several factors might increase the risk and are highly associated with the disease; 
including tobacco and alcohol consumption (McLaughlin et al., 1988; Hashibe et al., 
2013), and human papillomavirus (HPV) (Chaturvedi et al., 2011, 2013). Statistically, 
oral cancer incidence is higher in the elderly with more cases in the male population than 
female (information obtained from Cancer Research UK website). High dietary 
consumption of vegetables and fruits decreases the risk of oral cancer (Levi et al., 1998; 
Llewellyn et al., 2004). In addition, some studies show an increased risk in 
immunocompromised patients such as those undergoing haematopoietic stem-cell 
transplantation (Elad et al., 2010). Poor oral hygiene (Oji and Chukwuneke, 2012) and a 
weakened immune system (Sathiyasekar et al., 2016) also associated to contribute for 
oral cancer development.  
Oral cavity and oropharyngeal cancers mainly occur in the tongue, tonsil, 
oropharynx and other sites such as vestibule, buccal mucosa (the lining of the lips and 
cheeks), hard palate, soft palate, gingiva (gums), lips and floor of the mouth. Most of 
these cancers are oral squamous cell carcinoma (OSCC) and are derived from epithelial 
cells in the lining of the mouth (Figure 1.1). 
OSCC usually invades and destroys tissue in the immediate vicinity and spreads 
from the primary site, usually through the cervical lymph nodes following the path of 
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drainage (Silva et al., 2011). Metastasis in lymph nodes is associated with an almost 
50% reduction in 5-year survival (Vartanian et al., 2004). 
 
 
 
Figure 1.1: Prone sites for oral squamous cell carcinoma development. Most of the 
incidence originated from the tongue. Oral cancer spread is generally to the regional 
lymph nodes through lymphatic vessel. Almost a third of lymph nodes in human is 
situated in the head and neck region. The incidence rate (person per year) was obtained 
from Cancer Research UK website (Accessed in 2018). The image was acquired and 
modified from http://www.innerbody.com/image/mouth.html)).   
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1.2 Tumour Microenvironment 
In recent years, tumour microenvironment research has become the focus to 
study how cancer cells grow and interact. Reactive stroma or the stroma of tumour 
microenvironment is fundamentally different from the normal tissue stroma. Studies of 
tumour progression have shown that cancer cells are not the only drives but also the 
tumour microenvironment through genetic and epigenetic studies (You and Jones, 2012; 
Baxter et al., 2014). The complexity of tumour microenvironment comprises of a network 
of multiple cells, signalling molecules, extracellular matrix (ECM) and soluble factors 
which contributes as the driving force of tumour progression (Cukierman and Bassi, 
2012). The  multiple cells that make up the tumour microenvironment are inflammatory 
cells, endothelial cells, pericytes and fibroblasts (Joyce and Pollard, 2009). Cancer-
associated fibroblasts (CAF) has been shown to promote tumour growth (De Veirman et 
al., 2014; Shiga et al., 2015; Deying et al., 2017), progression (Shimoda, Mellody and 
Orimo, 2010; Bremnes et al., 2011) and migration (Erdogan et al., 2017) through 
paracrine signalling (van Zijl, Krupitza and Mikulits, 2011; Karagiannis et al., 2012). 
 
1.2.1 Tumour 
Tumour formation is linked with uncontrollable growth of cells. In this context, the 
word tumour and cancer can sometimes be used interchangeably, while in definition, it 
is different. A tumour can be either benign or malignant. A benign tumour does not 
progress into a highly invasive tumour and invade other tissue from their initial site. Even 
so, uncontrollable tumour growth of cell can overcrowd the tissue area causing some 
health problems. The increase in size can increase its surrounding pressure resulting in 
applied pressure to neighbouring organ causing discomfort, pain and problem. This 
physical change in the cavity that are not enclosed by hard structure, such as bone, 
permit a flexible tumour expansion. Unfortunately, differ to tumour growth in the brain, 
continuous increase in size is not permitted due to cranial space restriction and the 
additional unnecessary pressure provided by tumour expansion can be quite fatal. 
The progression of normal cell to cancer involves several pathological changes 
and processes. The first stage is dysplasia where cytological appearance is no longer 
normal, forming an abnormal tissue. These changes include the variable size and shape 
of the nucleus, increased staining of the nuclear, increase nuclear and cytoplasmic size 
ratio, increase cell mitotic activity, and lack of cytoplasmic features that are associated 
with normal differentiated cell of the tissue. In dysplasia, the relative number of various 
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type of cells seen in normal tissue are no longer observed. This stage is the transitional 
state between benign and to the premalignant tumour.  
The pre-malignant tumour or carcinoma in -situ is the stage where the abnormal 
cells are only at the site at which it is first formed. This is the precursor of cancer before 
it spreads to nearby normal tissue. Once all the conditions are acquired, the abnormal 
cell develops to become cancerous and can become malignant or invasive. At this stage 
the cells have the potential to spread not only to adjacent tissue area but also other parts 
of the body using the circulatory system.  
 
1.2.2 Reactive Stroma of the Tumour  
Reactive stroma of the tumour consists of the immune cells, endothelial cells 
making up the capillaries, activated fibroblasts, basement membrane and extracellular 
matrix (ECM). Fibroblasts are the dominant component in the tumour stroma and studies 
have shown these to be a notable factor influencing cancer growth, progression and 
metastasis (Kalluri, 2016). Different terms are used for fibroblast association in a certain 
environment such as in cancer, it is termed cancer-associated fibroblasts (CAF) or 
‘activated’ fibroblast. 
 
1.2.2.1 Fibroblast 
The fibroblast is the most versatile and extensively studied cell-type in biology in 
vitro due to its easy isolation and culture handling. They are resilient, survive stress and 
can grow from post-mortem human tissue. This gives fibroblast its plasticity. Resting or 
quiescent fibroblasts are defined as a non-epithelial, non-endothelial, non-immune cell 
with a mesenchymal-like cells lineage that are usually found in the interstitial stroma. It 
displays a spindle-shape morphology with noticeable actin cytoskeleton and vimentin 
filaments (Kalluri and Zeisberg, 2006). 
The quiescent fibroblast can be ‘activated’ and become specialised fibroblast 
known as myofibroblast or normal activated fibroblasts (NAFs). It was first observed in 
wound healing where they migrated to the wound area and generated extracellular matrix 
(ECM) providing scaffold for tissue regeneration (Räsänen and Vaheri, 2010). 
Transformation to myofibroblast gives the fibroblast the phenotype of contractile stress 
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fibres such as α-SMA and FN-EDA 1 (Tomasek et al., 2002). Furthermore, myofibroblast 
can proliferate, migrate, secrete soluble factors (TGF-β1, cytokines, chemokines, matrix-
metalloproteinase (MMP), etc.) and ECM (collagen I, III and IV, and fibronectin, etc.) and 
to assist in matrix re-modelling during wound healing. After the healing process is 
complete, the myofibroblast undergoes reprogramming to revert to quiescent fibroblast 
or apoptosis. This reversible phenotype process is not well understood but it is assumed 
that most fibroblast undergo the latter, a programmed cell death or nemosis to restore 
the population of resident fibroblast (Tomasek et al., 2002). 
 
1.2.2.2 Cancer-Associated Fibroblast 
Fibroblasts in tumour stroma remain in an ‘activated’ state, where they express 
soluble factors and ECM like those found by myofibroblasts. There are several terms of 
fibroblasts used for tumour stroma, but a widely known terminology is cancer associated 
fibroblasts (CAF) (Kalluri, 2016). CAF are distinguishable from normal fibroblasts 
phenotypically, functionally, as well as in different expression profiles of ECM 
components and growth factors (Kalluri and Zeisberg, 2006).  
Several markers were identified to characterize a CAF including α-SMA, 
fibroblast activation gene (FAP), tenascin-C, platelet derived growth factor receptor 
(PDGF-R), periostin, vimentin, desmin and fibroblast specific protein-1 (FSP-1) (Shiga 
et al., 2015; Kalluri, 2016). α-SMA expression is often identified with CAF (Busch and 
Landberg, 2015). CAF has demonstrated a heterogeneity within its population where a 
study identified a unique population expressing FSP-1 with lack expression of α-SMA 
and PDGF-R (Sugimoto et al., 2006). TGF-β can induce the phenotypic features of CAF 
in vitro during wound healing and organ fibrosis by mediating fibroblast activation 
(Dumont and Arteaga, 2000).  
The origin of CAF and its underlying mechanisms are still unclear. It was 
considered to originate from resident fibroblasts, adipocytes, epithelial cells (via 
epithelial-mesenchymal transition (EMT)), endothelial cells (via endothelial-
mesenchymal transition (EndoMT)) and even from hematopoietic stem cells (Shiga et 
al., 2015). CAF has shown to play a role in tumour development in breast (Aboussekhra, 
2011), pancreas (von Ahrens et al., 2017)), oral cancer (Li et al., 2015; N.-N. Lin et al., 
2017) and bone metastasis (Prajapati and Lambert, 2016).  
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1.2.2.3 Senescence fibroblast 
When cells undergo the state of arrest growth in response to oncogenic events, 
this incident is termed cellular senescence. It was firstly demonstrated in human 
fibroblasts of embryonic lung tissues where the proliferation rate ceased after replicative 
passaging (Ogrunc and d’Adda di Fagagna, 2011). Several factors can be associated to 
cellular senescence including epigenetic abnormalities, stress-induced premature 
ageing, telomere shortening, genomic damage, mitogen and proliferation-associated 
signals, and activation of tumour suppressors (Campisi, 2013; Wang, Cai and Chen, 
2017). Growth arrest is the hallmark of cellular senescence with permanent cell cycle 
arrest at G1 phase, although still metabolically active (Herbig et al., 2004). The 
senescent cells growth is permanently arrested unlike quiescence cells and its 
proliferative capability cannot be reverted.  
Cell senescence display a tumour suppressive mechanism by preventing the 
cells undergoing neoplastic transformation (Campisi, 2013). The senescent cells secrete 
numerous cytokines, proteases, growth factors and a collection of proteins, also known 
as senescence-associated secretory phenotype (SASP) which can influence 
surrounding cells and can contribute to ageing (Rodier and Campisi, 2011). Some 
studies have shown that senescent fibroblasts can enhance pro-metastatic phenotypes 
(Wang et al., 2017) and promote tumorigenesis (Krtolica et al., 2001; Ruhland et al., 
2016).  
Currently, the mechanism underlying cell senescence phenotype in terms of its 
trigger and maintenance is poorly understood. Therefore, there are limited amount of 
suitable marker and also lack of specificity targeting senescence cells (Althubiti et al., 
2014). Senescence-associated β-galactosidase (SA-βgal) activity is the most common 
marker to identify senescent cells in culture and tissue (Debacq-Chainiaux et al., 2009). 
p16 has been identified to be a senescent marker (Coppé et al., 2011) although not in 
all senescent cells (Haferkamp et al., 2009).  
 
1.2.3 Lymph nodes 
Lymph nodes form a part of the lymphatic system with an ovoid or kidney shape 
organ, playing an important role in immune system (Figure 1.2). The nodes primarily 
reside by B and T lymphocytes, as well as other leukocytes. This organ is crucial for 
proper functioning immune system by filtering foreign particles and sometimes cancer 
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cells. Not to be compared to kidney and liver, lymph nodes do not have the capability as 
a detoxifying function but more as a checkpoint populated with leukocytes to scrutinize 
the circulatory system from any invaders or foreign particles.   
 The highly organized structure of the lymph node is designed to assist the 
interactions between the cell of the immune system and the foreign invader. Fluids from 
surrounding tissue are drained into the lymph node through the afferent lymph vessels 
including the antigen-presenting cells (APC). The fluid will be circulated out of the lymph 
node through efferent lymphatic vessel after its journey around subcapsular sinus (SS) 
and the trabecular sinuses towards the medulla through the cortex (Harwood and Batista, 
2010). It is well compartmentalised to accommodate inflammatory cells.  
In cancer, the lymph node is highly associated with cancer metastasis. Cancer 
dissemination into distant parts is usually through vascular or lymphatic vessel although 
the mechanism is poorly understood. This organ is a useful predictor of patient survival 
where it is use to be the key parameters to determine the disease progression and 
treatment options (Morton et al., 2006). A specific chemokine has been shown to be the 
drive for cancer metastasis to lymph node such as in melanoma through CCL1/CCR8 
(Das et al., 2013). 
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Figure 1.2: Lymph node organisation and immune cells entry. The lymph node is bean-
shaped lymphoid organs encapsulated by a collagenous structure. The main structure is 
subdivided into three major sections: the medulla, the paracortex and the cortex. Naïve 
lymphocytes enter the organ either through afferent lymphatic vessel or high endothelial 
venules (HEVs), and exit via cortical or medullary sinuses, and efferent lymphatic 
vessels. Additionally, the dendritic cells (DCs) can enter the organ through the 
subcapsular sinus. The cortex comprises mostly of tightly packed B cells and follicular 
dendritic cells (FDCs) where they can arrange to form B cell follicles or germinal centres. 
In contrast, the paracortex regions comprise mostly of T cells, in T cell zone and 
fibroblastic reticular cells (FRCs), forming a network guiding the lymphocytes and DCs 
in the lymph nodes. MRC, marginal reticular cell; pre-cDC, precursor conventional DC. 
The image was reproduced and adapted from Girard, Moussion and Förster (2012).  
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1.3 Metastasis 
A cancer which is not infiltrative and remains localised is called benign. A tumour 
is termed malignant when it shows infiltration and invasion into the structures 
surrounding the primary tumour. Metastatic tumours develop when malignant cancer 
cells spread to other parts of the body either by the lymphatic or the blood circulation. In 
OSCC, metastasis is facilitated by epithelial-mesenchymal transition (EMT) which allows 
the epithelial cells to acquire a more mesenchymal phenotype enabling them more 
motility and migration. The tissue extracellular matrix (ECM) plays an important role in 
cancer spread. The matrix environment is active with numerous interactions occurring at 
this site such as cell signalling and transport of nutrients. It also functions in cell support 
by interaction with integrin receptors (Juliano and Haskill, 1993). In tumour environment, 
factors such as matrix-metalloproteinase (Kessenbrock, Plaks and Werb, 2010), 
chemokines (Sheu et al., 2008) and cancer-associated fibroblast (Junttila and de 
Sauvage, 2013) further facilitate the survival and growth of cancer cells. 
Cancer cells are thought to intravasate into the blood or lymphatic vessels 
allowing access to local and systemic circulation which facilitates metastasis (see Figure 
1.3). However, the factors contributing to intravasation of cancer cells are unknown. 
Tumour micro-environment comprises of stromal fibroblasts, endothelial cells lining 
blood and lymphatic vessels, and inflammatory cells which are important in cancer cell 
proliferation, adhesion, migration and invasion suggesting it may have in important role 
in metastasis. 
In local invasion, cancer cells undergo EMT as well as mesenchymal-epithelial 
transition (MET) to detach from the site of origin (Hagman et al., 2013). MET allows the 
cancer cells to re-associate with extracellular matrix (ECM) and anchors them to the new 
site. Mostly, cancer cells show immortality and unlimited division potential recruiting 
some proteins and factors to initiate angiogenesis, sustaining their growth and survival. 
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Figure 1.3: Concept of metastasis. Possible route of cancer spread (– – – →) which is 
either through lymphatic vessel (lymphatic spread) or blood vessels (haematogenous 
spread). The cancer grows from the tissue of origin and invades neighbouring tissue or 
spreads to distant sites. 
 
1.3.1 Theories of Metastasis 
The exact signals triggering cancer metastasis are not well understood. Paget 
originally proposed the “seed and soil” theory where the metastasized cancer cell (the 
seed) circulates in the blood or lymphatic system until it finds a suitable location in the 
human body (the soil) and starts to form cancer there (Fokas et al., 2007). The most 
common site for metastasis to occur is in bone as it always undergoing constant 
remodelling (Hadjidakis and Androulakis, 2006; Rucci, 2008). It also serves as a latent 
location for cancer cells to stay dormant before they start to spread later in life.  
The ‘chemoattractant’ theory of metastasis revolves around chemokines and 
their ability to attract cells expressing chemokine receptors. Recently, it has been 
reported that some cancer cells acquire upregulated expression of specific chemokine 
receptors (Müller et al., 2001; Khurram et al., 2010, 2014; Kim et al., 2012; Gantsev et 
al., 2013) which allows cancer cell movement along a chemotactic gradient hence 
facilitating metastasis. Lymph nodes with activated lymphocytes, macrophages and 
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endothelial cells are a rich source for chemokines and this has been proposed to attract 
the receptor expressing epithelial cells to the lymph node interior resulting in metastasis 
(Alitalo and Detmar, 2012; Karaman and Detmar, 2014). However, the specific 
mechanism of this transmigration of tumour cells from lymphatic circulation into lymph 
nodes is not well understood.  
 
1.4 Chemokines 
Chemokines are chemo-attractant cytokines, which can attract cells expressing 
the receptive receptor along a concentration gradient of the chemokine in a process 
called chemotaxis (see Figure 1.4). Chemotaxis is sensitive as it can be activated by a 
chemokine concentration as low as 1 nM in normal physiological conditions (Fox, 
Nakayama, et al., 2015). 
 
Figure 1.4: Chemotaxis. The receptive cell expressing chemokine receptor responds to 
chemokine concentration gradient. It can be either move towards to (chemo-attract) or 
away (chemo-repel) by the chemokine.  
 
Chemokines are small proteins with a molecular mass of 8 – 10 kDa. Their 
distinctive characteristic is the conserved cysteine residue, which separates the 
chemokines into four different groups (see Figure 1.5). The structure consists of three 
antiparallel β-sheets and N-terminal α-helix which are joined by two disulphide bridges. 
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At least 50 chemokines have been identified in human and are divided into four 
subfamilies based on the position of the conserved cysteine near the N-terminal (Balkwill, 
2012). 
 
 
Figure 1.5: The chemokine super-families. The structure is distinguished by the distinct 
location of the cysteine residues. Denoted by ‘X’ in the picture can be substituted to any 
other amino acid except cysteine. The cysteine residues form disulphide bonds holding 
the protein structure together. All super-families contain chemokine signature of two 
disulphide bridge except for C chemokine. CX3C chemokine contains a mucin-like region 
(purple) allowing it to be membrane-bound or soluble protein. 
 
Most chemokines belong to the CXC and CC families. The C chemokine family 
has only two known members. This group is unique as it only has one disulphide bridge 
compared to conventional chemokines with at least two disulphide bridges in the 
structure. CX3C chemokines are the fourth group in the family with fractalkine being the 
only member. It can exist as either membrane-anchored protein or as glycoprotein 
unbounded protein (Bazan et al., 1997; Tripp et al., 2001; Meyer dos Santos et al., 2011). 
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1.5 Chemokine Receptors 
Chemokine receptors are also known as G-protein coupled receptors. This type 
of receptor is embedded in the cell membrane with the N-terminus on the extracellular 
aspect of the cell membrane and 7-transmembrane α-helices structure that comprise 
three outer and inner loops (Figure 1.6). The C-terminal resides in the cytoplasm are 
connected to a heterotrimeric G-protein; comprising three different bodies: α, β and γ. 
Although there are nearly 50 chemokines identified, not all activate one specific 
chemokine receptor (see Table 1.1). Some receptors are shared between several 
chemokines and some of the chemokines can activate several chemokine receptors 
within the family (Zlotnik, Yoshie and Nomiyama, 2006). For example, in humans, the 
chemokine receptor CX3CR1 can only be activated by CX3CL1 (fractalkine). XCR1 can 
be activated by XCL1 and XCL2 but both have similar structure and differ by two amino 
acids. 
To date, 18 chemokine receptors have been reported (Zweemer et al., 2014) with 
six CXCR chemokine receptors, one XCR chemokine receptor, one CX3CR chemokine 
receptor and 10 CCR chemokine receptors (see Figure 1.7). Additionally, four atypical 
receptor (ACKR1 – 4) have the same structure as the chemokine receptor, although the 
ligand binding unable to activate the classical signalling pathway (Bonecchi and Graham, 
2016). Some of the chemokines share the same chemokine receptor or vice versa, 
providing a biased signalling with additional of atypical receptor contributing to the 
complexity of understanding them (Steen et al., 2014). The complex organisation and 
functions of chemokines and the receptors have been shown to be closely related to their 
evolutionary perspective (Zlotnik and Yoshie, 2012) (Figure 1.8). The phylogeny 
analysis amongst the chemokine receptor has shown that XCR1 are closely related to 
CXCR4, a well-known chemokine receptor in pathology. 
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Figure 1.6: The typical structure of chemokine receptor, a class of G-protein coupled 
receptor (GPCR). (Left) Typical transmembrane receptor structure (reddish pink) 
shown attached to a GPCR (blue-cyan) (image was obtained from RCSB PDB-101 
website). (Middle) A typical chemokine receptor backbone showing a seven-helical 
transmembrane protein (7-TPM) domain of the cell membrane. The image is the 
predictive protein structure of XCR1 receptor created using RaptorX software 
(http://raptorx.uchicago.edu/). (Right) XCR1 receptor with its surface shown. The image 
was produced using Pymol. 
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Figure 1.7: The chemokine receptors based on the family classification. Blue – CC 
chemokine; purple – CXC chemokine; green – CX3C chemokine; and red – C 
chemokine. Additionally, there is a small family of atypical chemokine receptor (ACKR) 
(in grey), a unified member by their incapability to initiate canonical chemokine signalling 
upon receptor activation. The receptor family classification is solely associated to the 
subfamily of its chemokine as there is no distinguishable identification between the 
receptors. Note that there is no CXCR7, as this has been re-classified to ACKR3. The 
other ACKRs were also reclassified to DARC (ACKR1), D6 (ACKR2) or CCX-CKR 
(ACKR4). 
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Table 1.1: Chemokine receptors and their respective ligands (in human).  
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Figure 1.8:  Phylogeny tree (in circular mode) of all chemokine receptors including the 
atypical chemokine receptors. The analysis shows that the XCR1 is closely related to 
CXCR4 (highlighted in red), the intensively studied chemokine receptor that is involved 
in many pathologies.   
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1.6 Functions of Chemokines and Chemokine Receptors  
Chemokines are involved in many biological processes. Their most common 
function is to mediate leukocyte trafficking in the immune response. The signalling 
mediates adhesion and migration of cells expressing the chemokine receptor. They are 
also involved in homeostasis (Zlotnik, Burkhardt and Homey, 2011) and with both 
autocrine (Menten et al., 2002; Tamgüney, Van Snick and Fickenscher, 2004; Kroeze et 
al., 2012) and paracrine signalling (Gortz et al., 2002; Heinrich et al., 2013). Chemokines 
have also been found to be expressed during human transplant rejection (Segerer et al., 
2001). CXC chemokines have also been shown to play an important role in chronic 
inflammation (Hannelien et al., 2012). 
Chemokines can promote neovascularization and tumour angiogenesis (Keeley, 
Mehrad and Strieter, 2011). CXCL1 to CXCL8 except CXCL4 (ligands for CXCR2), CCL2 
(ligand for CCR2), CCL11 (ligand for CCR3) and CCL16 (ligand for CCR1) are pro-
angiogenic chemokines with only four related chemokine receptors. Chemokines are 
also indirectly involved in organogenesis, making new lymph nodes during development 
and in cancer tissue (Gantsev et al., 2013). 
Chemokines also play a role in other pathologies such as diabetes where 
monocytes have been shown to increase inflammatory cytokines and chemokines 
production significantly by high glucose induction (Shanmugam et al., 2003) and 
CXCL10 expression resulting in failure of insulin-producing cells (Antonelli, Ferrari, 
Corrado, et al., 2014).  In autoimmune disease, recruitment of Th1 lymphocytes by 
CXCL10 increases production of interferon-γ and tumour necrosis factor-α, stimulating 
other cells producing the chemokine hence creating a high feedback loop (Antonelli, 
Ferrari, Giuggioli, et al., 2014). High levels of chemokine expression are also seen in 
cardiovascular disease where they contribute to vascular destruction and plaque 
development (Ross et al., 2012; Yao et al., 2014). 
A summary of general signal transduction for chemokine receptor when activated 
by its ligand can be found in Figure 1.9. 
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Figure 1.9: Downstream signalling of chemokine receptor upon activation by its ligand. 
Receptor transduction is closely related to cytokine signalling, although this information 
is generalised to normal cell compared to the complicated chemokine-chemokine 
receptor system associated with cancer pathology. The image at the top shows the 
activation of the chemokine receptor by its ligand (in purple) and the signalling pathways 
of the endogenous ligands (Gα, Gβγ complex, and β-arrestin protein).  
INTRACELLULAR 
EXTRACELLULAR 
INTRACELLULAR 
 
RECEPTOR 
ACTIVATION 
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1.7 Chemokines and Chemokine Receptors in Tumour Biology 
Chemokines and their receptors are involved in cancer-related inflammation 
(Mantovani et al., 2010). Although they recruit leukocytes to counter cancer cells, they 
can also have pro-cancer functions by controlling leukocyte infiltration, assisting 
angiogenesis, promoting cancer cell growth and survival, subverting the anti-tumour 
response and facilitating metastasis (Slettenaar and Wilson, 2006). This role is further 
supported by the fact that epithelial cancer cells can acquire higher levels of chemokine 
receptors compared to their normal counterparts. Increased chemokine expression in 
the cancer microenvironment influences the activity of the cancer cells including cell 
migration, adhesion, proliferation and invasion. The summary of chemokine and 
chemokine receptor involved in different types of cancer cells can be found in Table 1.2. 
Tumour development can be promoted by stimulation of angiogenesis. CXCR4 
positive cells usually metastasize to distant organs and induce angiogenesis by 
interaction with CXCL12 in oesophageal and gastric cancer (Hannelien et al., 2012). 
Although, other CXC chemokines have angiostatic effects and they attract anti-tumoral 
T lymphocyte, which reduces tumour growth. 
Chemokines have been shown to promote metastasis (Sarvaiya et al., 2013). 
The concentration gradient of CXCL12 promoted breast cancer cells movement and 
invasion similar to that seen in lymphocytes. Muller et al. (2001) showed the importance 
of CXCR7 and CCR7 in breast cancer invasion in vivo. Blood vessels consist of an 
endothelial cell lining that is separated from the tissue by a basal membrane and have 
been shown to express chemokine receptor (Murdoch, Monk and Finn, 1999) and 
release chemokines (Hillyer and Male, 2005; Speyer and Ward, 2011; Monnier et al., 
2012) which may induce adhesion and transmigration of cancer cells. It would be 
interesting to know if the endothelial cells express XCR1 receptor and produce hLtn for 
lymphocyte recruitment or cancer cell attachment. 
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Table 1.2: Chemokine receptors and chemokines expression in different types of cancer. 
Annotation: (n = Number of positive cases/Number of cases examined); S indicates 
obtained from serum or ascitic fluid; B.MET indicates bone metastasis; NA indicates data 
not available or not informed in the paper. 
Type of 
cancer 
Chemokine receptors and Chemokines 
References 
Primary tumour Metastasis 
Breast cancer CXCR4 (n=12[1], 
83/182[2], 63/103[3], 
113/200[4]), CXCR7 
(n=68/80[5], 43/103[3]), 
CCR4, CCR5, CCR6 
(n=72/207[6]) CCR7 (n= 
n=111/200[4], 89/207[6]), 
CCR10 (n=63/89[7]), 
CX3CR1 (n=105/202[8]), 
XCR1 (n=10[9]),  
CXCL12 (n=71/182[2], 
86/103[3], 38/100[4]), 
CCL2[10], CCL5 
(n=36/72[11]), CCL19 
(n=101/207[6]) 
CXCR4 
(n=62/100[4])), CCR7 
(n=77/100[4]), CCR10 
(n=59/68)[7],  
CXCL12 n=55/100[4]), 
CCL5 (n=26/47[10]), 
CCL21 (n=68/100[4]) 
[1] Müller et al., (2001),  
[2] Sun et al., (2014), 
[3] Schrevel et al., (2012), 
[4] Y. Liu et al. (2010),  
[5] Yuan et al., (2017),  
[6] Cassier et al. (2011), [7] 
H. Lin et al. (2017),  
[8] Jamieson-Gladney et 
al. (2011), 
[9] Yang et al. (2017), 
[10] (J. Wang et al., 2015), 
[11] Araujo et al. (2018) 
Cervical 
cancer 
CXCR4 (n=110/174[1]), 
CCR7 (102/174[1]), 
ACKR1 (n=168/227[2]), 
ACKR2 (n=162/227[2]), 
ACKR3 (n=34[3]), ACKR4 
(n=179/227[2]),  
CXCL8 (n=61/108[4]), 
CCL19 (n=55/62[5]) 
CXCR4 (n=32/35[1]), 
CCR7 (n=31/35[1]), 
ACKR1 (n=14/33), 
ACKR2 (n=21/33[2]), 
ACKR4 (n=20/33[2]),  
CXCL8 (n=27/43 [4]) 
[1] (Kodama et al., 2006), 
[2] Hou et al. (2013),  
[3] Tang, Xia and Xi 
(2016),  
[4] Yan et al. (2017),  
[5] Zhang et al. (2017) 
Lung cancer CXCR1[13], CXCR2[13] 
(n=262[1]), CXCR4 
(n=76/110[2], 62/154[3]), 
CCR2 (n=39/65[5]), 
CCR7 (24/40[6]), CCR9 
(n=39[7]), XCR1 (n=5[8]), 
ACKR3 (n=21/35[9]),  
CXCL1[10], CXCL5 
(n=75[11]), CXCL8 
(n=56/70[12], 49/120[13]), 
CXCL12 (n=47/150[3]), 
CXCL14 (n=24/35[9]), 
CCL2 (107/134[5]), 
CCL19[10], CCL21 
(n=48/100[4]), CCL25 
(n=39[7]), CCL4[14], XCL1 
(n=5[8]) 
CXCR4 (n=56/76[2], 
16/44[3], 62/100[4]), 
CCR7 (n=77/100[4], 
47/120[13], 19/24[6]), 
XCR1 (n=5[8])B.MET,  
CXCL8 (n=22/27[12], 
36/72[13]), CXCL12 
(n=20/42[3], 
55/100[4]), CCL19 
(n=55/120[13]), CCL21 
(n=68/100[4], 
25/120[13]), XCL1 
(n=5[8])B.MET  
[1] Saintigny et al. (2013),  
[2] Bi et al. (2017),  
[3] Wagner et al. (2009),  
[4] Y. Liu et al. (2010), 
[5] Zhang et al. (2013), 
[6] Yu et al. (2017),  
[7] Gupta et al. (2014),  
[8] T. Wang et al. (2015),  
[9] Choi et al. (2015),  
[10] Acharyya et al. (2012),  
[11] Wu et al. (2017),  
[12] Hosono et al. (2017),  
[13] Liu et al. (2015),  
[14] Cheng et al., (2016) 
Lymphoid 
leukaemia 
CCR3, CCR4, CCR7,  
CCL18 
- Balkwill (2012) 
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Lymphoma CCR3[1], CCR4[2], 
CCR10[3], 
 CCL17[4] 
- [1] Kleinhans et al. (2003),  
[2] Kumai et al. (2015),  
[3] Notohamiprodjo et al. 
(2005),  
[4] Peh, Kim and Poppema 
(2001) 
Melanoma CXCR2, CXCR4 
(n=31/71[1], 25/30[2]), 
CCR7 (n=18/30[2]), 
CCR10 (n=31/40[3]),  
CCL27 (n=18/40[3]), 
CCL28, CXCL1, CXCL8, 
CXCL12 (n=6/30[2]) 
CCR7 (n=16/19[2]),  
CXCL12 (n=11/19[2]) 
Balkwill (2012),  
[1] Scala et al. (2005),  
[2] van den Bosch et al. 
(2013),  
[3] Simonetti et al. (2006) 
Oral or/and 
oropharyngeal 
cancer 
CXCR1, CXCR2 
(n=47/85 [1]), CXCR4 
(n=24/40 [2], 54/60 [3]), 
CCR6 (n=4[4]), CCR7 
(n=4[4], 56/60 [3], 56/85 [5] 
54/90 [6]), XCR1 (n=10 
[7]), ACKR3 (n=30/35[8]),  
CXCL9 (n=46/50[9]), 
CXCL11 (n=25/35 [9]), 
CXCL12 (n=25/40 [2]), 
CCL2S[10], CCL3 
(n=40/98[10]) CCL21 
(n=NA [5]) XCL1 (n=10 [7]) 
CXCR4 (n=65/77[3]), 
CCR7 (n=73/77[3], 
4[4]),  
CCL3 (n=13/30[10]) 
[1] Qian et al. (2014),  
[2] Xia et al. (2012),  
[3] Al-Jokhadar et al. 
(2017).  
[4] Chen et al. (2013),  
[5] Shang, Liu and Shao, 
(2009),  
[6] Tsuzuki et al. (2006),  
[7] Khurram et al. (2010),  
[8] Xia et al. (2011),  
[9] Chang et al. (2013),  
[10] Ding et al. (2014) 
Ovarian 
cancer 
CXCR4 (n=26/44[1], 
241/241[2]), XCR1 
(n=55%/NA [3]),  
CXCL12 (n=40/44[1], 
199/289[1]), XCL1 & 
XCL2 (n=NA [3]) 
CXCR4 [4] [1] Jiang et al. (2006),  
[2] Popple et al. (2012),  
[3] Kim et al. (2012),  
[4] Balkwill (2012) 
Pancreatic 
cancer 
CXCR1 (n= 40/65 [1]), 
CXCR4 (n=34/60[2]), 
CCR4 (n=66/75[3]), 
CCR6 (n=25[4]), CX3CR1 
(n=56/104[5]),  
CXCL12 (n=52/60[2]), 
CCL20 (n=25[4]), 
CX3CL1 (n=70/104[5]) 
CXCR4 (n=28/35[2]), 
CX3CR1 (n=34/69[5]),  
CX3CL1 (n=44/69[5]) 
Balkwill (2012),  
[1] Chen, L. et al (2015),  
[2] J. Zhang et al. (2017),  
[3] Cheng et al. (2017),  
[4] Rubie et al. (2010),  
[5] Celesti et al. (2013) 
Stomach 
cancer 
CXCR2 (n=82/116[1], 
200/357[2]), CXCR4 
(n=40/50[3], 30/93[4]), 
CCR4 (n=79/103[5]), 
CCR7 (n=25/93[4], 
42/64[6]),  
CXCL1 (n=66/116[1]), 
CXCL12 (n=45/50[3])  
CXCR2 (n=4/8), 
CXCR4 (n=33/36[3], 
7/10[4]), CCR7 
(n=6/10[4], 35/39[6]),  
CXCL12 (n=34/36[3]) 
[1] Cheng et al. (2011),  
[2] Z. Wang et al. (2015),  
[3] Ying et al. (2012),  
[4] (Arigami et al., 2009),  
[5] Yang et al. (2015),  
[6] Mashino et al. (2002) 
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1.8 Chemokine – Chemokine Receptors in Oral Cancer 
Investigating biomarkers in saliva is potentially a useful tool for early detection of 
oral cancer (Prasad and McCullough, 2013). Saliva contains chemokines and the levels 
are highly elevated in the presence of cancer. OSCC can also be linked to inflammation 
where chronic inflammation impacts wound healing regulation allowing progression to 
cancer (Feller, Altini and Lemmer, 2013).  
Chemokines and chemokine receptors showed higher expression in oral cancer 
cell lines (OCCL) compared to normal oral epithelial cells (Khurram et al., 2010, 2014). 
Some studies have shown that chemokines in lymph nodes can attract cancer cells from 
the lymphatic circulation into the lymph node interior (Wiley et al., 2001; Mashino et al., 
2002). 
Most documented studies are in relation of chemokine and oral cancer 
progression are on CXCR4 receptor and its ligand CXCL12. CXCR4 expression is higher 
in metastatic oral cancer cells and clinical tissue (Delilbasi et al., 2004) while the ligand 
is only expressed in cancer but not normal oral cells (Uchida et al., 2003). CXCL12 
increases invasiveness and motility of CXCR4-positive cells (Ishikawa et al., 2006). The 
CXCL12/CXCR4 ligand-receptor interaction activates Src Family Kinase (SFK), 
extracellular signal-regulated kinases- ½ (ERK1/2) and Akt/Protein Kinase B (Akt/PKB) 
signalling (Uchida et al., 2003) as well as nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) pathway through CARD11-BCL10-MALT1 (CBM) complex 
(Rehman and Wang, 2009). 
Other chemokines such as CXCL1 show cytoplasmic expression in OCCL and 
activate the CXCR2 receptor to promote tumour angiogenesis, leukocyte infiltration and 
lymph node metastasis (Shintani et al., 2004). This chemokine is also produced by 
vascular endothelial growth factor (VEGF)-stimulated endothelial cells which induces 
invasion of CXCR2-positive oral cancer cells (Warner et al., 2008). Also, ACKR3 
(previously known as CXCR7) has also seen to be expressed in OSCC but not in normal 
epithelia however its ligand CXCL11 and CXCL12 have a moderate and high expression 
respectively in dysplasia and OSCC (Xia et al., 2011). 
Oral cancer cells also showed increase mRNA expression of CCR5 receptor 
when stimulated with CCL5 and increase the migration and production of matrix 
metalloproteinase-9 (MMP-9) (Chuang et al., 2009). Overexpression of CCR7 is seen 
highly associated with cervical lymph node metastasis where it facilitates higher 
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adhesion to lymph nodes, hence assisting metastasis (Shang, Liu and Shao, 2009). 
Additionally, the paper also shown a positive CCR7 expression in OSCC tissue and cell 
lines although no expression was detected in normal oral mucosa (Shang, Liu and Shao, 
2009). 
In summary, chemokines and chemokine receptors appear to have an important 
role in oral cancer progression, but the mechanism is not well understood as some of 
the other more prevalent cancer. This suggests a specificity of chemokine receptor 
expression in certain types of cancer. 
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1.9 Studies of XCR1 and hLtn in oral cancer 
 A recent study showed XCR1 expression outside the immune system for the first 
time with expression in inflamed oral epithelial cells and oral cancer cells (see Figure 
1.10) (Khurram et al., 2010). In addition, hLtn expression was found in epithelium 
adjacent to OSCC, invasive OSCC islands, metastatic tumour in the lymph nodes as well 
as in stroma (see Figure 1.11). 
hLtn expression was seen in both primary and metastatic tumours being present 
in the infiltrating leukocytes and the tumour stroma. hLtn and XCR1 expression was also 
seen in a range of OCCL at both the mRNA and protein level. However, the stimulus for 
hLtn release from epithelial cells remains unknown. There are only a few reported studies 
of hLtn and XCR1 receptor interaction in the context of cancer pathogenesis and spread. 
This is possibly due to the unique structure of the C chemokine itself which is not well 
established and researched as other chemokine families. This thesis will focus on of hLtn 
and its variant structures as well as their relationship with its receptor in oral cancer. 
 
Figure 1.10: Immunohistochemistry showing XCR1 expression in oral tissue samples. 
(A) Isotype (negative) control, (B) Normal mucosa, (C) Invasive OSCC islands, and (D) 
Metastatic tumour in lymph node (image taken with permission from Khurram et al. 
(2010)).  
(A) Negative control 
Expression of the chemokine receptor (XCR1) on oral tissue samples 
(B) Normal oral mucosa 
(C) Invasive OSCC islands (D) Metastatic tumour in lymph node 
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Figure 1.11: Immunohistochemistry showing hLtn expression in oral tissue samples. (A) 
Normal oral mucosa, (B) Normal mucosa adjacent to OSCC, (C) Invasive OSCC islands, 
and (D) Metastatic tumour in lymph node (image taken with permission from Khurram et 
al. (2010)). 
 
  
Expression of hLtn on oral tissue samples 
(A) Normal oral mucosa (B) Epithelium adjacent to OSCC 
(C) Invasive OSCC islands (D) Metastatic tumour in lymph nodes 
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1.10 XCR1 
1.10.1 Discovery 
XCR1 is a chemokine receptor that is only activated by hLtn, either XCL1 or XCL2 
(Yoshida et al., 1998). This was discovered by testing several known chemokine 
receptors as well as orphan receptors with only one of them inducing calcium 
mobilization by hLtn (Shan et al., 2000). It is also known as GPR5 as it belongs to the G-
protein coupled receptor family. 
 
1.10.2 Structure 
XCR1 is a transmembrane receptor spanning across the cell membrane and 
comprising of seven-transmembrane α-helix structure with three intra- and extra-cellular 
loops (see Figure 1.12). The N-terminus is located outside the cell and it is usually 
glycosylated. The C-terminus tail is lipoylated to the cell membrane by S-palmitoylation, 
attachment of palmitic acid to a specific cysteine residue via thioester linkage. The 
receptor is made up of 333 amino acids (see Figure 1.13). 
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Figure 1.12: Depiction of XCR1 chemokine receptor amino acids in two-dimensional 
arrangement. The structure consists of extracellular N-terminus and intracellular C-
terminus tail with three both extracellular and intracellular loops. The negatively charge 
extracellular amino acid residues (in red) have the potential to orientate the docking of 
the highly positively charge ligand based on their positioning for ligand-receptor binding. 
Additionally, there is a possibility of a post-translation modification of the N-terminal 
amino acid residues such as O-glycosylation (in pentagon) and tyrosine sulfation (in 
blue). The transmembrane residues largely consist of hydrophobic amino acids (in 
orange). The intracellular amino acids (in green) at the C-terminal tail and the ‘DRY’ 
motif (commonly found motif in chemokine receptors) are the possible residues that 
involves in receptor desensitization through β-arrestin signalling cascade. The C-
terminal tail is attached to the phospholipid bilayer through membrane raft. 
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Figure 1.13: XCR1 chemokine receptor protein sequence. Highlighted in yellow is the 
transmembrane α-helix sequence  
 
Although the protein sequence of XCR1 is known, the exact arrangement on the 
cell membrane has not been described. The sequence alignment shares the same trait 
of that in G protein-coupled receptor with similar length of transmembrane protein and 
~13% identical amino acids position identified (see Figure 1.14). When the sequence is 
aligned with known XCR1 protein sequences of other species such as mouse and rat, 
~69% and ~67% of the amino acids are conserved respectively and ~62% for both 
species alignments to human (see Figure 1.15). Kroczek and Henn (2012) reported 
antigen cross-presentation of mouse XCR1 receptor activated by hLtn suggesting that 
the receptor activation is less species specific but more structure dependant. Among all 
chemokine receptors, XCR1 is the only one that shows this unique functional 
characteristic 
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Figure 1.14: Multiple sequence alignment (MSA) between selected chemokine 
receptors families (CCR2, CXCR4, XCR1 and CX3CR1). Shaded in black indicating 
similar identity (*) of amino acid residues between the receptors while shaded grey is 
strongly similar residues (.). Highlighted in colours are the transmembrane α-helix 
sequence. Consensus: (*) similar identity, and (:) strongly similar. Alignment was 
performed using Clustal Omega and BOXSHADE. The information on the protein was 
obtained from UniProt database. 
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Figure 1.15: Comparison of XCR1 receptor between rat, human and mouse. Shaded in 
black indicating similar identity (*) of amino acid residues between the XCR1 receptors 
of selected species while shaded grey is strongly similar residues (.). Alignment was 
performed using Clustal Omega and BOXSHADE. The information on the protein was 
obtained from UniProt database.  
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1.10.3 Expression 
XCR1 is highly expressed on T-cell lymphocytes mainly CD4+ and CD8+ T-cells 
(Hedrick et al., 1997). The mRNA is strongly expressed in placenta and weakly in spleen 
and thymus (Yoshida et al., 1998). Recently, XCR1 has been shown to be expressed in 
dendritic cells in lymph nodes involved in antigen cross presentation (Kroczek and Henn, 
2012). XCR1 receptor expression has also been shown in normal oral mucosa and in 
OSCC (Khurram et al., 2010). Higher in vitro and in vivo expression was seen in oral 
cancer cells and OSCC compared to normal (Khurram et al., 2010).  
Recently, XCR1 expression has been reported in epithelial ovarian carcinoma 
(Kim et al., 2012) and breast cancer (Gantsev et al., 2013) with up regulation of XCR1 
receptor on the cancer cell surface. This is similar to some other chemokine receptors 
which have been reported to be upregulated in cancer cells to assist survival and growth. 
For example, overexpression of CXCR2 with CXCL1 and CXCL2 (the ligands) in breast 
cancer primes tumour survival at metastatic sites (Acharyya et al., 2012) and migration 
to sites of metastasis appears to involve CXCR4 with elevated expression in 23 different 
types of cancer (Balkwill, 2004b). It appears that the XCR1 receptor may also play a 
similar role in cancer although it is not known whether or not all type of cancer cells 
express XCR1. For example, (Khurram et al., 2010) found out that most OCCL express 
the receptor with variable levels of expression in a range of cell lines but Kim et al. (2012) 
showed that not all epithelial ovarian carcinoma express XCR1. Better understanding of 
XCR1 expression on epithelial cancer cells is needed to help characterise the role of 
XCR1 in other cancers. 
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1.11 hLtn (XCL1 & XCL2) 
1.11.1 Discovery 
The hLtn protein was first discovered during cytokine-producing profiling of 
mouse progenitor-T cell library (Kelner et al., 1994). It was found that this cytokine was 
similar to CC and CXC chemokines and only attracted lymphocytes but not monocytes. 
Hence, it was named lymphotactin. It was also found to be produced in activated CD8+ 
activated and progenitor T-cells with abundance in spleen and thymus. 
The human counterpart of this chemokine, human lymphotactin (hLtn) was 
discovered by three independent groups who named it ATAC (Activation-induced, T cell-
derived, and Chemokine-related molecule) (Muller et al., 1995), SCM-1 (Single C-Motif-
1) (Yoshie et al., 1995) and human lymphotactin (Kennedy et al., 1995). The gene is 
located on chromosome 1q23 in humans (Muller et al., 1995). 
Most of the previous studies focus on XCL1 rather than the second member of C 
chemokine family, XCL2 which is situated at chromosome 1q24 (NCBI, Gene ID: 6846). 
This protein has the same length and amino acids sequence to XCL1. The only sequence 
difference is the 7th and 8th amino acids which does not influence the protein structure. 
XCL2 has slightly higher affinity towards heparin even though the structure is very similar 
(Fox, Nakayama, et al., 2015). This is probably due to the presence of two basic amino 
acids Arginine and Histidine at the 7th and 8th position providing basic residue which 
important in protein – GAG interaction (Hileman et al., 1998).  
 
1.11.2 Structure 
hLtn belongs to the C-chemokine family which only has one disulphide bridge 
interconnected by Cys11 – Cys48. As a result, the structure is somewhat unstable allowing 
it to interconvert between two different conformations (Peterson et al., 2004). 
 hLtn has a molecular weight of 10 kDa (mature hLtn) or 12 kDa (with signal 
peptide). It has the basic structure of a chemokine, with three anti-parallel β-sheets and 
C-terminal α-helix (see Figure 1.16). The protein structure contains 15 basic amino acids 
making it a positively charged protein with a hydrophobic core and containing 114 amino 
acids overall (see Figure 1.17). Proteolytic cleavage removes the signal peptide located 
on Gly21 – Val22 leaving the mature hLtn with 93 amino acids (Peterson et al., 2004). 
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Figure 1.16: hLtn structure in physiological conditions. The canonical chemokine-fold for 
hLtn (left) and the novel dimeric four β-sheets structure (right) that was identified using 
nuclear magnetic resonance (NMR). The image was reproduced from Sun et al. (2011) 
using Pymol. 
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Figure 1.17: Human lymphotactin sequence. Total of 114 amino acids including signal 
peptide (1-21 AA) highlighted in grey and mature protein sequence in yellow (22-114 AA) 
(sequence obtained from Uniprot_P47992). 
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Kuloglu et al. (2001) investigated the solution structure of hLtn and found that it 
has a monomeric structure but with some evidence suggesting it also exists as a dimer. 
The structure is salt and temperature dependent (Kuloglu et al., 2002). It was also found 
that hLtn has two completely different, reversible protein conformations. The chemokine-
like fold is monomeric and predominates at higher salt concentrations and at 10oC 
temperature. The novel dimeric structure can be found at lower salt concentrations and 
at a temperature of 40oC. Interestingly, both are distributed equally in physiological 
conditions (temperature 37oC) (see Figure 1.18) and the conversion rate is ~1/s 
(Volkman, Liu and Peterson, 2009). It was suggested that this is due to the significant 
ionic strength required to hold the chemokine-fold. Molecular dynamic simulation also 
shows the importance of the salt concentration and temperature in the protein structure 
(Formaneck, Ma and Cui, 2006). The temperature dependence of ion-protein is sensitive 
to the local sequence especially at the C-terminal tail (Ma and Cui, 2006). It has been 
suggested that ionic charges in salt holds tryptophan of the α-helix structure pack 
together, conserving the structure (Lakemond et al., 2000; Raghuraman and 
Chattopadhyay, 2006). Volkman, Liu and Peterson (2009) speculated that Arg23 and 
Arg43 hold the key to both structures’ conversion by charge repulsion. But this only 
explains structural changes when considering the salt concentration. In the temperature 
scenario, dissociation of bonds holding the hydrophobic core is a probable explanation. 
Ala49, Ala53 and Val59 provide a hydrophobic pocket for tryptophan and hold the α-helix 
structure and the β-sheet together. High energy breaks the bond that holds the structure. 
Nevertheless, it is difficult to explain how this can be translated in vivo and how 
physiological conditions allowing equal distribution of both hLtn forms. 
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Figure 1.18: Distribution of hLtn forms at different temperatures. At low temperature, 
hLtn exists mostly in the canonical-chemokine fold (left) while a dimeric form exists at 
high temperatures 40°C (right). The structures are in equilibrium at 37°C (physiological 
condition, middle). 
 
The conformation change between two protein structures in hLtn is a two-step 
process with no intermediary stable species (Tyler et al., 2011). Some suggest that 
conformational change requires a “bridge” between the two structures (Sauer et al., 
2000). Other proteins such as the Mad2 spindle checkpoint protein and chloride 
intracellular channel 1 (CLIC1) are known to demonstrate the ability to switch between 
different fold (Bryan and Orban, 2010). Yet both are not as unique as hLtn as they form 
a stable intermediate variant while hLtn can interconvert without an intermediate. A 
model simulation shows that interconversion between two different protein 
conformations lies in the conserved local contacts that allow the reversible change 
(Camilloni and Sutto, 2009). Furthermore, the rearrangement is freely reversible with no 
effect from repeated temperature titrations (Tuinstra et al., 2007). Organic acids abrupt 
the disulphide bridge result in loss of tertiary and secondary structure as well as cold 
denaturation where the wild type hLtn is the most sensitive compared to the mutant 
variants (Sun et al., 2011).  
Kroczek and Henn (2012) reported cross-species activation of hLtn and XCR1. 
The study was performed using hLtn to activate XCR1 receptor in the mouse. By 
comparing the structure for several species (see Figure 1.19), 20 amino acids are shown 
to be conserved across species. This illustrates that hLtn activation of XCR1 may be 
related to the structure rather than specific amino acid sites on the protein. Further 
investigation of cross-presentation may elucidate further this theory.  
(Dorner et al., 1997) identified that almost 40% of hLtn is O-linked glycosylated 
and the remaining are terminally sialylated. Others also report that some of the hLtn 
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population is partially folded (Marcaurelle et al., 2001). hLtn can still activate Ca2+ 
signalling and chemotaxis without the presence of glycosylation but the biological activity 
is slightly reduced (Dong et al., 2005). This confirms that hLtn is functional even in 
unglycosylated form. Furthermore, producing hLtn using mammalian or insect cells will 
produce less yield and time consuming compared to E. coli while maintaining 
glycosylation. 
 
 
 
Figure 1.19: Comparison of hLtn (XCL1) in several species. (A) Alignment of XCL1 in 
different species). Shaded in black indicating similar identity (*) of amino acid residues 
between the receptors while shaded grey is strongly similar residues (.). All contains 114 
amino acids (including signal peptide) except for bovine and chicken (only 97 amino 
acids), and boar (110 amino acids). (B) Taxonomy of hLtn between the species. The 
protein sequences were obtained from UniProt website and the multiple sequence 
alignment (MSA) was performed using Clustal Omega and Boxshade.  
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1.11.3 Expression 
hLtn is primarily expressed in spleen and lung tissue (Kelner et al., 1994; Yoshida 
et al., 1999) but the specific cells expressing hLtn in these tissues have not been 
reported. Mostly, hLtn expression can be seen in activated CD8+ T-cells (Muller et al., 
1995), progenitor T-cells (Kelner et al., 1994), natural killer (NK) cells (Hedrick et al., 
1997), neutrophils (Huang et al., 2001) and lymphocytes to induce chemotaxis as part of 
the immune response.  
hLtn can also be expressed in non-lymphoid cells. Recently, the expression was 
reported in synovial fluid of patient with meniscal tears in their knee (Nair et al., 2015). 
Human intestinal mast cells also express multiple chemokines including hLtn due to its 
immunoregulatory role (Feuser et al., 2012). The synovial fluid of patients with 
rheumatoid arthritis has also been shown to contain hLtn indicating that hLtn play a role 
in the immune response and chronic inflammatory conditions outside the lymphoid 
system (Blaschke et al., 2003). 
 
1.11.4 Functions 
hLtn or XCL1 is a chemotactic chemokine which only attracts leukocytes and T-
cells. hLtn binds with high affinity to glycosaminoglycan (GAG) which is important for the 
interaction with lymphocytes in vivo (Peterson et al., 2004). 
Some studies suggest a role for hLtn in allograft rejection (Wang et al., 1998). 
The level of mRNA is highly upregulated in the transplant area whilst none is detectable 
in isografts. This suggests that hLtn is an immune system mediator, recruiting 
lymphocytes during organ rejection. 
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1.12 hLtn and XCR1 in Tumour Biology 
The first recorded involvement of hLtn and XCR1 in tumour biology was by 
Khurram et al. (2010). In this study, normal oral epithelial cell was shown to express 
XCR1 receptor as well as cancer cells. This was also the first time that XCR1 receptor 
expression was demonstrated outside the immune system and inflammatory cells. Oral 
cancer cell lines were also shown to contain hLtn mRNA and cytoplasmic protein.  
Six years ago, (Kim et al., 2012) showed that primary and metastatic human 
epithelial ovarian carcinoma cells express XCR1 receptor while the normal ovarian 
epithelial cells do not. It was also demonstrated that XCR1 receptor expression induced 
pro-metastatic behaviour in the cells. This suggests a role for the XCR1 receptor in 
facilitating metastasis.  
XCR1 was also found to be expressed in breast cancer which contributes to 
lymphoid neo-organogenesis (Gantsev et al., 2013). Müller et al. (2001) performed a 
screening of chemokine receptor expression and found no XCR1 expression in breast 
cancer cells and normal primary mammary epithelial cells except for malignant 
melanoma cells. This indicates that XCR1 is not necessarily expressed by all breast 
cancer cell lines. Even in OSCC, although, a range of all oral cancer cell lines express 
XCR1, the level varies widely (Khurram et al., 2010).  
OCCL contain cytoplasmic hLtn but the stimulus of secretion is not known 
(Khurram et al., 2010). It would be interesting to investigate factors that induce release 
of hLtn from cancer cells. This will allow an understanding of the mechanism in relation 
to metastasis. 
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1.13 hLtn (XCL1) Variants 
To study both hLtn functional structures, stable production of mutant variants is 
required. This would allow the hLtn10 and hLtn40 variants to remain locked in the 
designed state even at different temperature and physiological conditions. 
 
1.13.1 hLtn10 variant 
The first paper on the production of mutant hLtn10 was published in 2007 
(Tuinstra et al., 2007). The paper proposed the addition of a second disulphide bridge, 
which wild-type hLtn lacks in order to hold the protein structure into its canonical 
chemokine-fold. By comparing hLtn to a CC chemokine, CCL15 (see Figure 1.20), CC1 
and CC3 mutant sequences were acquired. Both were tested for chemokine functional 
activity. 
 
 
Figure 1.20: Sequence alignment for initial hLtn10 variant structure validation. The 
sequences were compared against a CC chemokine (CCL15) with three disulphide 
bridges to predict the placement of the second disulphide bond for hLtn to create the 
canonical chemokine fold. The CC1 mutant is based on the first disulphide alignment to 
CCL15, while the CC3 mutant disulphide is based on the additional unusual third 
disulphide bridge present in CCL15. The sequences were obtained from UniProt website 
and the MSA performed using ClustalOmega and Boxshade. The image was reproduced 
from Tuinstra et al. (2007). 
 
The CC1 mutant has a cysteine addition at location T10C and Ala-Cys dipeptide 
insertion between Gly32 and Ser33. hLtn lacks disulphide connection between the N-
terminal and the 30s loop compared to other chemokine family. Tuinstra et al. (2007) 
suggested that this locks the protein into hLtn10 conformation but may also restrict its 
biological function and mobility as it lacks cysteine on the 30s loop. A second design of 
hLtn10 variant was also constructed, CC3 by overlapping it with the third disulphide 
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bridge location of CCL15. The overlaid structure proposed hLtn mutation at V21C and 
V59C (see Figure 1.21). Both hLtn10 mutants retain their structure even when 
introduced to extreme temperature (hLtn40 conditions). Ca2+ flux activation was studied 
to determine functionality, with CC1 and CC3 both showing the same EC50 value (half 
maximal effective concentration) compared to the wild-type (normal hLtn). 
XCR1 is activated by hLtn but the mechanism is yet not fully understood. Some 
researchers suggest that N-terminus is important for receptor activation while others 
suggest the C-terminus is equally important for activation in vivo (Tuinstra et al., 2007). 
Tuinstra et al. (2007) showed that the N-terminus is important in XCR1 activation. 
Experiment was performed using truncated mutant protein where the first Valine of the 
mature hLtn sequence was replaced or the N-terminus has an additional resulting in no 
Ca2+ flux activation. Thus, the authors suggest that the C-terminus does not have a role 
in XCR1 activation. The variant that showed no response lacks the α-helix structure and 
adopts the hLtn40 conformation. However, Hedrick et al. (1997) reported that the 
truncated C-terminal hLtn is inactive and suggested it is likely to be important in vivo. 
This suggests that hLtn can behave rather differently in vivo. Some of the experiments 
reported in literature were performed using commercial hLtn lacking the first Valine 
indicating that this was functionally active in vitro (Khurram et al., 2010). These first 
Valine may thus not be essential, but the activity may be less compared to hLtn with 93 
amino acids. This remains to be elucidated. 
Tuinstra et al. (2007) replaced all the methionine residues in the hLtn sequence 
to accommodate the purification and cleavage process during protein production using 
cyanogen bromide (CnBr). Although it did not cause any major alteration to the protein 
structure, it is usually ideal to keep the protein sequence changes to a minimum to allow 
close resemblance to the natural form. Furthermore, although it was also reported that 
CC1 and CC3 both have the canonical chemokine-fold and activity, the paper only 
provides detail of the CC3 construct and not the other construct. This is probably due to 
the mutation applied where CC3 structure has more resemblance to the wild type hLtn 
which its 30s loop of the structure is not restricted. 
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Figure 1.21: hLtn10 mutant variant. Conversion of hLtn structure (left) to hLtn10 mutant 
variant (right) performed by adding an extra disulphide bridge, where Val21 and Val59 are 
both replaced by cysteine. The image was inspired from Sun et al. (2011) and created 
using Pymol. The protein structure files (ID: 1J9O and 2HDM) were obtained from PDB 
website. 
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1.13.2 hLtn40 variant 
To create hLtn40 variant, changing the only tryptophan in the sequence, Trp55 to 
aspartic acid (Asp) removes the α-helix structure that holds the hydrophobic core of the 
protein, allowing it to form the novel four β-sheets structure (see Figure 1.22) (Tuinstra 
et al., 2008). Due to their proximity, Ala49, Ala53 and Val59 together with Trp55 create a 
hydrophobic pocket, holding the α-helix structure in canonical chemokine-fold.  
In hLtn40, the N-terminus forms a new β-sheet structure, denoted as β0-sheet. 
While β1, β2 and β3 sheets still exist in the conformation, they undergo some changes. 
The β-sheets are slightly longer in hLtn40 and the β2-sheet is shifted forming an anti-
parallel β-sheet connection with the β1 and β3 strands (see Figure 1.23). Furthermore, 
the 30s and 40s loop of hLtn40 is shorter. This structure replaces virtually all the tertiary 
interactions in hLtn10 with different tertiary and quaternary contacts in hLtn40. 
Furthermore, the hydrophobic core region hidden in hLtn10 is exposed in hLtn40. This 
leads to dimer formation in solution. The Lys25 and Glu31 of hLtn40 stabilize the dimer by 
hydrophobic and electrostatic interaction (see Figure 1.24). In addition, the hLtn40 β2 
strand seems to rotate 180o during this conversion. The R groups of Val37, Phe39 and 
Thr41 that are buried in the hydrophobic core of hLtn10 structure are completely solvent-
exposed in hLtn40. Val37 and Phe39 contribute to the hydrophobic core of the monomer 
form and are essential in stabilising the canonical chemokine-fold. 
The hLtn40 variant has a high affinity for heparin (Tuinstra et al., 2008). This is 
important in vivo as glycosaminoglycans (GAGs) are a highly abundant component in 
the ECM and on the cell surface. A class of GAG, heparin/heparan (HSGAG) plays a 
role in biological activities such as cell adhesion (Sasisekharan, Raman and Prabhakar, 
2006). GAGs provide a platform for cell adhesion and interacts with the cell through cell-
substratum adhesion and hyaluronate in GAGs contributes to appropriate cell 
movement. The hLtn10 mutant can activate XCR1 in the presence of heparin whereas 
both the hLtn40 and wild type hLtn are unable to do so (Tuinstra et al., 2008). This raises 
the question of the role of the ECM in vivo or whether other molecules may be required 
to allow hLtn-XCR1 association. Also, heparin may be key as it provides hLtn with a 
tendency to remain in hLtn40 structure in vivo. Furthermore, while the active chemokine-
fold polymerizes and binds to the cell surface GAG (Hoogewerf et al., 1997), the wild 
type hLtn and hLtn10 variant have less or no affinity towards it (Tuinstra et al., 2008). 
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Figure 1.22: hLtn40 mutant variant. Conversion of hLtn structure (left) to hLtn40 mutant 
variant (right) is achieved by substituting tryptophan (W) to aspartic acid (D) in the α-
helix structure on position 55th amino acid. Tryptophan residue is responsible for holding 
the α-helix structure of canonical hLtn fold. The image was inspired from Sun et al. (2011) 
and created using Pymol. The protein structure files (ID: 1J9O and 2JP1) were obtained 
from PDB website).  
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Figure 1.23: Comparison of the β-sheets structure for hLtn10 (top) and hLtn40 (bottom) 
of wild type conformation. Amino acids in square boxes (□) are the one that involve in β-
sheet. Blue dotted-lines (  ) are the hydrogen bonds forming between the β-sheets. 
Amino acids in blue are basic while in orange are the residues that contribute to the 
structure hydrophobic core. The image was reproduced and adapted from Kuloglu et al. 
(2002) . 
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Figure 1.24: Hydrophobic and electrostatic stabilization of hLtn40 dimer. The image on 
the left is the dimer presented with the surface electrostatic potential. (A) Side view of 
protein dimer. Lys25, a basic amino acid (R group in blue) and Glu31, an acidic amino 
acid (R group in red) (shown in sticks) are solvent exposed, forming a salt bridge 
(combination of electrostatic interaction and hydrogen bonding with water). (B) Aerial 
view of the protein dimer displaying (C) the hydrophobic contacts (in orange) forming 
the dimer core (Leu24, Ala36, Ile38, Ile40) with white and grey surface shade. In monomer, 
the responsible R groups are solvent exposed, resulting in a totally different hydrophobic 
core contacts (refer Figure 1.23). The image was created using Pymol and the protein 
structure file (ID: 2JP1) was obtained from PDB website. 
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1.14 Studies on hLtn 
There are several studies on hLtn in relation to its use in potential as a therapeutic 
agent. (Cairns et al., 2001) stated that transforming myeloma cells to express hLtn, 
reduces their growth. By transfecting hLtn-expressing myeloma cells into nude (immune 
system inhibited) and BALB/c (laboratory-bred) mice, tumour growth was reduced. hLtn 
recruits CD4+ and CD8+ T-cell as well as neutrophils to the tumour sites as part of the 
antitumor response and this may explain these findings. 
A study by Fossum et al. (2015) used a XCL1-fusion protein to target influenza 
virus. The DNA vaccines encodes a dimeric XCL1-hemagglutinin fusion protein 
vaccibodies targeting XCR1 expressing dendritic cells to induce T-cell responses. Guzzo 
et al. (2013) discovered that hLtn inhibits HIV-1 virus entry to host cells at an early stage, 
although it requires the hLtn40 variant structure for the blockade. HIV-1 virus usually 
mimics surface receptors on the cell surface to allow fusion and entry (Wilen et al., 2012). 
The possible explanation is that the dimer is blocking the activation of XCR1 as the 
receptor is found to be novel co-receptor for XCR1 (Shimizu et al., 2009). 
hLtn also has potential as an antimicrobial agent (Nguyen and Vogel, 2012; 
Nagata, Nishiyama and Ikazaki, 2013). By using Nuclear Overhauser Effect 
Spectroscopy-Nuclear Magnetic Resonance NOESY-NMR, the dimer interface is 
observed to have clusters of high positively charged surface that can interact with 
bacterial membranes. 
Recently, cytomegalovirus was discovered to express vXCL1 (v denotes virus) 
with 96 amino acids and which can be used by the virus to hide from immune system 
(Geyer et al., 2014). The structure is similar to hLtn and can be detected 13 hours after 
infection. The vXCL1 can attract CD4(-) XCR1-expressing dendritic cells and subvert the 
immune response. 
CXCL10 and hLtn were recently adapted to form a fusokine, a fusion of two 
cytokines for therapeutic potential (Sanchez-Lugo et al., 2015) to increase the 
bioavailability and therapeutic potential of the chemokines. The result showed higher 
chemotactic effect compared to individual chemokines alone in attracting CXCR3 
expressing tumour cells. Although it is not known whether the fusokine can attract XCR1 
expressing cells as well. 
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1.15 Aims and Hypotheses of the Study 
hLtn and XCR1 have shown to be involved in oral cancer progression and may 
play a role in local spread and lymph node metastasis. Also, due to its metamorphic 
properties, we want to further understand the contribution of each hLtn conformation in 
cancer pathogenesis. 
The overall aim of this study is to investigate further the roles of hLtn and XCR1 
in OSCC in the context of the tumour microenvironment. Ultimately, the aim to produce 
a functional hLtn variant mutants with locked conformation and study their effect on the 
behaviour on oral cancer cell lines. The specific aims of each chapter are listed below: 
1) Chapter 2: Ex Vivo Expression of XCR1 and hLtn in Oral Cancer Tissues 
and Lymph Nodes 
 To investigate and quantify the ex vivo expression of XCR1 receptor and hLtn 
and to compare expression between primary tumour and metastatic deposits 
and correlate with clinicopathological features. 
 
2) Chapter 3: Regulation of XCR1 and hLtn (XCL1) Expression in Oral Cancer 
Cell Lines by hLtn & Conditioned Media from Oral Fibroblasts 
 To determine the role of hLtn in regulation of the XCR1 receptor in OCCLs. 
 To understand the role of fibroblasts, in context of tumour microenvironment 
on the expression of XCR1 and hLtn in OCCLs. 
 
3) Chapter 4: Design and Production of Recombinant hLtn Variants 
 To design and produce functional hLtn variants (WT, CC3 and W55D mutant).  
 
4) Chapter 5: The Effect of Recombinant hLtn on the Behaviour of Oral Cancer 
Cell Lines  
 To study the effect of hLtn and each locked conformation of hLtn on the 
behaviour of OCCLs in range of effects (proliferation, adhesion and 
migration). 
 
CHAPTER 2 
EX VIVO EXPRESSION OF XCR1 
AND hLtn IN ORAL CANCER 
TISSUES AND LYMPH NODES 
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CHAPTER 2: EX VIVO EXPRESSION OF XCR1 AND hLtn IN ORAL CANCER 
TISSUES AND LYMPH NODES 
2.1 INTRODUCTION 
XCR1 and hLtn expression has been shown to be present in normal and 
cancerous tissue. In case of oral mucosa, the expression is seen in the basal layer of 
normal epithelium, whereas expression is more diffuse in primary oral squamous cell 
carcinoma (OSCC) and metastatic deposits (Khurram et al., 2010). Due to the proximity 
and OSCC preference for lymphatic spread, metastasis is usually to lymph nodes. XCR1 
mRNA expression has been shown in normal placenta, spleen and thymus tissue 
(Yoshida et al., 1998). While in lung (T. Wang et al., 2015), breast (Yang et al., 2017), 
and ovary (Kim et al., 2012), XCR1 receptor is present only in cancerous tissue. While 
for hLtn, expression in tissue only has been shown in OSCC (Khurram et al., 2010) but 
none has been reported in other cancers. The literature is heavily focussed on the 
receptor but not on the ligand hLtn. This chapter further investigated the expression of 
XCR1 receptor and its ligand in primary and metastatic OSCC, and reactive lymph node. 
Literatures suggest that like other chemokines, spatial expression of XCR1 by tumour 
cells and hLtn in lymph node may contribute to lymphatic spread.  
 
2.2 AIM 
The aim of this chapter is to investigate and quantify the ex vivo expression of 
XCR1 receptor and hLtn and to compare expression between primary tumour and 
metastatic deposits and correlate with clinicopathological features. 
 
2.3 MATERIALS AND METHODS 
2.3.1 Materials 
List of detailed information of the materials (reagents, kits, equipment, software 
and miscellaneous) used in the chapter can be found in Appendix 1-5. 
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2.3.2 Tissue cohort 
Tissue samples were identified using the local pathology database and retrieved 
from the archive (ethical approval reference 07/H1309/150) (Table 2.1). A cohort of 15 
samples was chosen including five primary oral tumours with matched metastatic lymph 
nodes and, five reactive lymph nodes.  
Table 2.1: Clinicopathological data of the patient tissue cohort 
 
Tumour 
Total number of patients 5 
Sex 
Men 3 
Women 2 
Age: median [range] 66 [40-72] 
Tumour grade 
Well - 
Moderate 2 
Poor 3 
Tumour size (mm) 26 [9-50] 
Tumour invasion depth (mm) 8 [2-27] 
Lymphovascular invasion 2 
Perineural invasion 3 
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2.3.3 Haematoxylin and Eosin (H&E) Staining  
Principle: Haematoxylin is a basic dye that has the affinity to stain acidic or basophilic 
structures purplish blue. DNA in the nucleus, and RNA in ribosomes and in the rough 
endoplasmic reticulum are both acidic, thus haematoxylin binds to them and stains them 
purple. Eosin is an acidic solution (negatively charged) which stains basic or acidophilic 
structures red or pink. Cytoplasm contains many proteins, which are basic allowing eosin 
to bind to these proteins and stains them pink (Figure 2.1). Under optical microscopy, 
the observation of tissue can be described as the following: erythrocytes are cherry red; 
collagen is pale pink; cytoplasm is reddish pink and nuclei are bluish purple. 
 
Figure 2.1: Explanation of H&E staining. 
Procedure: 5 µm thick sections from FFPE (formalin-fixed paraffin-embedded) tissue 
blocks were mounted on SuperFrost® Plus microscope slide (Thermo Scientific, Paisley) 
and heated in an oven at 65°C for 15 minutes to allow the tissue to bind to the slide 
surface. Xylene was used to deparaffinise the tissue slides and ethanol to dehydrate the 
FFPE tissue. The sections were stained using a Leica ST4040 machine with setting 45 
seconds per solution as in Table 2.2. The tissue was covered in mounting media DPX 
(Cat#: 44581; Sigma-Aldrich, Dorset, UK) and glass cover slips used to cover the tissue. 
The slides analysed using a widefield light microscope attached with camera. Images 
were obtained using Cell^D software (Olympus, Essex, UK). 
  
Nucleus 
(Haematoxylin) 
Purplish-blue 
Cytoplasm 
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Normal cell 
Red blood cell 
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Table 2.2: Iteration washing step for haematoxylin & eosin (H&E) staining. 
No  Solution Function 
1  Xylene 
Deparaffinise the FFPE 
Intermediate clearing solvent 
2  Xylene 
3  Xylene 
4  99% IDA 
Dehydrate tissue section 5  99% IDA 
6  70% IDA 
7  Distilled water 
Tissue hydration 
8  Distilled water 
9  Harris’ haematoxylin (Shandon) 
Stain nucleus 
10  Harris’ haematoxylin (Shandon) 
11  Harris’ haematoxylin (Shandon) 
12  Harris’ haematoxylin (Shandon) 
13  Running tap water To remove residual haematoxylin 
14  0.1% (v/v) acid alcohol To remove the haematoxylin that does not attach 
15  Running tap water To remove residual acid alcohol 
16  
Scott’s Tap Water Substitute 
To intensify the blue colour from the haematoxylin 
stain  
17  Running tap water To remove residual Scott’s tap water 
18  Eosin Y – aqueous (Shandon) 
Stain cytoplasm 19  Eosin Y – aqueous (Shandon) 
20  Eosin Y – aqueous (Shandon) 
21  Running tap water To remove residual eosin 
22  99% IDA 
Dehydrate the tissue section 23  99% IDA 
24  99% IDA 
25  Xylene 
Intermediate clearing solvent 
26  Xylene 
27  Xylene 
28  Xylene 
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2.3.4 Immunohistochemistry (IHC) Staining by Precipitation 
Principle: IHC is a technique to investigate the distribution and spatial localization of 
specific protein of interest in tissue. The technique uses an antibody to target the epitope 
of the protein of interest. Biotinylated secondary antibody is used which binds to the 
primary antibody raised to recognise specific epitope of the animal used to produce the 
primary antibody. Avidin-biotin complex is added to further enhance the signal detection. 
For the enzyme substrate, peroxidase is added in conjunction of the chromogen used 
for optical identification of the antibody location on tissue section attachment. The 
mechanism of the staining is summarised in Figure 2.2 below. 
 
Figure 2.2: Illustration of steps involved in IHC. 
Procedure: 5 µm thick tissue sections were treated with xylene to remove wax and then 
in ethanol for 5 min twice each. Hydrogen peroxide (2%) in methanol was used to block 
endogenous peroxidase for 20 minutes. Heat-induced antigen retrieval (HIAR) was 
performed by submerging the slides in 10 mM sodium citrate buffer (pH 6.0) and heating 
for 8 min at maximum power in a microwave. Non-specific protein binding was blocked 
by incubating the tissue section for 30 min with 100% serum (goat serum for antibodies 
raised in rabbit and horse serum for antibodies raised in mouse). Polyclonal anti-human 
XCR1 antibody (Cat#: LS-A158; LS-Bio, Nottingham, UK) (concentration 10 µg/mL) and 
monoclonal anti-human XCL1 antibody (Cat#: LS-B5938; LS-Bio, Nottingham, UK)  
(concentration 20 µg/mL) were placed onto the respective slides overnight at 4°C. For 
1) Primary antibody 
addition 
Primary antibody was 
incubated to allow them 
to adhere to the epitope 
of the protein. 
2) Biotinylated 
secondary antibody 
addition 
Secondary antibody 
biotin-conjugated was 
added to bind to primary 
antibody epitope. 
3) Avidin-biotin 
complex (ABC) 
addition 
Pre-incubated avidin-biotin 
complex aliquot was used 
to enhance the signalling. 
4) Enzyme substrate 
addition 
NovaRed substrate with 
peroxidase added to react 
with the ABC to allow 
precipitation to occur, 
facilitating optical 
detection. 
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negative control and blocking, goat serum was used for XCR1 and horse serum for 
XCL1. The excess primary antibody was tipped, and the residual was washed off twice. 
All the washing steps were performed with PBS. Secondary antibody from Vectastain® 
Elite® ABC-HRP Kit with Peroxidase was incubated for 30 minutes in respective treated 
slides; rabbit IgG (Cat#: PK-6101, Vectastain, UK) for XCR1 while mouse IgG (Cat#: PK-
6102, Vectastain, UK) was used for XCL1. Avidin-biotin complex (ABC) solution was 
prepared 30 minutes before application onto the slides in accordance with the 
manufacturer’s instruction (VectorStain Elite ABC kit, 2 drops solution A + 2 drops 
solution B per 5 ml PBS). The slides were washed twice for 5 min each and the tissues 
were left in ABC solution for another 30 minutes. The slides were washed twice before 
incubated with Vector NovaRed peroxidase (HRP) substrate (Cat#: SK-4800, Vector 
Laboratories, UK) solution mix. The reaction was stopped with distilled water after 5 min 
or as soon as colour developed. Counterstaining was performed with haematoxylin and 
dehydrated before mounting the slides was mounted in DPX mounting media (Cat#: 
44581; Sigma-Aldrich, Dorset, UK) before analysis under light microscope. The images 
were taken using Cell^D software using light microscope (Olympus, Essex, UK). 
 
2.3.5 Immunohistochemistry Quantification 
IHC stained tissue was scanned using TissueFAXS Slide Loader 120 Histo 
(Wien, Austria). The analysis was performed using HistoQuest Analysis Software by 
Tissue Gnostics Imaging Solution (Vienna, Austria) to quantify the percentage of positive 
cell expression and the mean intensity stains of the positive expressing cells. Six regions 
of interests (ROIs) per slide of equal size were selected covering a total area of 0.3 mm2 
in each tumour section of primary and metastatic tumour as well as for their stromal 
region for analysis. The average percentage of positive cells were calculated by the 
software based on the threshold of NovaRed intensity level set by the user (information 
is available in Appendix 6).  
 
 
2.3.6 Statistical Analysis 
Paired Student’s t-test was used to identify the significance of the mean 
expression of the specimen.  
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2.4 RESULTS 
2.4.1 Histological Analysis of XCR1 and hLtn of Oral Cancer Tissue Sample. 
In normal oral epithelium, the XCR1 expression was predominantly seen in the 
basal layer (Figure 2.3). Expression can also be seen in lymphocytes in the superficial 
connective tissue. A similar trend was seen for hLtn expression. The basal cell staining 
pattern in normal epithelium suggests that XCR1 might be expressed by progenitor/stem 
cells as these reside in the basal layer of normal oral tissue. Staining for hLtn was 
somewhat different and only seen focally and not throughout the oral epithelial basal 
layer. Other than that, some fibroblasts population, patrolling lymphocytes and 
endothelial cells in the connective tissue was also stained with XCR1 and a weaker stain 
for hLtn. 
In primary oral squamous cell carcinoma (OSCC), XCR1 staining was seen in 
throughout the carcinoma epithelium with greater intensity in the basal compartment and 
areas of invading OSCC islands (Figure 2.4). Notably, the XCR1 staining was seen 
throughout the epithelium layer, not confined in the basal layer like in normal oral 
epithelium. Similarly, hLtn staining was also seen in the epithelium and the invasive 
epithelial islands. Expression of both XCR1 and hLtn by the same cells suggests a 
possible autocrine signalling mechanism in OSCC. Lymphocytes in the connective tissue 
are positively stained for XCR1 and hLtn. Similar staining seen by endothelial cells, 
although they have a weaker hLtn stain. Compared to the underlying connective tissue 
of normal oral mucosa, the fibroblast cells in the ‘reactive stroma’ stained with XCR1 and 
hLtn with a noticeable intensity. 
In the case of metastatic OSCC in the lymph node, the tumour cells showed 
strong staining for XCR1 and hLtn (Figure 2.5). The representative sample showed that 
the metastatic carcinoma populated the central region of the node and spread outward 
to the peripheral cortex. Lymphocytes and the endothelial cells in the metastatic node 
also showed XCR1 and hLtn expression, as well as the fibroblasts in the reactive stroma 
(see Appendix 7).  
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Figure 2.3: Normal oral mucosa (representative photomicrograph). (A) H&E staining at 
100× magnification, (B, C, D) XCR1 staining at 100×, 200× and 400× magnification 
respectively, and (E, F, G) hLtn staining at 100×, 200× and 400× magnification 
respectively. XCR1 and hLtn staining is seen in the basal oral epithelium. In the 
superficial connective tissue layer, lymphocytes and endothelial cells are positively 
stained with XCR1 and hLtn, although the latter is weakly stained. Some fibroblasts show 
weak XCR1 and hLtn staining. The angled arrow indicates a blood/lymph vessel. 
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Figure 2.4: Primary oral squamous cell carcinoma with invasive carcinoma to the 
underlying connective tissue (representative photomicrograph). (A) H&E staining at 100× 
magnification, (B, C, D) XCR1 staining at 100×, 200× and 400× magnification 
respectively, and (E, F, G) hLtn staining at 100×, 200× and 400× magnification 
respectively. XCR1 staining is seen throughout the oral epithelium and invasive 
carcinoma and not just the basal layer. Strong hLtn staining is also seen throughout the 
epithelium as well by the invasive carcinoma. Lymphocytes and endothelial cells also 
show XCR1 (weak for endothelial cells) and hLtn staining within the connective tissue. A 
noticeable population of fibroblasts also stain for XCR1 and hLtn. The angled arrow 
indicates a blood/lymph vessel. 
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Figure 2.5: Metastatic carcinoma in the lymph node where the invading carcinoma 
spreading outwards to the outer cortex (representative photomicrograph). (A) H&E 
staining at 100× magnification, (B, C, D) XCR1 staining at 100×, 200× and 400× 
magnification respectively, and (E, F, G) hLtn staining at 100×, 200× and 400× 
magnification respectively. The XCR1 and hLtn staining is seen the metastatic carcinoma 
and the lymphocytes. hLtn stain pattern distribution is weaker by lymphocytes in the 
cortex region. The total magnification and scale bar of the photomicrograph are as stated 
in their respective picture.  
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Lymphocytes 
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2.4.2 Histological Analysis or XCR1 and hLtn in Reactive Lymph Nodes 
In the cervical lymph nodes (Figure 2.6), diffuse XCR1 expression was seen in 
lymphocytes. B and T lymphocytes has been previously reported to express XCR1 and 
hLtn (Huang et al., 2001). Strong expression of hLtn was seen in germinal centres where 
mature B lymphocytes proliferate and differentiate, suggestive of hLtn involvement in B 
lymphocyte proliferation. Additionally, stronger XCR1 and hLtn staining was seen found 
in the cortex and paracortex peripheral region. Endothelial cells lining the vascular and 
lymphatic channels as well as the subcapsular sinus (SS) in the lymph nodes also 
expressed both XCR1 and hLtn. These may be important in trafficking lymphocytes and 
tumour into the lymph node.  
 
Lymphocytes 
Endothelial cell 
(A) H&E (200×) 
(B) XCR1 (200×) 
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Figure 2.6: XCR1 and hLtn staining in cervical lymph nodes (representative 
photomicrograph). (A) H&E, (B) XCR1, and (C) hLtn staining at 200× magnification. 
Staining for both was seen in lymphocytes in the peripheral cortex region and medulla. 
Endothelial cells also stained positive for both XCR1 and hLtn, as well as fibroblasts. 
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2.4.3 Quantitative Comparative Analysis of XCR1 and hLtn Expression in 
Primary and Metastatic Tumour. 
To understand whether OSCC progression correlates with the expression of 
XCR1 receptor and hLtn, the expression in patient tissue was quantified using 
HistoQuest software. Staining was evaluated in terms of positivity and the intensity in the 
tumour and the stroma.  
 High expression of XCR1 was present in OSCC with 90.68% ± 4.246 and 94.18% 
± 3.308 in primary and metastatic tumours respectively. There was no significant 
difference in staining between primary and metastatic tumour. However, regarding 
expression intensity, the metastatic tissue with 59.73% ± 7.889 was significantly higher 
(p=0.019) compared to the primary tumour with 34.27% ± 3.655 (Figure 2.7 (a)). In the 
stroma, the metastatic tumours had significantly higher XCR1 expression (p=0.0175) 
with a mean of 74.51% ± 16.51 than primary tumours (mean: 24.85% ± 2.076) (Figure 
2.7 (b)). No significant difference in expression intensity was detected between 
metastatic deposit stroma (mean: 37.22% ± 9.205) and primary OSCC stroma (mean: 
24.93% ± 2.074). 
 Unlike the hLtn distribution in the tumour tissue, there were no significance 
difference in staining between metastatic (mean: 95.57% ± 0.916) and the primary OSCC 
(mean: 72.19% ± 15.06) (Figure 2.8 (a)). The expression intensity in metastatic tumour 
(mean: 53.95% ± 8.756) was slightly lower than primary tumour (mean: 58.32% ± 3.219) 
with no significant difference. Moderate positive expression of hLtn in the stromal cells 
of both primary (mean: 48.35% ± 13.39) and metastatic OSCC (mean: 71.67% ± 9.771) 
was observed (Figure 2.8 (b)). A similar pattern was identified for the expression 
intensity. Both the amount of positive expression and the intensity of staining for hLtn 
between primary and metastatic tumour was not significantly different. 
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Figure 2.7: Histological quantification of XCR1 positive and intensity expression 
between primary and metastatic in oral (A) tumour and (B) stroma (n=5). The settings 
can be referred in Appendix 6.  
(A) 
(B) 
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Figure 2.8: Histological quantification of hLtn positive and intensity of expression 
between primary and metastatic in oral (A) tumour and (B) stroma (n=5). The settings 
can be referred in Appendix 6. 
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2.5 DISCUSSION 
The results show XCR1 and hLtn are present in oral tissue, in normal reactive 
lymph nodes as well as primary and metastatic oral squamous cell carcinoma (OSCC). 
This is in agreement with the novel findings of Khurram et al. (2010) showing XCR1 
expression in oral tissues. From the results of this investigation and the previous study, 
XCR1 expression can be seen primarily in the basal (Khurram et al., 2010). This raises 
the possibility that XCR1 could be a stem cell or basal layer marker in oral epithelia. This 
is quite interesting as the basal layer of oral epithelium is highly populated with 
adult/progenitor stem cells (Costea et al., 2006), and the expression profile of XCR1 
appears similar to that of CD44, a stem cell marker seen in normal human oral mucosa 
(Papagerakis et al., 2014). Another argument is that the epithelial lining in the mouth 
undergoes constant renewal to allow resistance to wear and tear in response to 
mastication, requiring constant tissue renewal. Another argument is that XCR1 might 
serve as positional marker allowing the cells to distinguish their position in the tissue. 
The examination of the OSCC tissue suggests that XCR1 and hLtn are expressed 
at the primary as well as metastatic stage. Chemokine receptors are known to be 
upregulated in cancer and it is thought this facilitates the growth and dissemination of 
the tumour. Previous studies have shown XCR1 expression in OSCC (Khurram et al., 
2010). This is not the case for other epithelial tissue. In breast cancer, XCR1 expression 
can only be seen in oestrogen receptor positive breast carcinoma and no expression is 
detected in normal primary breast epithelial tissue (Yang et al., 2017). In a similar way, 
normal ovarian tissue and ovarian epithelial cell lines derived from normal cells do not 
express XCR1, although it is found in both primary and metastatic ovarian cancers and 
cell lines (Kim et al., 2012). In lung, primary lung carcinoma shows a weak or absent 
expression which is upregulated in lung cancer bone metastasis (T. Wang et al., 2015). 
Most papers show qualitative and subjective assessment of the expression while 
neglecting the quantitative analysis or vice versa. Our results show that metastatic OSCC 
has higher XCR1 expression with nearly 80% positive expression by the tumour. A 
transcriptomic analysis has revealed that low expression of XCR1 correlates with cancer 
progression and poor prognosis in hepatocellular carcinoma (Yanru et al., 2018) which 
is contradictory to our result. The paper also mentioned XCR1 associates with migration 
and invasion but not proliferation of liver cancer cells. This is probably the tissue bias of 
chemokine receptor, where it behaves differently in different type of tissue/cell. 
Histological quantification performed showed that XCR1 receptor expression was high 
(more than 80% of the observed tumour population) in both primary tumour and lymph 
node metastatic OSCC compared to normal tissue. Furthermore, our assessment was 
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performed on OSCC tissue samples investigating the XCR1 receptor protein expression 
rather than the transcriptomes. 
hLtn was found to be expressed in mammary gland yet no further description was 
available in breast cancer (Yang et al., 2017). hLtn mRNA was confirmed to be 
expressed in primary lung cancer and associated with bone metastasis in clinical 
samples (T. Wang et al., 2015). In ovarian carcinoma, hLtn was shown in both epithelial 
ovarian carcinoma ascites and cell lines (Kim et al., 2012).  
Connective tissue components such as endothelial cells also stained strongly for 
XCR1. This is important as OSCC cells can influence endothelial cells to form blood or 
lymphatic vessels resulting in angiogenesis and facilitating tumour growth and 
metastasis. This supports the idea that the hLtn and XCR1 interaction can contribute to 
angiogenesis in oral cancer, i.e. tumour or stromal can act on endothelial cells 
expressing XCR1 (Keeley, Mehrad and Strieter, 2011).  
Other chemokines have been shown to be important during cell development in 
zebrafish (Bussmann and Raz, 2015), directing cells to appropriate destination in the 
body. The XCR1/hLtn axis can recruit intraepithelial lymphocytes (IEL) to fight the 
infections and invasion as first line of defence as seen in intestinal immune homeostasis 
(Ohta et al., 2016). IEL has been shown to express XCR1 and hLtn (Khurram et al., 
2010), and can be a potential source of hLtn in the OSCC mucosa. This may further 
facilitate tumour cell migration and invasion. Our results also show lymphocytes 
expressing XCR1 in the superficial connective tissue near the basal oral epithelium with 
strong hLtn expression.  
The reactive lymph nodes stained positive for both hLtn and XCR1 suggesting 
XCR1/hLtn axis is integral in the organ. Lymph nodes contain T lymphocytes, natural 
killer cells, neutrophils and B lymphocytes and have been shown to express the XCR1 
receptor and its ligand (Kelner and Zlotnik, 1995; Kennedy et al., 2000; Huang et al., 
2001). Interestingly, expression can be seen in germinal centres, suggesting that XCR1 
and hLtn are involved in mature B cell proliferation and differentiation. There is strong 
evidence that the hLtn-XCR1 axis can activate MAPK signalling in cells to promote 
cellular division in cancer (Khurram et al., 2010; Yang et al., 2017). XCR1-hLtn 
interactions may contribute to B cell differentiation, but there is a lack of published 
evidence. Dendritic cells (DC) are involved in programming lymphocytes through 
antigen-presentation. Some evidence suggests that the XCR1-hLtn axis facilitates 
maintenance of immature dendritic cells by T lymphocytes (Park and Bryers, 2013; Ohta 
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et al., 2016). Follicular dendritic cells are involved in antigen processing with B cells (El 
Shikh et al., 2010), which is why the germinal centre stain positive for XCR1 .  
Previous studies have shown that human dendritic cells harvested from bone 
marrow do not express XCR1 receptor (Huang et al., 2001). Although some also reported 
that CD11c+CD141+ DC subsets originating from the same group do express XCR1 
(Bachem et al., 2010). This shows that only a certain subset of DC expresses XCR1, but 
these studies were performed using cells harvested from circulating plasmacytoid DC 
and not those that are resident in lymph nodes. Another study in mice showed that XCR1 
is expressed in a DC subset (Yamazaki et al., 2013) and the cross-presentation antigen 
contributes to recruitment of memory T cells in infection (Alexandre et al., 2016) and 
facilitates T cell survival (Ohta et al., 2016). In addition, the peripheral and stromal 
expression of XCR1 and hLtn may provide a platform for hLtn to attract XCR1+ 
carcinoma and contribute to growth, spread and intranodal extension into lymph nodes. 
In conclusion, the results provide information to support a possible route of lymph node 
metastasis through the XCR1-hLtn axis.  
The stromal expression seen in our results suggests that endothelial cells in 
normal, OSCC and lymph node tissue are positive for XCR1 and hLtn. Endothelial cells 
have been shown to express chemokine receptors that mediate endothelium organo-
specificity, however not much is known about XCR1 and hLtn endothelial cell expression 
in other organs (Hillyer and Male, 2005; Crola Da Silva et al., 2009). This is expected as 
chemokine-chemokine receptor interactions contribute to extravasation of lymphocytes 
into blood vessels, allowing them to patrol the circulatory system and move towards the 
site of injury or infection (Middleton et al., 2002). Dendritic cells also can move across 
lymphatic endothelium with using a similar mechanism (Vaahtomeri et al., 2017). 
Fibroblasts also expressed XCR1 with more prominent staining seen in the OSCC 
stroma. XCR1 expression by human gingival fibroblasts has also been reported in one 
study (Khurram et al., 2010) but a different study reported lack of expression 
(Buskermolen, Roffel and Gibbs, 2017). A possible explanation is probably due to 
fibroblast heterogeneity and differential expression between person to person (Sriram, 
Bigliardi and Bigliardi-Qi, 2015). 
The presence of hLtn was also seen in the extracellular matrix of oral tissue and 
lymph node stroma. The extracellular matrix is abundant with glycosaminoglycans (Yue, 
2014), which allows the hLtn dimer to bind (Fox, Tyler, et al., 2015) providing a gradient 
concentration in the stroma. The expression of XCR1 receptor and hLtn in OSCC and 
lymph node tissue can be summarized in Figure 2.9. The results suggest that hLtn and 
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XCR1 has the potential to influence oral cancer progression by moderating cancer cell 
survival and spread. 
 
2.6 SUMMARY 
This chapter shown that XCR1 receptor and its ligand expression are present in 
all investigated cases in both primary carcinoma and its metastatic counterpart. 
Metastatic stromal cells express higher total expression indicating its function further in 
the disease. Furthermore, XCR1 could be useful as an oral cancer biomarker. Additional 
data of XCR1 and hLtn expression in OSCC tissue are required to provide a statistically 
significant clinicopathological correlation.  
 
 
Figure 2.9: Summary map of XCR1 and hLtn expression based on IHC staining. 
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CHAPTER 3: REGULATION OF XCR1 AND XCL1 EXPRESSION IN ORAL CANCER 
CELL LINES BY hLtn & CONDITIONED MEDIA FROM ORAL FIBROBLASTS 
3.1 INTRODUCTION 
Chemokine receptors are very sensitive to external stimuli which leads to 
receptor desensitization through internalisation and recycling of the receptor (Ferguson, 
2001). This is highly dependent on external stimuli such as receptor activation upon 
ligand engagement (Kroeze et al., 2012), hypoxia (Schioppa et al., 2003), reactive 
oxygen species (Saccani et al., 2000), or change in pH and ionic strength (Dairaghi et 
al., 1997).  
Previous studies have shown that most chemokines can act in an autocrine 
manner (Kroeze et al., 2012). Expression of both hLtn and XCR1 by OCCL suggests that 
hLtn may have the potential to act on XCR1 expressing cells in an autocrine manner. 
The previous chapter gives us an insight into the expression of XCR1 receptor and its 
ligand by oral carcinoma tissue. Therefore, this chapter aimed to investigate whether 
exposure of oral cancer cells to wild type hLtn influences the expression of XCR1 
receptor at the mRNA level and protein expression on the cell surface. 
Additionally, this chapter will investigate the cross-talk between oral fibroblast and 
cancer cell lines. It is well known that cancer progression is highly influenced by the 
tumour microenvironment. This chapter investigates whether soluble factors expressed 
by oral fibroblasts can affect the expression of XCR1 receptor and hLtn by oral cancer 
cell lines (OCCLs). This was performed by exposing OCCLs to conditioned media from 
primary oral fibroblasts. Several types of oral fibroblasts were selected such as normal 
oral fibroblast (NOF), myofibroblasts (‘activated’ NOF), senescent NOF and cancer-
associated fibroblasts (CAF).  
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3.2 METHODS 
3.2.1 Materials 
List of detailed information of the materials (reagents, kits, equipment, software 
and miscellaneous) used in the chapter can be found in Appendix 1-5. 
 
3.2.2 Basic Cell Culture  
All oral cancer cell lines were acquired from the Department of Oral and 
Maxillofacial Pathology in the School of Clinical Dentistry, the University of Sheffield 
(Table 3.1). The human primary normal oral fibroblasts (NOF) were isolated as 
previously described by Hearnden et al. (2009) (Sheffield Research Ethics Committee 
Ref. 09/H1308/66) (Table 3.2). Human primary oral cancer-associated fibroblasts (CAF) 
were isolated from fresh tissue from patients with OSCC undergoing resections within 
Charles Clifford Dental Hospital (Sheffield Research Ethics Committee Ref. 13/NS/0120, 
STH17021; CAF002 and CAF004) were kindly provided by Amy Harding and Dr. Helen 
Colley (Kabir et al., 2016). All experiments were performed under sterile conditions in a 
Class II biohazard laminar flow cabinet. Good cell culture practice (GCCP) guidelines 
were exercised during the whole process.  
 
3.2.2.1 Passaging the Cells 
Cells were grown in T75 cell culture flasks with filter caps (Greiner Bio-One Ltd, 
UK) until ~80% confluent. Media was aspirated, and the cells washed with phosphate 
buffered saline (PBS) (Sigma-Aldrich, Dorset, UK) without Mg2+ or Ca2+. After two 
washes, PBS was removed. 2-3 mL of Trypsin-EDTA solution (Sigma-Aldrich) was 
added for 3-5 minutes at 37oC in an incubator. Cells were dislodged using gentle 
agitation and 3 mL of media added to the flask to neutralise the trypsin. This was 
transferred to a Falcon tube and centrifuged at 1000×g for 5 minutes. The supernatant 
was decanted, and the cell pellet re-suspended in fresh medium followed by addition to 
a new T75 flask. 
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Table 3.1: Table description of oral cancer cell lines and respective culture media. 
Cell line Description 
H357 
Description: Human oral squamous cell carcinoma from a 74-year-old male 
patient. Tissue origin: Tongue. (ECACC 06292004) 
Culture media: Keratinocytes growth media (KGM) (see Appendix 8) 
SCC4 
Description: Human squamous cell carcinoma from a 55-year-old male patient. 
Adherent cell line with epithelial-like morphology. Tissue origin: Tongue. (ATCC® 
CRL-1624) 
Culture media: Dulbecco’s Modified Eagle’s Medium (DMEM) (low glucose) and 
Ham’s Nutrient Mixture F12 combination (ratio 1:1) containing 10% FCS, 2 mM L-
glutamine and 1% (v/v) Penicillin/Streptomycin. 
FADU 
Description: Human squamous cell carcinoma derived from 56-year-old male 
patient. Adherent cell line with epithelial morphology. Tissue origin: Pharynx. 
(ATCC® HTB-43TM) 
Culture media: Eagle's Minimum Essential Medium (EMEM) containing 10% 
FCS, 2 mM L-glutamine and 1% (v/v) Penicillin/Streptomycin.  
TR146 
Description: Human oral squamous cell carcinoma derived from a 67-year-old 
female neck node. Tissue origin: Buccal. (ECACC 10032305) 
Culture media: HAMS-F12 containing 10% FCS, 2mM L-glutamine and 1% (v/v) 
Penicillin/Streptomycin 
BICR16 
Description: Adherent cell line derived from a recurrent OSCC of a Caucasian 
male. Tissue origin: Tongue. (ECACC 06031001) 
Culture media: DMEM (low glucose) containing 10% FCS, 2 mM L-glutamine and 
1% (v/v) Penicillin/Streptomycin. 
BICR22 
Description: Adherent cell line of a lymph node metastasis OSCC of a Caucasian 
male. Tissue origin: Tongue. (ECACC 04072106) 
Culture media: DMEM (low glucose) containing 10% FCS, 2 mM L-glutamine and 
1% (v/v) Penicillin/Streptomycin. 
All the information on the item catalogue number is available in Appendix 1 
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Table 3.2: Table description of human primary fibroblasts and their respective culture 
media. 
Cell line Description 
NOF 
Description: Human primary normal oral fibroblast extracted from the buccal of 
health volunteers attending the Charles Clifford hospital. Tissue origin: Buccal 
Culture media: Dulbecco’s Modified Eagle’s Medium (DMEM) (low glucose) 
containing 10% FCS, 2 mM L-glutamine and 1% (v/v) Penicillin/Streptomycin. 
CAF 
Description:  Human primary oral cancer-associated fibroblasts isolated from 
fresh tissue from patients with OSCC undergoing resections in Charles Clifford 
hospital. Tissue origin: CAF002 obtained from floor of the mouth and CAF 004 
from lateral tongue. 
Culture media: Dulbecco’s Modified Eagle’s Medium (DMEM) (low glucose) 
containing 10% FCS, 2 mM L-glutamine and 1% (v/v) Penicillin/Streptomycin. 
All the information on the item catalogue number is available in Appendix 1 
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3.2.2.2 Cell Storage in Liquid Nitrogen 
 Cells were counted, and a 1 × 106 cells/mL suspension prepared using 10% (v/v) 
dimethyl sulfoxide (DMSO) (Sigma-Aldrich) in growth medium. Then, 1 mL of the cell 
suspension was pipetted into a cryovial and sealed tightly. The cryovial was stored in a 
freezing container (Nalgene®, Sigma-Aldrich) containing propan-2-ol. The container was 
stored at -80oC for 24 hours before transferring the cryovial into a liquid nitrogen 
container. 
 
3.2.2.3 Thawing Cells from Liquid Nitrogen Storage 
A cryovial containing the desired cell line was removed from the liquid nitrogen 
container using appropriate safety protection and thawed in a 37oC water bath. The 
contents were transferred to a Falcon tube and 2 mL of respective growth media was 
added. The cell suspension was centrifuged (RT, 1000×g) for 5 minutes to remove 
DMSO from the solution. The pellet was re-suspended in 1 mL respective growth media 
and transferred to a T75 flask. 10 mL media was added afterwards and incubated in 5% 
CO2 at 37oC. The growth medium was replaced every 2-3 days. 
 
3.2.2.4 Quantification of cell number and concentration 
The number of cells present in a suspension was quantified using a 
haemocytometer with Trypan blue exclusion. The cells were collected as described in 
Section 3.2.2.1 and resuspended in 2-5 mL growth medium. 5 µL of cell suspension was 
mixed with an equal amount of Trypan blue solution 0.4% (Sigma-Aldrich, UK) was 
transferred haemocytometer with a glass cover slip. Living cells do not take-up the dye, 
while the dead cells are stained blue. The total number of viable cells was estimated as 
below: 
 
  
Number of viable cells
mL
 = 
n × dilution factor × 104
4
  
n = total number of cell in four squares 
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3.2.3 Flow Cytometry Analysis for XCR1 Surface Receptor Expression 
Principle: Flow cytometry is a powerful tool to analyse the surface protein expression. 
This can be performed by either using a directly conjugated antibody or unconjugated 
antibody, where the latter requires addition of appropriately labelled-secondary antibody 
for detection. Propidium iodide (PI), a fluorescent DNA intercalating agent can assist in 
the evaluation cell viability. PI is unable to cross a healthy cell membrane allowing it to 
distinguish live and dead cells in flow cytometry analysis. Dead cells tend to bind non-
specifically to many reagents leading to a false positive result.  
Procedure: Cells were washed and fully detached using cell-dissociation buffer (Cat#: 
13151014; Thermo Fisher Scientific, Paisley, UK). Detached cells were then re-
suspended in serum free medium at a density of 1 × 105 cells per tube. Tubes were 
centrifuged at 500×g for 5 minutes at room temperature and the supernatant was 
carefully removed. 500 µL of flow buffer (PBS + 10% FCS) was added to each tube. 10 
µg/mL of anti-XCR1 human antibody (extracellular domain) IHC-plusTM LS-A158 (human 
anti-rabbit) (LifeSpan Bioscience Inc., WA, USA) was added for 60 minutes on ice. 
Unbound antibody was removed using three washes in flow buffer. Cells were re-
suspended in 500 µL of flow buffer followed by addition of 8 µg/mL goat anti-rabbit IgG 
(H+L) secondary antibody, Alexa Fluor® 488 conjugate (Life Technologies Ltd, Paisley, 
UK). All steps were performed on ice with minimal exposure to light. Cells were incubated 
with the secondary antibody 30 minutes followed by three further washes. Cells were re-
suspended in 500 µL flow buffer and kept on ice before flow cytometry cell analysis using 
BD FACSCalibur (BD Bioscience) with BD CellQuestTM Pro software (BD Bioscience, 
Oxford, UK). Prior to the run, all samples were treated with propidium iodide (1 µg/mL) 
for cell viability evaluation. The run was stopped when the 10,000 cells threshold was 
reached. The data analysis was performed using FlowJo (LLC, USA). For the 
assessment of the effect of hLtn on the XCR1 receptor expression, the OCCLs were 
treated with hLtn (Peprotech) (concentration: 100 ng/mL) in low-serum medium 
(containing 1% FCS) (LSM) for 24 hours at 37oC. The vehicle control flask was incubated 
with LSM only. 
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3.2.4 mRNA Expression Analysis 
qPCR is a powerful tool to quantify mRNA expression of target genes in cells. It 
requires RNA extraction from the cells followed by RNA translation into complementary 
DNA (cDNA). This is because the primer probe for real-time PCR requires DNA for 
amplification. The primer probe with a fluorescence label binds to complementary 
sequence on the DNA strands. When it is amplified, a fluorescence signal is induced and 
quantified. Two different systems are usually employed: SYBR green and TaqMan 
probe. While SYBR green is cheap and easy to use, TaqMan is more specific and 
sensitive (Soltany-Rezaee-Rad et al., 2015). In this study, real-time PCR was performed 
using TaqMan probes for XCR1 and hLtn while for α-SMA, SYBR Green technique was 
employed.  
 
3.2.4.1 Total RNA Extraction and Purification from Cultured Cells 
The extraction and purification of RNA from cultured cells was carried out using 
an ISOLATE II RNA Mini Kit (Cat#: BIO-52072; Bioline Reagents Limited, London, UK) 
in accordance with the manufacturer’s instructions. The samples were homogenised by 
adding 350 µL of lysis buffer RLY (containing 250 µL lysis buffer RLY and 3.5 µL β-
mercaptoethanol) per sample and vortexed vigorously. The lysate was filtered by loading 
into a 2 mL collection tube through an ISOLATE II filter (violet) and centrifuged (1 min at 
11,000×g). The filter was discarded, and RNA binding conditions were adjusted by 
adding 350 µL 70% ethanol to the homogenised lysate followed by mixing using a 
pipette. The ISOLATE II RNA mini column (blue) was placed in a 2-mL collection tube 
for RNA binding. The cell lysate was loaded onto the column and centrifuged (30 s at 
11,000×g). A new collection tube was then used and 350 µL of membrane desalting 
buffer (MEM) was used to desalt the silica membrane. Centrifugation was performed to 
dry the membrane (1 min at 11,000×g). DNase I was prepared by adding 10 µL DNase 
I to 90 µL reaction buffer for DNase I (RDN). 95 µL of the mixture was applied directly to 
the centre of the silica membrane which was incubated at room temperature for 15 
minutes. Three washing steps were carried out: the first wash using 200 µL wash buffer 
RW1, the second wash and third washes using 600 µL wash buffer RW2. Each washing 
step required centrifugation (30 s at 11,000×g for the first and second and 2 minutes at 
11,000×g for the third wash). After the third wash, the column was placed into a 
nuclease-free 1.5 mL collection tube (supplied with the kit) to collect the RNA. Elution 
was performed by adding 60 µL of RNase free H2O directly to the centre of silica 
membrane, incubating for 1 minute and then centrifuging at 11,000×g) for a minute. The 
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concentration of eluted RNA was estimated using a NanoDrop 1000 Spectrophotometer 
(Thermo Scientific, DE, USA). For storage, RNA was kept at -80°C. 
 
3.2.4.2 Measurement of RNA concentration and purity 
High purity of the extracted RNA is essential, and the observed A260/280 ratio 
must be ~2.0. The RNA concentration required for cDNA reverse transcription was 
calculated using the equation below. 
 
  
Total volume of RNA required (per 10mL) = 
100 ng/mL
Total concentration of RNA (ng)
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3.2.4.3 High Capacity cDNA Reverse Transcription 
Reverse transcription is required as the qRT-PCR probe can only be used on 
DNA. Therefore, transcription of RNA samples is essential and was carried out using 
High Capacity cDNA Reverse Transcription Kit (Cat#: 4368814; Life Technologies Ltd, 
Paisley, UK). The master mix solution (reagents supplied in kit) was prepared (see Table 
3.3). The components were thawed and placed on ice. 
Table 3.3: High Capacity cDNA RT master mix (all supplied in the kit). 
Components 
Volume/Reaction (µL) 
with MultiscribeTM without MultiscribeTM 
10× RT Buffer 2.0 2.0 
25× dNTP Mix (100 mM) 0.8 0.8 
10× RT Random Primers 2.0 2.0 
MultiscribeTM Reverse Transcriptase 1.0 - 
RNase Inhibitor 1.0 1.0 
Nuclease-free H2O 3.2 4.2 
TOTAL per reaction 10.0 10.0 
 
10 µL of RT master mix was pipetted into individual PCR tubes along with 10 µL 
of the RNA sample. 500 ng of RNA was used per sample reaction. Samples were briefly 
centrifuged to spin down the contents and eliminate any air bubbles. The tubes were 
then placed in DNA Engine Dyad® Peltier Thermal Cycler (Bio-Rad Laboratories Ltd., 
Hertfordshire, UK) to run on a set programme (see Table 3.4). For the negative control, 
nuclease-free H2O was used. Each RNA sample is prepared with and without Multiscribe 
to determine the extent of RNA contamination and the effectiveness of real-time PCR. 
cDNA was stored at -20°C prior to further use. 
Table 3.4: Thermal cycler programme for cDNA RT reaction. 
 Step 1 Step 2 Step 3 Step 4 
Temperature (°C) 25 37 85 4 
Time (min) 10 120 5 ∞ 
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3.2.4.4 Quantitative Real-time PCR (qRT-PCR) using Taqman probe 
cDNA quantification for XCR1 and hLtn (XCL1) mRNA was performed using 
TaqMan probes (information available in Table 3.5). The XCR1 specific primers were 
ordered from Life Technologies. To analyse the data, primers to β-2-microglobulin (B2M) 
was used as an endogenous control. A control tube with nuclease-free water was 
included to ensure the integrity of the sample run. 
The master mix solution (including the probes) (see Table 3.5) was prepared and 
mixed gently. 9.5 µL of this solution was pipetted into respective wells of a 96 well PCR 
semi-skirted plate (STARLAB (UK) Ltd, Milton Keynes, UK). 0.5 µL of cDNA samples 
were added to respective wells and nuclease-free water used in negative control wells. 
The plate was sealed using advanced polyolefin StarSeal film (STARLAB (UK) Ltd, 
Milton Keynes, UK). All components were thawed on ice prior to preparation. 
Table 3.5: TaqMan master mix. 
Component Volume (µL) 
TaqMan Gene Expression Master Mix  
(Cat#:4369016; Life Technologies, Paisley, UK) 
5.0 
B2M probe (TaqMan Gene Expression Assays) 
(Cat#:4331182; Life Technologies, Paisley, UK)  
Amplicon length: 64  
R
e
fe
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n
c
e
 
g
e
n
e
 
0.5 
XCR1 probe (TaqMan Gene Expression Assays) 
(Cat#:4331182; Life Technologies, Paisley, UK)  
Amplicon length: 61 
T
a
rg
e
t 
g
e
n
e
 
0.5 
XCL1 probe (TaqMan Gene Expression Assays) 
(Cat#:4331182; Life Technologies, Paisley, UK)  
Amplicon length: 108 
Nuclease-free water (Cat#:AM9914G; Life Technologies, Paisley, UK) 3.5 
TOTAL per each sample 9.5 
 
The plate was centrifuged (1000×g, 2mins, RT) before being loaded into the 
7900HT Fast Real-Time PCR System (Life Technologies Ltd, Paisley, UK). The desired 
setting on SDS v2.4 (Life Technologies Ltd, Paisley, UK) was chosen before the run and 
RQ Manager 1.2.1 software (Life Technologies Ltd, Paisley, UK) was used as an 
analysis and quantification tool.  
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3.2.4.5 Quantitative Real-time PCR (qRT-PCR) using SYBR Green. 
The quantification of the α-SMA cDNA was performed using a SYBR Green 
technique. The primers with specified sequence was purchased from Sigma-Aldrich 
(Table 3.6). The endogenous control of U6 snRNA was used.  
Table 3.6: List of primers for mRNA expression analysis using SYBR Green technique. 
Name Sequence Supplier 
U6 snRNA 
(Reference gene) 
Fwd 5’-CTCGCTTCGGCAGCACA-3’ 
Sigma-Aldrich, 
UK 
Rev 5’-AACGTTCACGAATTTGCGT-3’ 
α-SMA 
(Target gene) 
Fwd 5’-GAAGAAGAGGACAGCACTG-3’ 
Rev 5’-TCCCATTCCCACCATCAC-3’ 
The melting curve of the primers are available in Appendix 9. 
 
The master mix solution was prepared and mixed gently (Table 3.7). The solution 
was then pipetted into respective wells of a 96 well PCR semi-skirted plate (STARLAB 
(UK) Ltd, Milton Keynes, UK) and 0.5 µL of cDNA samples were added into respective 
wells. Nuclease-free water used in negative control wells. The plate was sealed using 
advanced polyolefin StarSeal film (STARLAB (UK) Ltd, Milton Keynes, UK). All 
components were thawed on ice prior to preparation. The reference and target gene 
samples were prepared separately. 
Table 3.7: SYBRTM Green Master Mix 
Component Volume (µL) 
SYBRTM Green PCR Master Mix (Cat#:4309155; Thermo-Fisher Scientific, 
Paisley, UK) 
5.0 
Forward primer (concentration: 20 µg/mL) 0.5 
Reverse primer (concentration: 20 µg/mL) 0.5 
Nuclease-free water (Cat#:AM9914G; Life Technologies, Paisley, UK) 3.5 
TOTAL per each sample 9.5 
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3.2.4.6 qRT-PCR Analysis 
The quantitation of the qRT-PCR data was performed using the ∆∆Ct method 
(Livak and Schmittgen, 2001; Schmittgen and Livak, 2008). The relative expression 
levels were calculated and compared between the untreated samples (treatment control) 
and treated samples. These samples were compared to respective reference gene of 
the samples (housekeeping gene) to normalize the variation in individual sample quality 
and quantity. The normalized values (∆Ct value) were then used to calculate the ∆∆Ct 
values using the equation below. 
 
 
3.2.5 Exposure of Oral Cancer Cell Lines (OCCLs) to Oral Fibroblast Conditioned 
Media 
Procedure: Normal oral fibroblast (NOF) and cancer-associated fibroblast (CAF) cells 
were derived as described in Section 3.2.2. The NOF cells were also differentiated into 
myofibroblasts and senescence fibroblasts (Section 3.2.6 and 3.2.7 respectively). The 
cells were left in SFM for another 24 hours to obtain the ‘conditioned media’. Conditioned 
media was recovered, filter-sterilised (0.22 µm) to remove cell debris and either used 
immediately for experimentation or stored at -20°C until required. Concurrently, the 
OCCLs were seeded and incubated with SFM for 24 h prior treatment with conditioned 
media obtained from the oral fibroblasts. Additionally, for senescent NOFs, the cells were 
induced with genotoxic stimuli and cultured for 14 days before collecting conditioned 
media (details available in Section 3.2.7). For vehicle control, the oral cancer cells were 
treated only with SFM. The summary of the experiment can be found in Figure 3.1 and 
Figure 3.3. 
 
 
Calculation for the ∆Ct values of the treated and untreated samples 
∆Cttreated = ∆Ct targettreated  −  ∆Ct referencetreated 
∆Ctuntreated = ∆Ct targetuntreated  −  ∆Ct referenceuntreated 
 
∆∆Ct value for the treated samples 
∆∆Ct sampletreated = ∆Ct sampletreated  −  ∆Ct sample untreated 
Relative Quantification (RQ) = 2-∆∆Ct 
Fold difference = log 2 (RQ) = -∆∆CT 
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Figure 3.1: Experimental design for the treatment of OCCLs with conditioned medium 
from NOF, myofibroblast and CAF on OCCLs.  
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3.2.6 Transforming Growth Factor-beta 1 (TGF-β1) Treatment of Normal Oral 
Fibroblast 
Procedure: The cells were seeded at an appropriate cell density and left to attach for 
overnight. Before treatment with 5 ng/mL of TGF-β1 (R&D system, Abingdon, UK) for 24 
hours, the cells were cultured in serum-free media (SFM; containing DMEM 
supplemented with 2mM L-glutamine.  
 
3.2.6.1 Immunocytochemistry 
Procedure: Coverslips were sterilised with 70% ethanol for at least 10 minutes followed 
by washing twice with PBS and leaving to dry. 5 × 104 cells were seeded onto each 
coverslip and left to attach overnight in an incubator at 37°C. Medium was aspirated, and 
cells were washed with PBS three times. Cells were fixed using 100% methanol at room 
temperature for 20 minutes before the cells were permeabilized with 4 mM sodium 
dexoxycholate in dH2O for another 10 minutes. Cell were then incubated with blocking 
buffer (2.5% (w/v) BSA in PBS) for 30 min before antibody treatment to reduced non-
specific binding. Incubation with an α-SMA FITC-conjugated primary antibody (1:100 in 
blocking buffer) (Cat#: ab8211, Abcam, Cambridge, UK) was performed for an hour at 
37ºC in the dark. Coverslips were then washed with PBS three times before addition of 
a drop of VectaShield antifade mounting medium with DAPI (Cat#: H-1200; Vector 
Laboratories, Peterborough, UK). Coverslips were then carefully transferred onto glass 
slides before viewing the staining using a fluorescence microscope. Nail polish can be 
used to immobilize and seal the coverslip. The slides were kept covered in aluminium 
foil at 4°C for storage and analysed as soon as possible to reduce the chance of photo-
bleaching. 
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3.2.7 Senescence-induced Normal Oral Fibroblast with Genotoxic Stimuli 
Principle: Senescent cells behave differently to normal cells. It is a state where the cells 
do not grow but are still able to perform functions such as synthesis and secretion of 
proteins. NOF cells were treated with hydrogen peroxide (H2O2) to induce oxidative 
stress allowing pre-mature senescent within a short period of time (Chen, Ozanne and 
Hales, 2007).  
Procedure:   NOFs were to approximately 70% confluence before treatment with 500 
µM H2O2 (Cat#: 10687022; Fisher Chemical, Loughborough) in serum-free media for 2 
hours. Immediately after incubation, the H2O2 was removed and the cells were left in 
growth media for 14 days to allow cells to senesce. Media was changed every 2-3 days.  
To determine if the induction of senescence was successful, senescence-associated β-
galactosidase staining assay was performed (refer Section 3.2.7.1). 
 
3.2.7.1 Senescence-Associated β-galactosidase Staining Assay 
Principle: This assay is to determine cellular senescence by using β-galactosidase as 
a biomarker (Debacq-Chainiaux et al., 2009). Senescence is characterized by arrest 
growth and inability to undergo DNA synthesis, a characteristic shared with quiescent 
cells. Although the enzyme overexpression and accumulation are specific to senescent 
cells, it is not required during the process to senescence. The X-gal reacts with the β-
galactosidase enzyme that accumulates in senescent cells and reacts to form a blue 
precipitate indicating positive cell senescence (Figure 3.2). 
 
Figure 3.2: Principle of the β-galactosidase assay. X-gal reacts with β-galactosidase 
yielding galactose and (A) 5-bromo-4-chloro-3hydroxyindole. Later this spontaneously 
dimerizes and oxidized into (B) 5,5’ dibromo-4,4’-dichloro-indigo, an intense insoluble 
blue precipitate. 
 
(B) (A) 
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Procedure: The assay was performed using a senescence detection kit (Cat#: ab65351 
Abcam). 1 × 104 cells were seeded per well of reaction for 24 h. Cells were washed with 
PBS twice before adding 500 µL of fixative solution for 20 minutes. A total of 500 µL of 
staining solution was added to each well overnight in an incubator at 37ºC 5% CO2. The 
plate was covered in aluminium foil to exclude light. The composition of the staining 
solution is as below: 
 25 µL of 20 mg/mL X-gal (20 mg/mL 20 mg lyophilized X-gal was dissolved in 1 
mL DMSO), 
 470 µL of 1× staining solution, and 
 5 µL of staining supplement. 
For analysis, a light bright-field microscope with attached camera was used to estimate 
the percentage of blue stained cells per microscopic field. 
 
3.2.8 Statistical Analysis 
All the experimental data are presented as at least three independent 
experiments performed in triplicate unless stated otherwise with mean ± SEM. Student’s 
t-test was used to analyse the statistical significance of XCR1 mRNA and protein 
expression, and hLtn (XCL1) mRNA expression of the treatment sample compared to 
the experimental control using Graph Pad Prism 7 (La Jolla, CA, USA). All the mRNA 
data analysis in this chapter were compared to a normalised vehicle control (in fold 
change). A p-value <0.05 was considered as statistically significant and denoted with * 
symbol.  
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Figure 3.3: Experimental design for treatment of OCCLs with CM from senescent-NOFs. 
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3.3 RESULTS 
3.3.1 Effect of hLtn on XCR1 Surface Expression in OCCL 
3.3.1.1 XCR1 Surface Receptor Expression in OCCL 
An initial experiment was performed to quantify the surface expression of the 
XCR1 receptor in different oral cancer cell lines (refer Table 3.1). All the selected cancer 
cell lines expressed the receptor to varying degrees (Figure 3.4) The highest expression 
was seen in SCC4 cell line with more than 88% ± 2.256 of the cell population expressing 
XCR1 and the lowest was by H357 cell line with 29% ± 2.829. SCC4 cells showed a 
wider forward-scatter cell population suggesting that the cell size is larger than all other 
cell lines, possibly providing a larger surface area for XCR1 receptor on its surface. 
TR146, FADU and BICR22 cell lines all showed moderate expression (mean 32% ± 
0.6658, 36% ± 0.2999 and 42% ± 3.732 respectively). BICR16 cell line, a recurrent 
carcinoma has quite a high expression of XCR1 receptor with 68% ± 0.2848 expression. 
Further information on the flow cytometry analysis such the dot plot for the size scatter-
gram, dot-plot channel for cell viability and target protein are available in Appendix 10. 
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Figure 3.4: Oral cancer cell lines surface expression of XCR1 receptor. (A) Histogram 
diagram of XCR1 receptor expression for each cell lines, where shift to the right signifies 
greater expression of XCR1 in the cell population. (B) Bar chart summarising the 
percentage expression. Three independent experiments were performed with triplicates. 
Data is expresses in mean ± SEM.  
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3.3.1.2 Regulation of XCR1 Receptor Expression in OCCL through hLtn 
Stimulation 
This part of the study was to observe whether hLtn can act in an autocrine manner 
and influence expression of its receptor. Several oral cancer cell lines were used to 
compare the receptor expression (refer Table 3.1). The oral cancer cell lines: H357, 
SCC4, FADU, TR146, BICR16 and BICR22 were derived from OSCC. 
Positive expression of XCR1 on normal oral keratinocytes and OCCLs has been 
reported previously (Khurram et al., 2010). XCR1 cell surface expression was observed 
in all the tested cell lines in the current study (refer Figure 3.4).  For the surface protein 
expression (Figure 3.5), only the oral squamous cell carcinoma-derived cell lines (H357, 
SCC4 and FADU) showed significant changes in their surface XCR1 expression after 
exposure to hLtn (100 ng/mL) for 24 hours. FADU showed an increase (~16%) and SCC4 
showed a decrease (p=0.0145) of the XCR1 surface receptor expression (refer to Table 
3.8 for the mean and p-value). H357 surface XCR1 expression was reduced by 8% while 
FADU showed an increase ~16% in the surface receptor expression after the treatment. 
BICR22, TR146 (both lymph node metastatic-derived cell lines), and BICR16 (a 
recurrent carcinoma-derived) showed a trend for decreased in receptor expression but 
this reduction was not significant.  
Exposure to 100 ng/mL hLtn resulted in a significant upregulation in the XCR1 
mRNA expression in SCC4 cells (mean 1.287 ± 0.05785, p=0.0077) but not in other cell 
lines (Figure 3.6). 
Table 3.8: Result of XCR1 expression after treatment with hLtn for 24 hours. 
Cell 
line 
XCR1 Expression (%) 
p-value 
Untreated Treated Differences 
SCC4 88.67 ± 2.256 72.83 ± 3.099 -8.14 ± 2.839 0.0145* 
H357 36.66 ± 0.299 29.02 ± 3.323 -15.83 ± 3.833 0.0456* 
FADU 39.13 ± 2.829 55.37 ± 4.720 +16.23 ± 5.503 0.0420* 
TR146 42.00 ± 3.732 36.37 ± 0.203 -5.633 ± 3.738 0.2063 
BICR16 68.83 ± 0.285 62.37 ± 3.340 -6.467 ± 3.352 0.1259 
BICR22 32.80 ± 0.666 20.63 ± 6.274 -12.17 ± 6.309 0.1260 
* indicates p<0.05 
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Figure 3.5: Percentage of XCR1 expression by the oral cancer cell lines (OCCLs). The 
bars with white-box pattern represent the respective OCCLs (colour coded) without 
treatment and the fully coloured bars represents the OCCLs exposed to hLtn (Peprotech) 
treatment (100 ng/mL). FADU cells showed an upregulation of the surface protein 
receptor (in dashed box) compared to other OCCLs. Three independent experiments 
were performed with triplicates with error bar in SEM. (* p-value<0.05, ** p-value<0.01, 
and NS is not significant).  
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Figure 3.6: XCR1 mRNA expression. The OCCLs were treated with hLtn (100 ng/mL) 
(Peprotech) for 24 hours. The relative expression was compared to the endogenous 
control of β-2-myoglobulin (B2M) and expressed as fold change (normalised to control). 
The graph represents minimum and maximum (with median line). (** p-value<0.01, and 
NS is not significant).  
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3.3.2 Effect of Normal Oral Fibroblast, Myofibroblast, and Cancer-associated 
Fibroblast Conditioned Medium on the Expression of XCR1 and hLtn mRNA 
by OCCLs. 
Oral fibroblasts comprise most of the mesenchymal cells in the oral stroma. 
Therefore, to study their interaction with the oral cancer cells, we investigated several 
types of oral fibroblasts that can exist in an OSCC stroma; including normal oral fibroblast 
(NOF), myofibroblasts and cancer-associated fibroblasts (CAF). Indirect co-culture was 
used to study the effect of secreted factors in the media (conditioned media) by NOF, 
myofibroblast and CAF on oral cancer cell lines (OCCLs) and the level of expression of 
XCR1 receptor and XCL1 (hLtn) determined. 
 
3.3.2.1 Phenotype Assessment of α-SMA expression for Oral Fibroblast 
Cells.  
The α-SMA protein expression was compared between the normal oral fibroblast 
(NOF804 was used in this experiment) and its myofibroblast counterpart (or ‘activated’ 
NOF). TGF-β1 exposure resulted in an increase in α-SMA protein in NOF (Figure 3.7) 
after 24 hours and the expression lasted for a further 24 hours in serum-free media 
(Figure 3.8). No noticeable expression was seen in NOF without the treatment. Cancer-
associated fibroblast (CAF), expressed the α-SMA protein without exposure to TGF-β1 
(Figure 3.9). Preliminary exposure of TGF-β1 to CAF showed no impact on the α-SMA 
fibres expression. Phenotypically, our result showed that cancer-associated fibroblasts 
are similar to the oral myofibroblast. 
For the α-SMA mRNA expression (Figure 3.10), the results were similar to 
protein expression. The relative expression was compared to the endogenous 
housekeeping U6 small nuclear RNA (U6 snRNA). Normal oral fibroblasts (NOF804) 
exposed to TGF-β1 for 24 hours, and cancer-associated fibroblasts (CAF002 and 
CAF004) had a similar high relative expression of α-SMA mRNA (p=0.0152, p=0.0091 
and p=0.005 respectively).  α-SMA mRNA expression was detected even in unstimulated 
cancer-associated fibroblasts.  
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Figure 3.7: Representative photomicrograph of α-SMA expression seen by 
immunofluorescence in normal oral fibroblast (NOF804). The treatment consists of (A) 
without and (B) with 5ng/mL of TGF-β1 treatment after 24 hours. The cell nucleus is 
stained in blue (DAPI) and the α-SMA fibres in green (FITC). (Magnification: 400×). 
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Figure 3.8: Representative photomicrograph of α-SMA immunofluorescence expression 
in stimulated normal oral fibroblast (NOF804). The treatment consists of (A) without and 
(B) with 5 ng/mL of TGF-β1 treatment for 24 hours and further left in SFM for another 24 
hours (total of 48 hours). The cell nucleus is stained in blue (DAPI) and the α-SMA fibres 
in green (FITC). (Magnification: 400×). 
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Figure 3.9: Representative photomicrograph of α-SMA immunofluorescence of cancer-
associated oral fibroblast (CAF). Two populations of CAF were stained (refer Table 3.2 
for the tissue origin): (A) CAF002 (from floor of the mouth) and (B) CAF004 (from lateral 
tongue). The cell nucleus is stained in blue (DAPI) and the α-SMA fibres in green (FITC). 
(Magnification: 400×). 
  
DAPI   α-SMA 
DAPI   α-SMA 
(A) 
(B) 
C
A
F
0
0
4
 
C
A
F
0
0
2
 
Chapter 3: Regulation of XCR1 and XCL1 Expression in Oral Cancer Cell Lines by hLtn and by 
Conditioned Media from Oral Fibroblasts 
Functional Role of the Chemokine Receptor XCR1 and Its Bioengineered Ligand in Oral 
Squamous Cell Carcinoma 103 
 
Figure 3.10: α-SMA mRNA expression in oral fibroblasts. Normal oral fibroblasts (NOF) 
were exposed to TGF-β1 (5 ng/mL) (Abcam) for 24 hours to promote transformation into 
myofibroblasts. Similarly, additional 24 hours of treatment in SFM was performed to 
compare the expression. Cancer-associated fibroblasts were not treated and αSMA 
expression compared to NOF in fold change (normalise to control). Endogenous control 
to U6 snRNA was used. The graph represents with minimum to maximum (with median 
line). (* p-value<0.05, ** p-value<0.01, and NS is not significant). 
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3.3.2.2 Effect of Conditioned Media from Normal Oral Fibroblast, 
Myofibroblast, and Cancer-associated Fibroblast on OCCL XCR1 and 
hLtn mRNA Expression. 
In continuation from the phenotype assessment of the oral fibroblast derivatives, 
an experiment was performed to investigate the effect of conditioned media (CM) derived 
from the fibroblasts on selected oral cancer cell lines, SCC4 and H357 cells by using an 
indirect co-culture method. After the exposure to the CM for 24 hours, both the mRNA 
expression of XCR1 and hLtn were investigated.  
The XCR1 mRNA expression by SCC4 cells was upregulated after the treatment 
with CM derived from normal oral fibroblast (NOF), and the cancer-associated fibroblasts 
(CAF002 and CAF004) (Figure 3.11 (A)). The highest XCR1 mRNA fold increase was 
from exposure to CM derived from NOF (mean 2.57 ± 0.284), followed by CAF002 (mean 
2.213 ± 0.2113) and CAF004 (mean 1.453 ± 0.1473) which was significant when 
compared to normalised vehicle control (treated with SFM only) (p=0.0052, p=0.0046, 
and p=0.0371 respectively). Interestingly, CM from myofibroblasts showed a significant 
downregulation of XCR1 mRNA expression in SCC4 (mean 0.4426 ± 0.1354, p=0.0146). 
In the case of XCL1 mRNA expression by SCC4 cells, a similar trend was seen 
(Figure 3.11 (B)). However, only exposure to the CM from myofibroblasts (mean 0.3372 
± 0.1264, p=0.0146) and CAF004 (mean 1.633 ± 0.1768, p=0.0232) showed a significant 
change. The result was similar to that in XCR1 where CM from myofibroblast upregulate 
and CAF004 downregulated the XCL1 mRNA expression. 
For H357 cells, we observed that the XCR1 mRNA expression had a similar trend 
to SCC4 cells (Figure 3.12 (A)). CM from NOF caused significant upregulation of XCR1 
mRNA in H357 cells (mean 2.68 ± 0.5961, p=0.0479). In contrast to CM from 
myofibroblasts, the mRNA expression was significantly downregulated (mean 0.4844 ± 
0.0334, p=0.0001). Both CM from CAF002 and CAF004 showed no significant changes 
in the mRNA expression. 
Expression of XCL1 mRNA in H357 cells (Figure 3.12 (B)) was significantly 
downregulated after exposure to CM from myofibroblasts (mean 0.3608 ± 0.1252, 
p=0.0069). Both CAF002 and CAF004 conditioned media displayed a significant 
upregulation in the XCR1 mRNA expression in H357 cells (mean 2.306 ± 0.3538, 
p=0.021 and mean 1.629 ± 0.167, p=0.0197 respectively).  
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Figure 3.11: mRNA expression of SCC4 cells after exposure to conditioned media from 
normal oral and cancer-associated fibroblasts (NOF and CAF respectively). The relative 
quantification of (A) XCR1 and (B) XCL1 mRNA expression was compared to the 
normalised control (in fold change). Endogenous control to B2M was used. The graph 
represents with minimum to maximum (with median line). (* p-value<0.05, ** p-
value<0.01, and NS is not significant). 
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Figure 3.12: mRNA expression of H357 cells after exposure to conditioned media from 
normal oral and cancer-associated fibroblasts (NOF and CAF respectively). The relative 
quantification of (A) XCR1 and (B) XCL1 mRNA expression was compared to the 
normalised control (in fold change). Endogenous control to B2M was used. The graph 
represents with minimum to maximum (with median line). (* p-value<0.05, ** p-
value<0.01, *** p-value<0.001, and NS is not significant).  
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3.3.3 Effect of Senescence-induced Fibroblast Conditioned Medium on OCCLs 
XCR1 and hLtn mRNA Expression. 
In Chapter 2, results show that the XCR1 expression in OSCC was upregulated 
compared to its normal counterpart. The epidemiological data on oral cancer shows a 
significantly increased risk of disease in patients over 45 with further increased rate with 
ageing (Ram et al., 2011). Cellular senescence is highly associated with age, 
contributing to higher risk of developing further disease (van Deursen, 2014; Childs et 
al., 2015). Senescent fibroblast have been shown to have the potential to promote 
tumorigenesis (Krtolica et al., 2001). Therefore, in this sub-chapter we investigated the 
potential of cross-talk between senescence fibroblasts and oral cancer cells in relation 
to chemokine receptor XCR1 and its ligand hLtn. 
 
3.3.3.1 Phenotype Assessment of the Senescence-induced Oral Fibroblast 
Cells. 
X-gal staining was used to compare senescence in normal oral fibroblast cultures 
(Figure 3.13). A small percentage of senescent cells was detected in NOF (mean 11.6% 
± 1.435) following hydrogen peroxide for 2 hours and 14 days in growth media, more 
than 80% of the NOFs were senescent compared to NOF (p<0.0001).  
 
3.3.3.2 Effect of Conditioned Media from Senescence-induced Normal Oral 
Fibroblast on OCCLs XCR1 and hLtn mRNA Expression. 
Following the assessment of the senescence phenotype assessment, the 
conditioned media from s-NOF was collected and used to study its effect on XCR1 and 
hLtn mRNA expression in SCC4 and H357 cells by using an indirect co-culture method. 
After the exposure to the CM for 24 hours, mRNA expression of XCR1 and hLtn was 
examined.  
The SCC4 cells showed a significant downregulation in both XCR1 (mean 0.3214 
± 0.07342, p=0.0008) and hLtn (mean 0.0076 ± 0.0015, p<0.0001) mRNA expression 
when compared to the normalised vehicle control (Figure 3.14). No significant changes 
in H357 cells in either mRNA expression level was observed.  
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Figure 3.13: Senescence-associated β-galactosidase (SA-β-gal) assay of senescence 
normal oral fibroblast (s-NOF804). (A) Representative image of the cells with and without 
hydrogen peroxide treatment for 2 hours after 14 days. (B) The percentage of senescent 
cells with and without treatment with 500 µM H2O2 (an average of five different optical 
views) with SEM. (**** p-value<0.0001). (Total magnification: 400×). 
  
  
(A) 
(B) 
SA-β-gal 
W
it
h
o
u
t 
H
2
O
2
 t
re
a
tm
e
n
t 
W
it
h
 H
2
O
2
 t
re
a
tm
e
n
t 
Chapter 3: Regulation of XCR1 and XCL1 Expression in Oral Cancer Cell Lines by hLtn and by 
Conditioned Media from Oral Fibroblasts 
Functional Role of the Chemokine Receptor XCR1 and Its Bioengineered Ligand in Oral 
Squamous Cell Carcinoma 109 
 
Figure 3.14: mRNA expression of SCC4 (in red) and H357 (in blue) cells after exposure 
to the conditioned media from senescence-induced normal oral fibroblast (s-NOF804). 
The relative quantification of (A) XCR1 and (B) XCL1 mRNA expression was compared 
to normalised control (in fold change). Endogenous control to B2M was used. The graph 
is represented with min to max bar (with median line). (*** p-value<0.001, **** p-
value<0.0001, and NS is not significant).  
(B) 
(A) 
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3.4 DISCUSSION 
3.4.1 Regulation of XCR1 Surface Expression in OCCL through hLtn Stimulation. 
XCR1 receptor expression has been shown in oral normal and carcinoma tissue, 
as well as several oral cancer cell lines (OCCL) (Khurram et al., 2010). The evidence in 
Chapter 2 and results in this chapter support the previous findings (refer Section 3.31). 
XCR1 was expressed by all selected OCCL with varying degrees of expression. SCC4 
cells showed the highest percentage of XCR1 expression (~80%) and the lowest was 
H357 cells (~35%) similar to the findings of by Khurram et al. (2010). Both OCCLs was 
derived from tongue OSCC. Recurrent OSCC-derived BICR16 cells population had 
~70% expression of XCR1. Both TR146 and BICR22 are derived from neck lymph node 
OSCC metastasis, which originate from buccal and tongue mucosa respectively and 
show moderate expression of XCR1 receptor (~40% and ~30% respectively). A 
transcriptomic analysis has revealed that low expression of XCR1 correlates with cancer 
progression and poor prognosis in hepatocellular carcinoma (Yanru et al., 2018) which 
is contradictory to our result. This is probably chemokine receptor tissue bias, where the 
receptor behaves differently in different type of cell. Histological quantification performed 
in Chapter 2 showed that XCR1 receptor expression was high (more than 80% of the 
observed tumour population) in both primary tumour and lymph node metastatic OSCC 
compared to normal tissue. Furthermore, our assessment was performed on OSCC 
tissue samples investigating the XCR1 receptor protein expression rather than the 
transcriptomes. Variations in expression are probably due to the OCCLs originating from 
different patients with different risk factors, sites and associated factors. Tumour 
heterogeneity within a cell line population can also effect the expression of chemokine 
receptors as seen in breast cancer cell line (Norton, Popel and Pandey, 2015). 
Furthermore, this heterogeneity can also arise from the stem cell-like cancer cells 
population within the cancer cell lines (Kondo, 2007). This could also influence the 
expression of XCR1 in OCCLs. 
Our findings suggest that the activation of XCR1 receptor by its ligand hLtn can 
regulate the XCR1 mRNA transcript and receptor surface expression. Only H357 and 
SCC4 cell lines, derived from tongue OSCC were found to significantly downregulate the 
surface receptor protein. Both TR146 and BICR22, lymph node metastatic cell lines, as 
well as recurrent cell line, BICR16 showed a decrease in XCR1 expression but the result 
was not significant. FADU was the only cell line which showed an upregulation of XCR1. 
A possible explanation for this is that this cell line is derived from pharynx compared to 
others which are derived from tongue and buccal mucosa (oral cavity). Both oral cavity 
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and pharynx have different development (German and Palmer, 2006), presentation and 
prognosis with distinct pattern of cancer growth and spread (Tshering Vogel, Zbaeren 
and Thoeny, 2010). 
Receptor downregulation may be due to the surface receptor desensitization and 
internalisation after activation. The β-arrestin signalling pathway is involved in 
desensitization of chemokine receptors such as CCR2 and CCR7, that leads to receptor 
internalisation and recycling (Bennett, Fox and Signoret, 2011). Two different types of 
internalisation of a chemokine receptor exist: an agonist-independent (Class A); and 
agonist-dependent (Class B) chemokine receptor desensitization. To date, the only 
chemokine receptor known to belong to Class B are the agonist-treated CXCR4, CCR2 
and CCR5 (Bennett, Fox and Signoret, 2011). Moreover, CCR2 and CCR5 receptors 
can also undergo internalisation through clathrin or caveolin-mediated endocytosis, 
although this is cell-type dependent (Bennett, Fox and Signoret, 2011). The agonist itself 
can influence the fate of the activated receptor such in CCR5 receptor, it follows the 
recycling route, however this may be agonist specific due to promiscuity of chemokine-
chemokine receptor binding.  
Interestingly, β-arrestin interactions with the intracellular domains of different 
chemokine receptors appears to have different functional effects. Interaction with specific 
residues (Ser or Thr) of the C-terminus tail initiate receptor internalization and 
desensitization, essential requirement for β-arrestin-mediated signalling event (Borroni 
et al., 2010; Smith and Rajagopal, 2016). Certain chemokine receptor requires additional 
binding to the third intracellular loops to induce the process. This was also observed in 
the G-protein coupled opioid receptor (Cen et al., 2001). Nevertheless, even without β-
arrestin mediation, the receptor can still be internalized but not recycled (Vines et al., 
2003). XCR1 contains C-terminal Ser/Thr residues, providing a possibility of receptor 
internalisation through β-arrestin. This give an indication that XCR1 receptor 
internalisation could belong to Class B. Chemokine receptors including XCR1 have 
complex mechanism of regulation which are not well understood. Further investigation 
is required to confirm this signalling pathway. 
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3.4.2 Effect Indirect Co-culture of Oral Fibroblast Conditioned Medium on OCCL 
XCR1 and hLtn mRNA Expression. 
Oral fibroblasts the most dominant constituent of the cell population in OSCC 
stroma and play a vital role in tumour growth, invasion and metastasis. Several types of 
oral fibroblast were chosen: normal oral fibroblasts (NOF), myofibroblasts and cancer-
associated fibroblasts (CAF). Our results correlate with previous findings on the 
‘activated’ phenotype of myofibroblast and CAF (Kalluri, 2016).  
Two CAFs were used to compare effect of their conditioned media. Cell 
population is distinct in each human giving a unique expression profile. Additionally, 
unlike immortalized epithelial cell line, fibroblast subpopulation is heterogeneous 
(Sriram, Bigliardi and Bigliardi-Qi, 2015). In oral fibroblasts, even different area in the 
mouth; e.g. gingival fibroblast and periodontal ligament fibroblast has different fibroblasts 
population with distinct functions and expression profile (German and Palmer, 2006). 
CAF have been shown to express different markers between normal fibroblasts and 
CAFs in nemosis (a novel way of fibroblast activation (Vaheri et al., 2009)) further adding 
to fibroblast heterogeneity. 
Cancer progression is a dynamic process involving changes in cancer cells, 
stroma and also changes in extracellular matrix topology which contributes to increased 
matrix stiffness and chemokine secretion by CAF (Kharaishvili et al., 2014). In ovarian 
cancer, CAF has been shown to secrete numerous chemokines (CCL5, and CXCL1,11 
and 12), cytokines and soluble factors to facilitate its progression (Thuwajit et al., 2017). 
The results showed that the mRNA transcripts of both XCR1 and hLtn (XCL1) 
had a similar trend in both SCC4 and H357 cells when exposed to conditioned media 
(CM) from the fibroblasts. CAF-CM upregulated XCR1 and hLtn (XCL1) transcripts in 
SCC4. In contrast, myofibroblast-CM showed a downregulation in both transcripts 
compared to NOF. This was unexpected as our initial assumption was that the 
myofibroblast-CM would be similar to that of CAF due to their phenotype similarity. Both 
myofibroblast and CAF express similar markers and soluble factors such as vimentin, α-
SMA, VCAM1, ICAM1, cytokines and matrix metalloproteinase (MMP) (Kalluri, 2016), 
although enhanced in the latter.  
Previously, conditioned media harvested from endometrial carcinoma CAF has 
been shown to contain chemokines that promote the proliferation and migration of 
endometrial carcinoma cell lines. Additionally, human CAFs promoted the growth and 
tumorigenesis compared to normal fibroblast through CXCL12/CXCR4 axis in a 
xenograft model (Teng et al., 2016). The chemokine-chemokine receptor interaction 
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increases PI3K/Akt and MAPK/Erk through paracrine signalling, and MMP-2 and MMP-
9 in an autocrine manner. CAF-CM has also been shown to induce proliferation and 
angiogenesis in ovarian cancer cells in vitro through TGF-β1, VEGF and PCNA (mRNA 
only) (Xu et al., 2013), and regulating invasion, migration, proliferation, and apoptosis in 
hepatocellular carcinoma (Ding et al., 2015). Oral CAFs were found to secrete cytokines 
and regulate heat-induced apoptosis in OCCL through the CXCL9/CXCR3 axis (Bian et 
al., 2012). This suggests that the oral CAFs may be able to influence oral cancer cell 
behaviour in a paracrine-dependent manner through the hLtn/XCR1 axis. 
Another part of our experiment was to investigate the effect of CM from 
senescence-induced normal oral fibroblast (s-NOF). CM from s-NOF significantly 
influenced the regulation of mRNA expression for both XCR1 and hLtn (XCL1) in SCC4 
cells. Our findings show that the senescence-associated secretory phenotype (SASP) 
from senescent fibroblast greatly reduces transcript expression when compared to 
normalised vehicle control. This showed that senescent cells can control the expression 
of XCR1 and hLtn through paracrine signalling. 
Our initial hypothesis was based on the correlation between cancer incidence 
and increasing age, and the increased presence of senescent cells (Campisi, 2013).  
Conversely, senescent-aged fibroblasts induce proliferation of prostate epithelial cells 
through secretion of CCL5 (Eyman et al., 2009). There is a possibility that the senescent-
aged fibroblasts produce different soluble factors than those that are stress-induced 
fibroblast either by genotoxic stimuli (i.e.: H2O2 or cisplatin) or replicative senescence. 
Ectopic expression of CXCR2 has been shown to cause premature senescence via a 
p53-dependent mechanism where the cells undergo oncogene-induced cellular 
senescence (OIS) and secrete multiple CXCR2-binding chemokines regulated by the 
NF-κB and C/EBPβ transcription factors (Acosta et al., 2008; Guo et al., 2013). SASP 
has been seen to have the potential to promote and supress tumour progression (Lecot 
et al., 2016). SASP involves the secretion of numerous growth factors, inflammatory 
cytokines and proteases, rendering a favourable microenvironment for tumour growth 
(Velarde, Demaria and Campisi, 2013). Therefore, our result suggests that SASP may 
suppress tumour progression by influencing XCR1/hLtn signalling.  
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3.5 SUMMARY 
Results in this chapter demonstrate that XCR1 function is affected by autocrine 
signalling through its ligand. Paracrine signalling by the soluble factors secreted by 
cancer-associated fibroblasts can highly influence the production of XCR1 and hLtn by 
promoting their mRNA transcript in oral cancer cells. This shows the importance of the 
tumour microenvironment in supporting the progression of OSCC through XCR1 
receptor and hLtn. Further investigation of the identity of the other soluble factors present 
in the conditioned medium can be examined through specific chemokine ELISA or by 
use of mass spectrometry to profile the protein components. 
 CHAPTER 4(a) 
DESIGNING THE RECOMBINANT 
PROTEIN hLtn 
Chapter 4 (a): Designing the Recombinant hLtn Variants  
 
Functional Role of the Chemokine Receptor XCR1 and Its Bioengineered Ligand in Oral 
Squamous Cell Carcinoma 116 
CHAPTER 4(a): DESIGNING THE RECOMBINANT PROTEIN hLtn VARIANTS 
4.1 INTRODUCTION 
In the modern biotechnology era, pure, soluble and functional proteins are in 
increasing demand. Natural protein sources do not always meet the requirements for 
quantity, price and ease of isolation; thus recombinant technology is the method of 
choice to fulfil this demand (Rosano and Ceccarelli, 2014). Recombinant cell factories 
are constantly employed to produce the proteins. Escherichia coli (E. coli) is a commonly 
used as the host due to its low cost, rapid and high-density growth, and the vast 
availability of compatible molecular tools facilitating protein expression by its low cost 
(Chen, 2012). Alas, expression of recombinant proteins with E. coli often encountered 
with insoluble and/or non-functional proteins despite of all its advantages. Overcoming 
these obstacles require new approaches such as the use of strategies focusing on either 
controlled expression of target protein in an unmodified form or by fusion protein 
modifications using solubility tags (Sørensen and Mortensen, 2005). 
This chapter will discuss the design for production of hLtn and its mutant variants 
(the wild type, CC3 variant and W55D variant) that will be used in further experiments. 
The first part of this chapter will explain the design of the recombinant hLtn DNA 
sequence and its considerations. The next part mainly involves the methodology behind 
protein production and purification. Several optimisations are required for protein 
expression and purification. SDS-PAGE and Western blotting was used for protein 
confirmation. For recombinant hLtn activity and efficacy, the harvested protein was 
compared with commercial recombinant human lymphotactin (XCL1) (Cat#:300-20; 
Peprotech, London, UK). XCR1-expressing cells were used to measure the functional 
activity of the recombinant hLtn using calcium signalling assay. 
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4.2 METHODS 
4.2.1 Protein Sequence Analysis 
The protein sequences used in this chapter were obtained from the NCBI website 
(https://www.ncbi.nlm.nih.gov/protein). The tertiary structure and detailed information of 
the protein was acquired from the RCSB Protein Data Bank (PDB). The structure of the 
recombinant fusion protein was generated using the RaptorX tool and then investigated 
and presented using Pymol. Additionally, the protein sequence was analysed using 
Expasy ProtParam for a theoretical molecular weight of the protein and distribution of 
amino acid residues of the protein. List of the tools used are listed in Table 4.1. 
Table 4.1: List of software tools and its function with link. 
Software 
tool 
Function Link 
Protein Data 
Bank (PDB) 
To obtain 3D 
information of 
previously 
crystalized protein 
structure 
http://www.rcsb.org/pdb/home/home.do 
Pymol 3D protein structure 
investigation and 
imaging 
https://www.pymol.org/ 
Expasy 
ProtParam 
Compute theoretical 
information (various 
physical and 
chemical 
parameters) of given 
protein stored in the 
protein database or 
user’s protein 
sequences 
http://web.expasy.org/protparam/ 
RaptorX Create prediction of 
protein structure 
tertiary structure 
based on existing 
protein crystal 
structure data 
http://raptorx.uchicago.edu/StructurePrediction/predict/ 
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4.3 STUDY DESIGN 
4.3.1 Recombinant Fusion Protein Design 
The recombinant DNA sequence of XCL1 or hLtn was constructed based on the 
wild type hLtn sequence obtained from the NCBI website (NP_002986) (Figure 4.1). 
Alternatively, the detailed information regarding the protein can be obtained from UniProt 
KB website (P47992). Several considerations are required to produce and purify the 
recombinant hLtn.  
Expression organism. The production machine used was E. coli because this 
bacterial system is well established, inexpensive, requires less time and produces a 
higher yield compared to mammalian, yeast (Baeshen et al., 2014) and insect cells 
(Gecchele et al., 2015). Most human proteins undergone post-translational modification 
(PTM) such as glycosylation and this also the case for hLtn. Glycosylation is a unique 
mechanism in mammalian cells which tags produced proteins for them to be recognized 
by specific mammalian cells. Many proteins such as antibodies are not functional unless 
glycosylated. hLtn is unique because even though it is glycosylated, the protein is still 
active when unglycosylated although this form has lower activity (Dong et al., 2005).  
Fusion protein design. Small recombinant proteins are difficult to produce as 
they are susceptible to degradation by E. coli. Moreover, small proteins are difficult to 
detect using gel electrophoresis. Polyhistidine-tag is usually incorporated into the 
sequence to facilitate purification. This is not feasible for hLtn as the N-terminal is 
important for receptor recognition and activation (Rajagopalan and Rajarathnam, 2006). 
While, truncation of N-terminal has been shown to improve the agonistic properties of 
chemokine (Lee et al., 2002), adding polyhistidine will abolish the ligand activity. A fusion 
partner is often incorporated to increase protein stability followed by linker region 
containing a cleavage site before target protein. This is summarized in Figure 4.2 below. 
Each fusion protein domain will be explained in detail below.  
Target gene/protein. The design has five important components with hLtn 
sequence being the main. hLtn contains 114 amino acids including a signal peptide 
(Figure 4.1) whereas mature hLtn only contains 93 amino acids. Only the mature 
sequence is planned to be incorporated in the sequence design in the current study due 
to the inability of E. coli to cleave the signal peptide. Note that throughout this chapter, 
hLtn is referred to human XCL1 (UniProtKB-P47992) and not its paralog human XCL2 
(UniProtKB-Q9UBD3). 
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Figure 4.1: Human lymphotactin sequence. Total of 114 amino acids including signal 
peptide (1-21 AA) highlighted in grey and mature protein sequence in yellow (22-114 AA) 
(UniProtKB-P47992). 
 
 
Figure 4.2: Basic expression vector configuration for high throughput expression in E. 
coli for (A) cytoplasmic protein and (B) membrane protein. The difference in the 
configuration is the location of the purification tag, either N- or C-terminal. T7 promoter 
is used to control the recombinant protein expression in E. coli. Tandem affinity tags are 
essential for high-throughput assay where protein expression initiation, protein solubility 
and soluble detection involves large tag, while purification requires smaller tag. UTR: 
Untranslated region.   
 
Affinity tag. Several affinity tags are commonly used to facilitate recombinant 
protein purification. The most commonly affinity tag is a polyhistidine-tag, ranging from 2 
– 10 histidine residues. A cleavable polyhistidine-tag allows production of a large quantity 
(approximately 10 – 100 mg) of highly pure protein (Kimple, Brill and Pasker, 2013). 
Commercial expression vectors are designed with at least an affinity tag and sometimes 
specific to a certain plasmid such as glutathione S-transferase (GST)-tag to pGEX vector 
and maltose binding protein (MBP)-tag to pMAL and pIVEX vectors (Kimple, Brill and 
Pasker, 2013). The pET24a plasmid with a strong T7 promoter was chosen as an 
        10         20         30         40         50 
MRLLILALLG ICSLTAYIVE GVGSEVSDKR TCVSLTTQRL PVSRIKTYTI 
        60         70         80         90        100 
TEGSLRAVIF ITKRGLKVCA DPQATWVRDV VRSMDRKSNT RNNMIQTKPT 
       110  
GTQQSTNTAV TLTG 
(A) 
(B) 
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expression vector because it is ideal for expressing soluble, nontoxic recombinant 
proteins in E. coli with high levels of expression. The plasmid contains two different 
affinity tags: T7 tag, which also a reporter tag and a C-terminal His-tag (Figure 4.3). Both 
tags are in the multiple cloning site (MCS) region and can be manipulated accordingly 
using appropriate endonucleases. Cytoplasmic expression is preferred for the proposed 
recombinant protein (refer Figure 4.2), therefore the polyhistidine sequence will be 
purposely added at the N-terminus of the fusion protein. The usual strategy is to prefer 
a N-terminal polyhistidine-tag; and if the recombinant protein does not express or is 
insoluble, a C-terminal polyhistidine-tag will be considered. 
 
 
Figure 4.3: pET24a expression plasmid for protein expression from Novagen. The pET-
24a vector contains the N-terminal T7 promoter and kanamycin resistance selection 
marker. 
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Fusion partners. An alternative method to increase the stability and solubility of 
the recombinant protein is by adding a fusion partner. There are a number of solubility-
enhancing fusion proteins including glutathione-S-transferase (GST), maltose binding 
protein (MBP), disulphide oxidoreductase (DsbA), nutilization substance A (NusA), small 
ubiquitin-related modifier (SUMO), thioredoxin (TrxA), and hyper-acidic protein tags 
(Lebendiker and Danieli, 2014). For our experiments, the solubility enhancer considered 
was the lipoyl domain from B. stearothermophilus, an acidic fusion partner. Lipoyl 
domains can be found in various species but 1LAC, a lipoyl domain from Bacillus 
stearothermophilus (Dardel et al., 1993) containing 85 amino acids was selected. The 
lipoyl domain provides an electrostatic protection which reduces protein aggregation, 
thus providing an adequate time to allow correct protein folding. Another advantage of 
the lipoyl domain is it is extremely soluble and often prevents formation of inclusion 
bodies of the recombinant protein as well as resistant to protease activity.   
Linker protein. To increase the flexibility of the protein during purification and 
cleavage, a linker region was added connecting the His-Lipoyl domain to the hLtn 
sequence. The linker region also further increases the solubility of the protein. It acts as 
a “neck” which gives mobility to the tag proteins allowing them to attach more easily to 
the purification column. The length of the linker used is 19 amino acids as this has been 
previously shown to increase the solubility and protein folding and unfolding  (Robinson 
and Sauer, 1998).  
Cleavage proteases. The majority of the recombinant hLtn design (see Figure 
4.2 (A)) for the protein sequence design) and production procedure was adopted from 
Peterson et al. (2004) with some modifications to fit our purification scheme. Peterson’s 
method made some modifications to the hLtn sequence; (1) conversion of Methionine 
(Met) to Alanine (Ala): M63A and M72A, and (2) insertion of the tripeptide G-M-V at the 
beginning of the mature sequence. The G-M dipeptide is required for CNBr treatment 
which removes the protein tag during purification and the conversion of Met tot Ala is to 
remove the possibility of unintentional cleavage of the hLtn. The initial cleavage protease 
of choice was Factor Xa which recognize IEGR↓ protein sequence. Alternatively, TEV 
protease was used for another construct which recognizes the amino acid sequence 
ENLYFQ↓G. Both were added to facilitate removal of the tag region from the mature 
hLtn. 
Restriction sites. For protein expression, the pET24a plasmid was used (refer 
Figure 4.3). In order to ligate the recombinant sequence into the plasmid, several 
strategic restriction sites were included to allow transfer of the target DNA sequence into 
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other plasmids. A NdeI restriction site was positioned at the beginning of the sequence, 
BamHI positioned inside the linker region and EcoRI at the end. The restriction sites are 
essential to cut the recombinant DNA ends and ligate them into the expressing vector. 
The DNA sequence is then optimized by GenScript (Appendix 11). A stop codon TAA 
increases the efficiency of translational termination suggested by the vector 
manufacturing company and another terminal codon TAG was also included.  
By considering above specifications, two fusion protein designs were considered: 
fusion protein hLtn (IEGR) and hLtn (TEV) (Figure 4.4). The 3D structure of the fusion 
proteins was generated using online tool RaptorX (Chicago, USA) (Figure 4.5). 
Additionally, the differences between the hLtn variants, wild type, CC3 and W55D 
mutants can be found in Figure 4.6. 
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Figure 4.4: Recombinant fusion protein hLtn design. (A) Base design template of the 
fusion protein with specific locations of endonuclease restriction site. Protein sequence 
of the recombinant fusion protein with (B) Factor Xa and (C) TEV protease cleavage 
sites.  
(B) 
(C) 
(A) 
1-6  His6-tag 
7-8  Short linker 
9-92  Lipoyl domain from B. stearothermophilus 
pyruvate dehydrogenase multienzyme complex   
93-111  Amino acids linker 
112-115  Protease recognition site 
115116  Cleavage site 
116-208  Matured hLtn peptide 
        10         20         30         40         50         60  
HHHHHHSGAF EFKLPDIGEG IHEGEIVKWF VKPGDEVNED DVLCEVQNDK AVVEIPSPVK  
 
        70         80         90        100        110        120  
GKVLEILVPE GTVATVGQTL ITLDAPGYEN MTFGGGSGGG SGGGTGGGSG GGIEGRVGSE  
 
       130        140        150        160        170        180  
VSDKRTCVSL TTQRLPVSRI KTYTITEGSL RAVIFITKRG LKVCADPQAT WVRDVVRSMD  
 
       190        200  
RKSNTRNNMI QTKPTGTQQS TNTAVTLTG  
        10         20         30         40         50         60  
HHHHHHSGAF EFKLPDIGEG IHEGEIVKWF VKPGDEVNED DVLCEVQNDK AVVEIPSPVK  
 
        70         80         90        100        110        120  
GKVLEILVPE GTVATVGQTL ITLDAPGYEN MTTGSDTGEN LYFQGGSEVS DKRTCVSLTT 
 
       130        140        150        160        170        180  
QRLPVSRIKT YTITEGSLRA VIFITKRGLK VCADPQATWV RDVVRSMDRK SNTRNNMIQT 
 
       190          
KPTGTQQSTN TAVTLTG  
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Figure 4.5: Fusion protein sequence prediction generated using RaptorX online tool 
(Chicago, USA). The 3D protein structure was created using Pymol (Schrödinger, LLC, 
USA). The 3D structure of the fusion protein with (A) Factor Xa and (B) TEV cleavage 
site. Each section has specific functions to facilitate hLtn production and purification. The 
fusion protein contains N-terminal polyhistidine-tag followed by a lipoyl domain, linker 
region, protease cleavage site and mature hLtn.  
(B) 
(A) 
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Figure 4.6: The recombinant hLtn variant constructs. (A) Base design for the 
recombinant fusion protein. (B) The recombinant protein sequence for wild type, CC3 
and W55D mutants.  
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4.3.2 Recombinant Fusion Protein Expression and Purification 
Two steps are involved in producing the protein: Upstream and downstream 
processing. The upstream processing mostly involves preparation of the expression 
plasmid and downstream processing involves the protein purification.  
Bacterial host strains. To initiate protein expression, the first consideration is to 
select the appropriate expression system that is suitable to express the recombinant 
fusion protein. As explained earlier, the E. coli system is the most practical and has been 
used previously to express hLtn (Volkman, Liu and Peterson, 2009), although several 
modification were considered for the fusion protein containing hLtn. Two different E. coli 
strains were considered for the expression which were BL21 (DE3) and C41 (DE3). C41 
(DE3) strain is derived from BL21 (DE3) with several modification to accommodate 
expression of toxic proteins (Dumon-Seignovert, Cariot and Vuillard, 2004). As we have 
no information of the fusion protein behaviour in E. coli, this optimization was considered. 
Protein purification method. There are several types of purification, but a 
suitable purification method must be considered to ensure optimal recombinant protein 
purification. Immobilized metal affinity chromatography (IMAC) was considered to be the 
most appropriate method. Metal ions that are usually used for IMAC are copper, nickel, 
zinc, and cobalt. Each metal has a different affinity and specificity towards the 
polyhistidine tag (Figure 4.7). Nickel is the best choice with moderate-high affinity and 
moderate specificity to polyhistidine. Additionally, the purification format was also 
considered. Batch purification was opted for as it enables longer incubation time (up to 
24 hours) and can be performed at low temperature (4°C) when compared to spin column 
and cartridge methods.  
Buffer content. Common buffer recipes for protein purification are either a Tris-
base or sodium phosphate buffer. The buffer recipe was a modification from Volkman 
(2006) and Tuinstra (2008). Sodium phosphate buffer with pH 7.5 was preferable to 
mimic physiological condition. Expasy ProtParam analysis shown that the theoretical 
isoelectric pH (pI) for the fusion protein (Table 4.2) and the mature hLtn variants (Table 
4.3) are ~6 and ~10 respectively. As a rule of thumb, the buffer pH should be ~2 pH units 
above or below the pI. This is to facilitate the protein purification allowing it to be charged 
in the buffer solution. The buffer pH must be precisely controlled as this is required to 
keep the protein charged, thus allowing electrostatic repulsion to prevent the protein from 
aggregating. Also, it is important to keep in mind that a basic pH is essential to avoid the 
His protein from being protonated which would reduce its binding to the metal ions. 
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Furthermore, addition of glycerol can help reduce protein aggregation (Lebendiker and 
Danieli, 2014). IMAC purification can sometimes introduce binding besides the target 
protein. Addition of 10 mM imidazole can further reduce contamination by unwanted His-
rich proteins produced by E. coli. 
 
 
Figure 4.7: Polyhistidine-tag affinity and specificity towards different metals ions. Metal 
ion with higher specificity to polyhistidine has a lower affinity and vice versa. The metal 
ions that are usually used in IMAC purification are copper (Cu2+), nickel (Ni2+), zinc (Zn2+) 
and cobalt (Co2+). 
 
By using all the information, the flow of protein production is summarized in Figure 4.8. 
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Table 4.2: Expasy ProtParam analysis for recombinant HL.IEGR-hLtn and HL.TEV-hLtn. 
 HL.IEGR-hLtn HL.TEV-hLtn 
Number of amino acids 209 amino acids 198 amino acids 
Molecular weight 22163.92 Da (~22 kDa) 21671.42 Da (~22 kDa) 
Theoretical pI 6.41 5.98 
Total number of 
negatively charged 
residues (Asp + Glu) 
24 25 
Total number of 
positively charged 
residues (Arg + Lys) 
22 21 
Extinction coefficient  
(M-1 cm-1 at 280 nm 
measured in water) 
Abs 0.1% (=1 g/L) 
assuming all pairs of Cys resides form cystines 
14105 
0.636 
15595 
0.720 
assuming all Cys residues are reduced 
13980 
0.631 
15470 
0.714 
Estimated half-life 
3.5 hours (mammalian reticulocytes, in vitro) 
10 min (yeast, in vivo) 
>10 hours (E. coli, in vivo) 
Instability index (II) 
28.34 19.27 
This classifies the protein as stable 
Aliphatic index 77.27 80.10 
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Table 4.3: Expasy ProtParam analysis for recombinant hLtn variants. 
 Wild type CC3 mutant W55D mutant 
Number of amino acids 93 amino acids 
Molecular weight 
10229.70 Da 
(~10 kDa) 
10237.71 Da 10158.58 Da 
Theoretical pI 10.63 10.16 10.36 
Total number of 
negatively charged 
residues (Asp + Glu) 
6 7 
Total number of 
positively charged 
residues (Arg + Lys) 
15 
Extinction coefficient  
(M-1 cm-1 at 280 nm 
measured in water) 
Abs 0.1% (=1 g/L) 
assuming all pairs of Cys resides form cystines 
7115 
0.696 
7240 
0.707 
1615 
0.159 
assuming all Cys residues are reduced 
6990 
0.683 
6990 
0.683 
1490 
0.147 
Estimated half-life 
30 hours (mammalian reticulocytes, in vitro) 
>20 hours (yeast, in vivo) 
>10 hours (E. coli, in vivo) 
Instability index (II) 
25.51 21.82 28.04 
This classifies the protein as stable 
Aliphatic index 74.30 68.06 74.30 
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Figure 4.8: Upstream processing for hLtn protein production 
 
pCMV6-Entry-hLtn  
(from Origene) 
Previously established: 
pCMV-Entry hLtn CC3 
(V21C/V59C) 
Design recombinant DNA sequence: 
His6 – Lipoyl linker – (IEGR) – hLtn sequence 
DNA sequence synthesis 
Codon optimized by GenScript in pUC57 plasmid 
Transfer construct into pET24a plasmid 
Previously established: 
pET24a-HLTEV-hLtn WT  
Restriction sites: (pET24a-HLTEV: NdeI-BamHI) 
and (hLtn WT: BamHI-EcoRI) 
 
Transformation 
E. coli strain DH5-α – for safekeeping 
E. coli strain BL21 (DE3) – for protein expression 
E. coli strain C41 (DE3) – for protein expression 
Protein purification 
Optimization 
Compare IEGR vs TEV expression 
Compare expression by BL21 vs C41 
Compare induction method: IPTG vs Auto-
induction 
Site-directed mutagenesis 
pCMV6-Entry- hLtn W55D  
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CHAPTER 4(b): PRODUCTION OF THE RECOMBINANT hLtn VARIANTS 
4.1 INTRODUCTION 
The E. coli system has been a ubiquitous system to express recombinant protein, 
even for those of eukaryotic origin. However, there are some challenges in expressing 
the protein in its original form as nearly half of all proteins of human origin are 
glycosylated. Glycosylation has an important functional and structural influence in many 
key biological processes (Krištić and Lauc, 2017). hLtn has an unusual feature of O-
linked glycan attached to a C-terminal structure in a portion of the purified protein from 
mammalian culture. While there are some proteins that are not functional without 
glycosylation, hLtn has been shown to activate its receptor with lower activity (Dong et 
al., 2005).  
Production and purification of hLtn using the E. coli system has been established 
previously (Volkman, Liu and Peterson, 2009). Various techniques have been applied to 
produce hLtn variants available in the literature, notably by Volkman’s group where 
changes in certain amino acids to accommodate the purification and structural analysis.  
Most of the protein produced this way forms protein aggregates which result in insoluble 
protein. In this chapter, further possibility was explored to produce a soluble protein.    
Protein insolubility is the common challenge in protein production and purification. 
It is time consuming due to introduction of additional purification steps as well as 
decreasing the protein yield (Rosano and Ceccarelli, 2014).  This problem is partially due 
to 1) expression in a different system such as expressing a mammalian protein in 
bacterial system; 2) improper protein folding due to macromolecular crowding, where 
exposed hydrophobic core allowing protein tendency to form dimer and 3) incorrect 
disulphide linkage due to protein-protein interaction. 
The aim of this chapter is to implement an alternative method to produce and 
purify the chemokine protein.  Additionally, by introducing a lipoyl domain to the fusion 
protein (as discussed in Chapter 4a), we attempted to reduce the formation of protein 
aggregation.  
  
Chapter 4(b): Production of the Recombinant hLtn Variants 
 
Functional Role of the Chemokine Receptor XCR1 and Its Bioengineered Ligand in Oral 
Squamous Cell Carcinoma 133 
4.2 EXPERIMENTAL 
4.2.1 Materials 
List of detailed information of the materials (reagents, kits, equipment, software 
and miscellaneous) used in the chapter can be found in Appendix 1-5. 
. 
 
Table 4.1: Primer designs used for the cloning and sequence check of hLtn into pET24a 
vectors. 
Name Sequence 
T7 promoter Fwd 5’-TAATACGACTCACTATAGGG-3’ 
T7 terminator Rev 5’-GCTAGTTATTGCTCAGCGG-3’ 
Lipoyl check  
Fwd 5’-AAACATGACGTTTGGCGGTGG-3’ 
Rev 5’-CATTCTGAACTTCGCACAGC-3’ 
hLtn check 
Fwd 5’-CATATGCATCATCATCATCATCACTCGGGTG-3’ 
Rev 5’-GAATTCATTAACCCGTCAGCGTCACTGC-3’ 
 
 
4.2.2 E. coli Culture and Growth Media Preparation 
Three different E. coli strains were used: DH5-α, BL21 (DE3) and C41 (DE3). 
The E. coli culture was provided by Dr. Tuck Seng Wong (ChELSI Institute and Advanced 
Biomanufacturing Centre, Department of Chemical and Biological Engineering, The 
University of Sheffield). Tryptone-yeast extract (TYE) culture media was prepared with 
16 g tryptone, 10 g yeast extract, 5 g sodium chloride in 1 L and sterilized by autoclaving. 
TYE agar plates were prepared with 10 g tryptone, 5g yeast extract, 4 g sodium chloride, 
15 g agar, and sterilize by autoclave. Appropriate antibiotics were added into the agar 
before plating (100 µM ampicillin or 50 µM kanamycin). 
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4.2.3 Molecular Cloning 
4.2.3.1 Site-directed Mutagenesis of W55D 
The pCMV6 Entry-XCL1 (NM_002995) human chemokine construct (Cat#: 
SC309015; Cambridge Bioscience Ltd., Cambridge, UK) was purchased from OriGene. 
The mutagenic primer (Table 4.2) was designed using the OneClick programme (link: 
http://tucksengwong.staff.shef.ac.uk/OneClick/). The PCR mixture can be found in Table 
4.3 and the programme in Table 4.4. 
Table 4.2: Primers used for the mutagenesis. 
W55D 
(OneClick)  
Fwd 5’-CAAGCCACAGACGTGAGAGACGTGGTCAGGAGCATGGACAGGAAAT-3’ 
Rev 5’-GTCTCTCACGTCTGTGGCTTGTGGATCAGCACAGACTTTTAGGCCA-3’ 
 
Table 4.3: PCR mixture. 
Component Stock conc’ 
Volume per Reaction (µL) 
TubeF 
(Forward Primer) 
TubeR 
(Reverse Primer) 
Distilled Water - 41.5 41.5 
Cloned Pfu reaction buffer 10× 5 5 
dNTPs 10 mM each 1 1 
DNA template 100 ng/µL 0.5 0.5 
Primer 1 
20 µM  
(20 pmol/µL) 
1 0 
Primer 2 
20 µM 
(20 pmol/µL) 
0 1 
Pfu Turbo DNA Polymerase 2.5 U/µL 1 1 
Total  50  50 
 
Table 4.4: Two-stage PCR programme. 
Step 
Temperature 
(°C) 
Time 
1 95 2 minutes 
2 95 30 seconds 
3 55 30 seconds 
4 72 5 minutes 18 seconds 
5 - Go to Step 2, repeat 9 times 
6 - Pause, mix TubeF and TubeR, redistribute equally, and continue 
7 95 30 seconds 
8 55 30 seconds 
9 72 5 minutes 18 seconds 
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10 - Go to Step 7, repeat 19 times 
11 72 10 minutes 
12 8 Hold 
 
4.2.3.2 Restrictive Digestion 
The reaction mixture for restrictive digestion was as Table 4.5 below. The 
reaction mixture was incubated in PCR machine at 37°C. PCR product was purified using 
QIAquick PCR purification kit (Cat#: 28106; QIAGEN, Manchester, UK) or QIAquick gel 
extraction kit (Cat#: 28706; QIAGEN, Manchester, UK).  
Table 4.5: Reaction mix for restrictive digestion. 
Component Stock conc’ Volume (µL) Final conc’ 
Water  88 – x  
Buffer 4 10× 10 1× 
PCR plasmid 
product/Plasmid 
Measure using 
Nanodrop 
x  
Restriction enzyme 1: 
BamHI (NEB) 
20 U/µL 1 20 U/100 µL 
Restriction enzyme 2: 
EcoRI (NEB) 
20 U/µL 1 20 U/100 µL 
Total  100  
 
 
4.2.3.3 Ligation of hLtn Variants Gene Sequence into pET-24a 
The ligation was achieved using a PCR machine. The reaction mixture used was 
prepared as in Table 4.6 below. The reaction mixture was incubated in PCR machine at 
16°C. After the reaction, 5 µL was transformed into E. coli strain DH5-α. 
Table 4.6: Ligation reaction mixture. 
Component Stock conc’ Volume (µL) Final conc’ 
Water  16 – x – y  
Buffer 10× 2 1× 
Digested plasmid 
Measure using 
Nanodrop 
x 50 ng 
Digested insert 
Measure using 
Nanodrop 
y 
3× the amount of plasmid used 
(3 insert molecules: 1 plasmid 
molecule) 
T4 DNA ligase (NEB) 
400 cohesive 
end unit/µL 
2 40 U/µL 
Total  20  
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4.2.3.4 Polymerase Chain Reaction (PCR) 
The reaction mixture used was prepared as in Table 4.7 below. The reaction 
mixture was incubated in PCR machine using programme described below (Table 4.8). 
The PCR products were purified using QIAquick PCR purification kit or QIAquick gel 
extraction kit. The template DNA was separated from the PCR product using DNA gel 
electrophoresis followed by gel extraction. For PCR purification, 1-2µL DpnI was added 
into the PCR mixture and was incubated for overnight at 37°C to remove methylated or 
hemi-methylated template DNA prior to the purification step. 
Table 4.7: PCR reaction mixture. 
Component Stock conc’ Volume (µL) Final conc’ 
Water  36  
HF Buffer 5× 10 1× 
dNTP mix 10 mM each 1 0.2 mM each 
Forward primer 
20 µM (20 
p.mol/µL) 
1 0.4 µM 
Reverse primer 
20 µM (20 
p.mol/µL) 
1 0.4 µM 
Template DNA 
Measure using 
Nanodrop 
0.5  
Phusion DNA 
polymerase (NEB) 
2 U/µL 0.5 1 U/50 µL 
Total  50  
 
Table 4.8: PCR programme. 
Step 
Temperature 
(°C) 
Time 
1 98 30 seconds 
2 98 10 seconds 
3 72 30 seconds 
4 72 60 seconds 
5 - Go to Step 3, repeat 29 times 
6 72 2 minutes 
7 8 Hold 
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4.2.3.5 Gel Extraction (Nucleospin Gel and PCR Clean Up) 
The DNA gel extraction was executed using QIAquick Gel Extraction Kit 
(QIAGEN, Manchester). The desired DNA band was excised with the help of a 
transilluminator for the band location visualisation. The gel piece was then transferred 
into a 15 mL centrifuge tube and the weight of the gel was recorded to determine the 
volume of buffer required. For each 100-mg agarose gel, 200 µL Buffer NTI was required. 
The tube was then incubated in 50°C water bath with gentle shaking. When the gel was 
fully dissolved, the tube was briefly vortexed. The dissolved gel was pipetted up to 700 
µL onto a spin column and centrifuged at 5000 rpm at RT for 1 minute. The flow through 
was discarded and the protocol continued until all solutions was applied to the column. 
The column was washed with 700 µL Buffer NT3 and the column was left to stand before 
centrifugation. The centrifuge was set at 5000 rpm at RT for 1 minutes. The flow-through 
was again discarded and the column washed with Buffer NT3 for the second time. 
Maximum speed centrifugation at RT for additional 2 minutes was used to remove 
residual ethanol. The column was then placed in a fresh 1.5 mL centrifuge tube before 
incubating at 70°C for 5 minutes using a thermoblock. Consequently, Buffer NE was also 
incubated on the thermoblock. The DNA was eluted with 35 µL Buffer NE and left to 
stand at RT for 2 minutes. Maximum speed centrifugation for 1 minute was used to obtain 
the DNA. DNA quantification was performed using NanoDrop (Thermo Fisher Scientific, 
Paisley, UK) 
 
4.2.3.6 Gene Sequencing Analysis 
Eurofin Sequencing (Eurofin Genomics UK, Wolverhampton, UK) service was 
used to identify the sequence quality of the plasmid. The sequence was then analysed 
using FinchTV (PerkinElmer, UK) or ApE plasmid software (by Wayne Davis, University 
of Utah, USA). Protein sequence translation was performed using Expasy Translate Tool 
(https://web.expasy.org/translate/). 
 
4.2.4 Bacterial Transformation using CaCl2 Heat-Shock Method 
Principle: Calcium chloride (CaCl2) transformation is a laboratory tool to incorporate 
plasmid DNA into prokaryotic cells. The positively charged calcium ions (Ca2+) bind to 
the negatively charge outer core of the lipopolysaccharide (LPS) of the bacterial cell wall 
as well as encasing the negatively charged plasmid DNA. This promotes molecular 
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binding of the two components. Heat shock is applied to ferry the plasmid DNA into the 
bacterial cell through pores in the cell membrane which forms when cells are chilled (on 
ice) and heated at 42°C for a short time. 
Procedure: An overnight culture of E. coli was grown in 5 mL 2×TYE media at 37°C, 
250 rpm. 50 µL of the overnight culture was then inoculated in 5 mL 2×TYE media and 
grown at 37°C with shaking at 250 rpm. The optical density (OD) was monitored at 600 
nm. When OD600 reached ~0.5-0.6, 1-mL aliquot per transformant was transferred to a 
sterile 1.5 mL microcentrifuge tube. Following centrifugation at 2800 rpm, RT, for 2 
minutes, the supernatant was removed by pipetting, followed by gentle re-suspension of 
the cells in 500 µL sterile pre-chilled 50 mM CaCl2, re-centrifugation and removal of the 
supernatant before incubating the cells in CaCl2 on ice for 30. For transforming intact 
plasmid, 10 minutes of incubation is acceptable. Cells were heat shocked at 42oC for 1 
minutes and further incubated in ice for additional 2 minutes. 800 µL of pre-warmed 
2×TYE media (37°C) was added and cells left to grow at 37°C, 250 rpm for 60 minutes. 
Subsequently, TYE agar plates were pre-warmed (with antibiotics) at 37oC. The cells 
were centrifuged at 2800 rpm, RT, for 2 minutes and most of the media removed. The 
remaining 200-300 µL media was used to re-suspend the cells gently before plating them 
on pre-warmed agar plates. The plates were incubated overnight at 37°C to allow the 
transformed colony to grow. 
 
4.2.5 Isolation of plasmid DNA using QIAprep Spin Miniprep Kit 
The plasmid DNA was isolated from E. coli DH5-α using QIAprep Spin Miniprep 
Kit (Qiagen, Manchester, UK). 3 mL of overnight culture (with plasmid of interest) was 
harvested by centrifugation (5000 rpm, RT, 2 minutes). The excess media was removed 
by inverting and tapping the tube carefully on paper towel. Cell pellet was re-suspension 
was performed by vortexing in 250 mL Buffer P1. Cells lysis was achieved by adding 250 
µL Buffer P2. The lysis was performed by gently inverting the tube, not exceeding 5 
minutes. Once lysed, 350 µL Buffer N3 was added immediately followed by centrifugation 
(maximum speed, RT, 10 minutes). The supernatant was transferred to a Qiagen column 
and centrifuged at 5000 rpm at RT for 2 minutes. The flow-through was discarded prior 
to adding 750 µL Buffer PE to the column. The flow-through was discarded following 
centrifugation at 5000 rpm at RT for 2 minutes before a final centrifuge at maximum 
speed at RT for additional 2 minutes to remove residual ethanol. The column was placed 
in a fresh 1.5 mL centrifuge tube to collect the eluted DNA using 35 µL of Buffer EB. The 
Chapter 4(b): Production of the Recombinant hLtn Variants 
 
Functional Role of the Chemokine Receptor XCR1 and Its Bioengineered Ligand in Oral 
Squamous Cell Carcinoma 139 
tube was left stand for 2 minutes for good DNA recovery before centrifuged at maximum 
speed at RT for 2 minutes. The DNA concentration was measured using a NanoDrop 
1000 Spectrophotometer (Thermo Scientific, DE, USA).  
 
4.2.6 DNA Purification (QIAquick PCR Purification Kit) 
The DNA purification was performed using QIAquick PCR purification kit. A ratio 
of 5 parts buffer PB to 1-part DNA sample was mixed and vortexed briefly in a 1.5-mL 
centrifuge tube. The entire mixture was then transferred into a Qiagen column and 
centrifuged at 5000 rom at RT for 2 minutes. The flow-through was discarded and the 
column was washed with 750 µL Buffer PE. Column was centrifuged and the flow-
through was discarded. An additional 2 minutes of centrifugation at maximum speed was 
used to remove residual ethanol. The column was then placed in a fresh 1.5-mL 
centrifuge tube to elute the DNA using 35 µL Buffer EB. The elution was collected by 
centrifugation at maximum speed for 2 minutes. DNA concentration was measured using 
NanoDrop. 
 
4.2.7 DNA Gel Electrophoresis 
Procedure: 0.7% (w/v) agarose gel was prepared in 1×TBE buffer (by dissolving 0.35g 
of agarose in 50 mL buffer). The percentage of gel used is dependent on the size of the 
DNA fragment to be analysed. Low percentage gels (0.7-0.8%) are used for high Mw 
DNA fragments and high percentage gel (1-1.5%) for low Mw DNA fragment. To ensure 
the agarose was fully dissolved, heating was performed using microwave. 2 µL of 
ethidium bromide solution was added and the gel was casted using gel caster, gel tray 
and gel comb when only the agarose gel temperature cooled to room temperature. The 
gel allowed to cool down and solidify, before loading 6 µL of 1 kb DNA ladder (Cat#: 
N3232L; New England Biolabs, Hitchin, UK) and appropriate volume of DNA samples. 
The electrophoresis was run at constant voltage of 100 V for 60 minutes. The gel image 
was captured using a gel documentation system. 
 
Chapter 4(b): Production of the Recombinant hLtn Variants 
 
Functional Role of the Chemokine Receptor XCR1 and Its Bioengineered Ligand in Oral 
Squamous Cell Carcinoma 140 
4.2.8 Protein Overexpression using the E. coli system 
4.2.8.1 TEV Protease 
Cell- based protein expression was carried out using E. coli strain BL21 (DE3). 
Cells were transformed with the pRSET vector containing TEV A Protease constructs 
(engineered for higher expression) using the CaCl2 heat-shock method, and plate 
inoculation was carried out on 2×TYE agar supplemented with 100 µM ampicillin. Protein 
expression was initiated in 2×TYE media with 100 µM ampicillin using isopropyl β-D-
thiogalactopyranosidase (IPTG) at final concentration of 1 mM when the growth reached 
~ 0.6 OD. Cells were incubated at 25°C with shaking at 250 rpm for 24 hours to allow 
expression to occur. Cells were harvested post-expression and centrifuged at 8000 rpm 
for 15 minutes at 4°C. Cell pellets were either analysed for protein expression or stored 
at -20°C. 
 
4.2.8.2 hLtn variants 
Protein overexpression was carried out using both E. coli strain BL21 (DE3) and 
C41 (DE3) to identify most suitable strain. Cells were transformed with a pET24a vector 
containing respective hLtn variants constructs (wild type, CC3 and W55D mutants) using 
the CaCl2 heat-shock method. Plate inoculation was carried out on 2×TYE agar 
supplemented with 50 µM kanamycin. Protein expression was initiated in TYE auto-
induction media (Studier, 2014) with 50 µM kanamycin. Expression was performed at 
25°C in an incubator shaker at 250 rpm for 24 hours. Cells were harvested post-
expression and centrifuged at 8000 rpm for 15 minutes at 4°C. Cell pellets were either 
analysed for protein expression or stored at -20°C. 
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4.2.9 Analysis of Protein Expression 
4.2.9.1 SDS-PAGE Analysis 
Procedure: A 15% acrylamide-SDS gel was prepared for the analysis throughout the 
experiments due to the low molecular weight of the protein expressed. There were two 
parts of the gel preparation: the resolving gel (lower part) and the stacking gel (upper 
part). The composition of each layer was as described in Figure 4.1 below. Following 
the addition of the polymerisation initiators, the gel was allowed to solidify, before loading 
5 µL of PageRulerTM unstained broad range protein ladder (Cat#: 26630; Thermo Fisher 
Scientific) and appropriate volume of protein sample. The electrophoresis was run at 
constant voltage of 200 V for 40 minutes. Protein gel was stained with Commassie 
Brilliant Blue staining dye and counterstained with de-staining solution. The gel image 
was captured using gel documentation system. 
 
Figure 4.1: Protein electrophoresis and the composition of a 15% SDS-polyacrylamide 
gel. 
 
  
Gel comb 
Stacking gel (for one gel): 
2.05 mL DDI H2O 
1.65 mL 30% Acrylamide 
1.25 mL 0.5 M Tris-HCl (pH 6.8) 
0.05 mL SDS 
5.0 µL TEMED 
25 µL APS 
 
Resolving gel (for one gel): 
2.05 mL DDI H2O 
1.65 mL 30% Acrylamide 
1.25 mL 1.5 M Tris-HCl (pH 6.8) 
0.05 mL SDS 
2.5 µL TEMED 
25 µL APS 
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4.2.9.2 Western Blot 
Procedure: Prior running a western blot, protein gel electrophoresis as described 
previously was performed (refer Section 4.2.9.1). For wet transfer, a piece of Immobilon 
P Transfer Membrane (Millipore) pre-treated with 100% methanol for 45 seconds 
followed by rinsing in distilled water. The Watman papers, sponges and the transfer 
membrane were thoroughly soaked in 1× transfer buffer containing 10% (v/v) methanol 
(prepared from 10× transfer buffer containing 12 mM Tris base, 96 mM glycine in 1 L). 
The whole unit stack was prepared and placed in a X-cell II Blot Module (Cat#: EI9051; 
ThermoFisher Scientific, Paisley, UK). The blot module was inserted into the running 
chamber and locked. The blot module and running chamber were submerged in 1× 
transfer buffer and run at 30 V for 60 minutes. The membrane was carefully transferred 
in 1× TBS (prepared from 10× TBS containing 500 mM Tris base and 1.5 M NaCl 
adjusted to pH 7.6 in 1 L) for 10 minutes twice. Membrane was then incubated in 1× 
blocking buffer from the Penta.His HRP Conjugate Kit (QIAGEN, Manchester, UK) for 1 
hour. 1× TBST (containing 20 mM Tris base, 500 mM NaCl, 0.05% (v/v) Tween-20 and 
0.2% (v/v) Triton x-100 adjusted to pH 7.5 in 1 L) was used to wash the membrane for 
10 minutes twice followed by another wash with 1×TBS for another 10 mins. Incubation 
of membrane with the Anti-His antibody solution from the Penta.His HRP Conjugate Kit 
(dilution 1:1000 in 1× blocking buffer) was performed for 1 hour. After antibody 
incubation, the membrane was washed in 1× TBST for 10 minutes twice followed by TBS 
for another 10 minutes.  
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4.2.10 Protein Purification of Recombinant Protein 
Principle: Nickel resin purification is an immobilised metal affinity chromatography 
(IMAC) method that is widely utilised in purifying recombinant proteins with polyhistidine 
tags (Block et al., 2009). There are other metals that can be used to charge the column 
such as zinc, cobalt and copper but generally, nickel resin offers the highest yield. The 
binding is achieved through electrostatic attraction to the nickel beads or resin, although 
non-specific binding can occur which can be reduced by addition of sodium chloride to 
the buffer. The polyhistidine binds tightly with micromolar affinity to the metal and can be 
removed by addition of a high concentration of imidazole, which competes with the 
polyhistidine tag for binding to the column. 
 
4.2.10.1 Polyhistidine Tag-Nickel Purification using Fast Protein Liquid 
Chromatography (FPLC) 
Procedure: Histidine tagged proteins purification was carried out using HisTrap HP 5mL 
column (GE Healthcare Life Sciences) on an ÄKTA Pure FPLC system (GE Healthcare 
Life Sciences). Cell sonication was performed to lyse the cell (settings: total time of 10 
minutes (10 seconds on, 20 seconds off) with 70% sonicating amplitude). Binding buffer 
was composed of 50 mM Tris-HCl pH 8.0, 300 mM NaCl, 10 mM imidazole, 10% (v/v) 
glycerol and 0.1% (v/v) 2-mercaptoethanol. Lysis buffer was composed of binding buffer 
with 2 tablets of PierceTM protease inhibitors mini tablets (Thermo Fisher Scientific), 10 
µg/mL DNase, 10 µg/mL RNase and 10 µg/mL lysozyme. The elution buffer was 
composed of 50 mM Tris-HCl pH 8.0, 300 mM NaCl, 250 mM imidazole, 10% (v/v) 
glycerol and 0.1% (v/v) 2-mercaptoethanol (added before use). Purified protein sample 
fractions were collected, aliquoted and analysed, or stored at -80°C in 10% glycerol 
solution for long-term storage.  
 
4.2.10.2 Polyhistidine Tag-Nickel Purification using Batch Resin 
Procedure: Soluble protein fractions were transferred into 50 mL Falcon tube with the 1 
mL nickel resin, equal to 1 column volume (CV). Binding buffer was composed of 50 mM 
sodium phosphate (NaH2PO4) buffer, 300 mM NaCl and 10 mM imidazole (pH 7.5). Lysis 
buffer was composed of binding buffer with 2 tablets of PierceTM protease inhibitors mini 
tablets (Thermo Fisher Scientific), 10 µg/mL DNase (Brand), 10 µg/mL RNase (Brand) 
and 10 µg/mL lysozyme (Brand). The wash buffer pH 7.5 was composed of 50 mM 
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sodium phosphate (NaH2PO4) buffer, 300 mM NaCl and 20 mM imidazole. The elution 
buffer was composed of 50 mM sodium phosphate (NaH2PO4) buffer, 300 mM NaCl and 
250 mM imidazole (pH 7.5). The mixture was then left overnight at 4°C on a rolling 
platform to allow even mixing. The solution was transferred into a filter column and 
allowed to flow through the column by gravity to remove any unbound protein. Samples 
were collected for analysis at each step. The resin was then washed with 5 CV wash 
buffer at least three times before eluting the protein. The resin was then treated with 
elution buffer and left for at least a minute before retrieving the sample. The eluted protein 
fractions were analysed to identify which fraction contained the desired protein. The flow 
of the nickel purification can be found in Figure 4.2. 
Buffer  
Binding 50 mM NaH2PO4 + 300 mM NaCl + 10 mM imidazole (pH 7.5) 
Lysis 
50 mM NaH2PO4 + 300 mM NaCl + 10 mM imidazole (pH 7.5) + protease 
inhibitors + 10 µg/mL DNase + 10 µg/mL RNase + 10 µg/mL lysozyme 
Wash 50 mM NaH2PO4 + 300 mM NaCl + 20 mM imidazole (pH 7.5) 
Elution 50 mM NaH2PO4 + 300 mM NaCl + 250 mM imidazole (pH 7.5) 
 
 
4.2.10.3 Desalting: Removal of Imidazole Salt from the Protein Solution 
Principle: Size exclusion chromatography is a technique to separate biomolecules 
according to differences in their molecular weight. A dextran gel matrix is usually used 
for gel filtration, where molecules larger than the largest pores are excluded from the 
matrix and are eluted first. Sephadex G-25 has a fractionation range of 1000 – 5000 Da.    
Procedure: The desalting process was performed using Sephadex G-25 in a PD-10 
desalting column (GE Healthcare Life Science, Buckinghamshire, UK). Both the column 
equilibration and elution buffer were composed of 50 mM phosphate buffer (NaH2PO4), 
300 mM NaCl and 10 mM imidazole (pH 7.5). The column was equilibrated by allowing 
the solution to enter the packed bed completely. The flow-through was discarded and 
approximately 25 mL equilibration buffer was used in total. Samples were applied in 2.5 
mL, samples less than his volume were brought up to 2.5 mL before application to the 
column. The sample was allowed to enter the packed bed completely before discarding 
the flow-through. For sample elution, 3.5 mL of buffer was used, and the eluate was 
collected. The process was repeated until all the sample was completely treated. The 
recovery protein range is 70 -90% of the initial concentration. 
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Buffer  
Wash & Elution 50 mM NaH2PO4 + 300 mM NaCl + 10 mM imidazole (pH 7.5) 
 
 
4.2.10.4 Fusion Protein Cleavage using TEV Protease A 
The fusion protein was separated into two domains by introducing TEV protease 
to the first-step of the purification. The protein was treated with protease overnight at 4°C 
on a rolling platform to allow even mixing (concentration ratio 1 OD280 TEV to 100 OD280 
protein).  
 
4.2.10.5 Second-step Polyhistidine Purification using Batch Resin 
Procedure: Protein soluble fractions were transferred into 50 mL Falcon tubes with the 
1 mL nickel resin, equal to 1 column volume (CV). The mixture was then left overnight at 
4°C on a rolling platform to allow even mixing. The solution was transferred into a filter 
column and allowed to flow through the column by gravity to remove any unbound 
protein. Samples were collected for analysis at each step. The resin was then washed 
with 5 CV binding buffer at least three times before eluting the protein. The resin was 
treated with elution buffer and left for at least a minute before retrieving the sample. The 
eluted protein fractions were analysed to identify which fraction contains the desired 
protein 
Buffer  
Binding 50 mM NaH2PO4 + 300 mM NaCl + 10 mM imidazole (pH 7.5) 
Wash 50 mM NaH2PO4 + 300 mM NaCl + 20 mM imidazole (pH 7.5) 
Elution 50 mM NaH2PO4 + 300 mM NaCl + 250 mM imidazole (pH 7.5) 
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1) Incubation with Ni-NTA 
resin at 4°C with 
constant rolling 
overnight. 
2) Transfer the soluble 
fraction + nickel resin 
onto a filter column and 
allow the flow-through 
by gravity. 
Sample of the flow-
through was collected 
for analysis. 
3) Wash the resin using 5 
CV wash buffer allow 
the buffer to flow by 
gravity. Sample of the 
wash buffer was 
collected for analysis. 
 
Wash buffer (pH 7.5): 
50 mM NaH2PO4 
300 mM NaCl 
20 mM imidazole 
 
4) Protein bound to the 
resin was removed 
using 2CV elution buffer. 
The resin was left in the 
buffer for at least 2 
minutes to increase 
protein removal yield in 
the first eluate. Sample 
of the eluate was 
collected for analysis. 
 
Elute buffer (pH 7.5): 
50 mM NaH2PO4 
300 mM NaCl 
250 mM imidazole 
 
First –step Purification (Negative Nickel resin) 
Ni-NTA 
Ni-NTA 
Ni-NTA 
Ni-NTA 
Solution with total 
intracellular protein 
Solution with total 
intracellular protein 
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5) Removal of the 
imidazole salt by 
running the eluate from 
first-step of the 
purification in a size 
exclusion column with 
Sephadex G-25. 
6) Cleavage of fusion 
protein to release 
mature hLtn peptide 
from the lipoyl domain. 
 
First-step eluate +  
TEV protease 
(Desalted) 
7) Capture of His.Lipoyl 
domain and His-TEV 
protease on a nickel 
resin 
  
Flow-through (Purified hLtn 
variants) 
8) Wash the resin using 5 
CV wash buffer allow 
the buffer to flow by 
gravity. Sample of the 
wash buffer was 
collected for analysis. 
 
Wash buffer (pH 7.5): 
50 mM NaH2PO4 
300 mM NaCl 
20 mM imidazole 
Second –step Purification (Negative Nickel resin) 
Collected 
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Figure 4.2: Flow diagram of the two-step IMAC batch purification with nickel resin 
protocol used for hLtn variants purification.  
9) Protein bound to the 
resin was removed 
using 2CV elution buffer. 
The resin was left in the 
buffer for at least 2 
minutes to increase 
protein removal yield in 
the first eluate. Sample 
of the eluate was 
collected for analysis. 
Additional washing 
using buffer with high 
imidazole concentration 
(500 mM) to strip any 
residual bounded 
protein 
 
High imidazole buffer (pH 
7.5): 
50 mM NaH2PO4 
300 mM NaCl 
500 mM imidazole 
 
10) Wash the resin for storage 
 
Wash buffer → distilled H2O 2× → 20% (v/v) Ethanol 2×; and 
storage in 20% (v/v) ethanol. 
Ni-NTA 
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4.2.11 Protein Analysis 
4.2.11.1 Protein Concentration Determination using UV-Spectrometer  
The concentration of the protein was measured by using a UV spectrometer at a 
wavelength 280 nm. The concentration was then corrected using the Beer-Lambert’s law 
equation. This was performed by considering the extinction co-efficient of each protein 
species obtained from Expasy ProtParam analysis (refer Chapter 4(a)).  
 
 
4.2.11.2 Calcium Flux Assay 
Principle: This method uses Indo-1 AM ester (Figure 4.3), a ratiometric fluorescent dye 
that is loaded into cells and can be detected by UV laser excitation to measure 
intracellular calcium levels. The emission wavelength depends on whether the dye binds 
to calcium (~420 nm) or is free (~510 nm). Intracellular calcium concentration changes 
can be determined by the ratio of the two wavelengths value (Dustin, 2000). 
Whilst, Indo-1 is not cell permeable, the addition of the potassium salt penta 
acetoxymethyl (AM) to the dye allows it to cross the cell membrane as well as increasing 
the solubility. Once inside the cell, an intracellular esterase will cleave the AM, leaving 
Indo-1 free to chelate to intracellular calcium. 
Procedure: To investigate the effect of the hLtn variants functional activity, highly XCR1-
positive OCCL (SCC4 cells) were used. 1 × 105 cells/mL were prepared in a centrifuge 
tube. Cells were re-suspended in 1 mL cell loading media (CLM) consist of Dulbecco’s 
PBS with MgCl2 and CaCl2 (Cat#: D8552; Sigma-Aldrich, Dorset) with 0.5% (w/v) BSA. 
Indo-1 AM (Cat#: 21030, AAT BioQuest (by Stratech), Suffolk). 4 µg/mL of Indo-1 AM (4 
µM) was added to the cell suspension and incubated at 37ºC for 30 in the dark. Gentle 
mixing of the solution was performed every 10 minutes. After incubation, the cells were 
centrifuged at 400×g for 5 minutes and re-suspended in CLM. The cells were left for 15 
minutes before starting the calcium flux analysis. The analysis was performed by using 
a BDTM LSRII flow cytometer (BD Bioscience, Oxford, UK). A detailed flow cytometer 
settings optimisation and preparation can be found in Appendix 12. The cells were kept 
A = ϵ × b × c 
Where; A is the absorbance, ϵ is the wavelength-dependent molar absorptivity co-efficient 
(M-1 cm-1), b is the path length and c is the analyte concentration 
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at 37ºC before the run to allow maximal calcium flux activity. The programme was 
executed at 200 events/s for 30 s before introducing the treatments. Ionomycin (1 
mg/mL) was used as positive control and all the hLtn variants (100 mg/mL) were tested. 
The data was then analysed using FlowJo software (LLC, Oregon, US). This method 
was adapted from protocol used successfully by the Feinstein Research Institute and 
others in UCL Institute of Health, London (Round, 2007). 
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Figure 4.3: Mechanism of ion channel gate activation by second messengers from inside 
the cell through the interaction of chemokine-chemokine receptor. The chemical 
structure of Indo-1 AM before entering the cell (top) and Indo1 inside the cell after 
removal of the penta-acetoxymethyl by intracellular esterase is also shown. 
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4.3 RESULTS 
4.3.1 Molecular Cloning of hLtn Expressing Vector 
4.3.1.1 Preparation of hLtn W55D from pCMV6 Entry-XCL1 (WT) by Site-
directed Mutagenesis 
The mutagenesis was performed on the pCMV6-Entry-hLtn plasmid from 
Origene, XCL1 (Myc-DDK-tagged)-Human chemokine (C motif) ligand 1 (Cat#: 
RC218177; Origene EU, Herford, Germany). The primers used for the mutagenesis were 
generated using OneClick Mutagenesis online tool and was performed as described in 
the methods section (see Section 4.2.3.1) to generate the mutagenic primers and 
experimental conditions. The expected total size of the PCR product was 5292 kb 
(pCMV6-Entry: 4947 kb + hLtn: 345 kb) and Figure 4.4 indicates that the whole plasmid 
amplification was successful (marked with an arrow) as evidenced by the thick band 
(Warburton et al., 2015). The DNA sequence for the protein variant identity was 
confirmed (Appendix 13). The pCMV6-Entry-hLtn CC3 mutant plasmid had already 
been established previously.  
 
Figure 4.4: PCR analysis of the site-directed mutagenesis from pCMV6-Entry-hLtn WT 
to W55D sequence. The product was monitored by DNA gel electrophoresis (1% (w/v) 
agarose gel). M: 1 kb DNA ladder (NEB). Lane 1:  PCR product. The theoretical size of 
the plasmid DNA is 5292 kb (shown at arrow ◄).  
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4.3.1.2 Preparation of Plasmid pET24a-HLTEV-hLtn Variants for Protein 
Expression 
The plasmid backbone was obtained from pET24a-HLTEV-p53.QMFL. Excision 
of the p53.QMFL sequence was performed using the restriction enzymes BamHI and 
EcoRI. The digested product was then separated using DNA gel electrophoresis to 
retrieve the desired plasmid backbone (Figure 4.5). Initially, the plasmid backbone was 
planned to be retrieved using the established pET24a-HLTEV-hLtn WT. However, due 
to the small size of the hLtn WT DNA sequence, it was difficult to discern if the digestion 
was successful (result not shown). Similarly, due to the small size (300 bp) of the target 
gene sequence (the CC3 and W55D mutants), the DNA sequence extraction was difficult 
to achieve. Alternatively, the gene sequence of CC3 and W55D mutants from the pCMV6 
cassettes (as described in previous Chapter 4(a)) were amplified using PCR (Figure 
4.6). The CC3 and W55D PCR products were treated with BamHI and EcoRI restriction 
enzymes before ligation using T4 DNA ligase with the previously digested pET24a-
HLTEV plasmid with the same endonucleases (to obtain DNA sticky ends). The ligated 
product was then transformed into E. coli strain DH5-α and the success of the ligation 
was monitored by growth of colonies on the kanamycin plate (Figure 4.7). 
 
Figure 4.5: DNA digestion of pET24a-HLTEV-p53 QFML at restriction site BamHI – 
EcoRI. The product was monitored by DNA gel electrophoresis (1% (w/v) agarose gel). 
The digested product consisted of pET24a-HLTEV (high molecular weight – arrow ◄) 
and p53 QFML (low molecular weight – arrow ) with sticky ends. The DNA size was 
determined 1 kb DNA ladder (NEB).  
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Figure 4.6: PCR amplification of CC3 and W55D variants peptide gene sequence from 
their respective pCMV6 cassette. The product was monitored by DNA gel 
electrophoresis (1% (w/v) agarose gel). The expected PCR product is around 300 base 
pairs (shown at arrow ◄). The DNA size was determined 1 kb DNA ladder (NEB).  
CC3 W55D 
10.0 – 
8.0 – 
6.0 – 
5.0 – 
4.0 – 
3.0 – 
2.0 – 
1.5 – 
1.0 – 
0.5 – 
Kilobases 
(kb) 
Chapter 4(b): Production of the Recombinant hLtn Variants 
 
Functional Role of the Chemokine Receptor XCR1 and Its Bioengineered Ligand in Oral 
Squamous Cell Carcinoma 155 
 
Figure 4.7: hLtn mutant variants plasmid ligation. The inoculated E. coli strain DH5-α 
colonies transformed with ligated product of pET24a-HLTEV with respective hLtn 
variants (CC3 and W55D mutants) on 2×TYE agar plate with kanamycin. The excision 
was performed at BamHI and EcoRI cleavage site of the gene construct. The control 
plate contained cut pET24a-HLTEV plasmid to observe the ligation background. 
  
W55D mutant 
CC3 mutant 
Vehicle control 
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4.3.2 Comparative Study of pET24a-(IEGR) and pET24a-(TEV) hLtn Constructs 
In this sub-chapter, two different plasmid constructs were studied to verify the 
best suited construct for the hLtn variants expression. The construct used was the 
plasmid containing hLtn wild type (as explained in Chapter 4(a)). Additionally, different 
modes of expression induction for either isopropyl-β-D-thiogalactopyranosidase (IPTG) 
or auto-induction were also considered. Initial protein expression was performed in E. 
coli strain BL21 (DE3) 
Protein gel electrophoresis was used to monitor the expressed protein. Result 
showed auto-induction is the preferred method for the fusion protein (Figure 4.8). There 
was no protein expression detected with IPTG induction. Protein expression with plasmid 
construct pET24a-(TEV) was higher than pET24a-(IEGR). The fusion protein size was 
estimated be around 26 kDa as examined using the protein gel. The fusion protein in 
silico analysis (refer Chapter 4 (a)) calculated that the theoretical molecular weight was 
~22 kDa. Therefore, western blot analysis for His-tag was performed to confirm the result 
obtained using protein gel. The result revealed that the protein size was around ~26 kDa 
when running on a protein gel (Figure 4.9). TEV construct expression was higher than 
the IEGR construct when examined for their total protein and soluble fraction. Due to 
lack of protein expression by pET24a-(IEGR) plasmid, the protein expression was 
proceed using the pET24a-(TEV) plasmid. 
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Figure 4.8: Comparison between fusion proteins constructs and different induction 
schemes. pET24a-(IEGR) and pET24a-(TEV) hLtn constructs were expressed using E. 
coli strain BL21 (DE3) monitored by Coomassie blue dye-stained SDS-PAGE (10% 
polyacrylamide gel). M: molecular weight standard (kDa). On the left (His.Lipoyl-IEGR 
construct): Lane 1: Total intracellular protein before induction. Lane 2: Total intracellular 
protein after IPTG induction. Lane 3: Total intracellular protein after auto-induction. On 
the right (His.Lipoyl-TEV construct): Lane 4: Total intracellular protein before induction. 
Lane 5: Total intracellular protein after IPTG induction. Lane 6: Total intracellular protein 
after auto-induction. The arrow ◄ is the expected fusion protein size (~26 kDa). 
  
135 – 
100 – 
75 – 
58 – 
46 – 
32 – 
25 – 
22 – 
Protein 
Ladder 
  
Chapter 4(b): Production of the Recombinant hLtn Variants 
 
Functional Role of the Chemokine Receptor XCR1 and Its Bioengineered Ligand in Oral 
Squamous Cell Carcinoma 158 
 
Figure 4.9: Western blot analysis between fusion proteins constructs. The pET24a-
(IEGR) and pET24a-(TEV) hLtn constructs was expressed using E. coli strain BL21 
(DE3) from SDS-PAGE (10% polyacrylamide gel). M: Novex® Sharp Pre-Stained Protein 
Standard (kDa) (Thermo Fisher Scientific). On the left (His.Lipoyl-TEV construct): Lane 
1: Soluble cell extract. Lane 2: Flow-through. Lane 3: Insoluble cell extract. On the right 
(His.Lipoyl-IEGR construct): Lane 4: Soluble cell extract. Lane 5: Flow-through. Lane 6: 
Insoluble cell extract. The arrow ◄ is the expected fusion protein (~26 kDa). Truncated 
fusion protein was also noticeable at arrow .  
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4.3.3 Comparative Study of pET24a-(TEV) hLtn Constructs using Different E. coli 
Strains and Induction Schemes 
E. coli C41 (DE3) and BL21 (DE3) were used to study the suitable strain to 
express the recombinant fusion protein. The success of the transformation into each 
strain was monitored by growth of the colonies on the kanamycin plate (Figure 4.10). 
The transformation rate was higher in BL1 (DE3) compared to C41 (DE3). Additionally, 
different induction schemes for the protein expression was also considered. The result 
of total intracellular protein analysis showed that there was no protein expressed through 
IPTG induction for both strains (Figure 4.11). Additionally, expression can be seen by 
both E. coli strains through TYE and TB auto-induction. There was a slight difference in 
the protein profile expression between C41 (DE3) and BL21 (DE3). BL21 (DE3) has 
much more ‘cleaner’ expression and no differences were observed between both auto-
induction media for the total protein expressed.  
To further ascertain the preferable conditions for the fusion protein expression, 
soluble and insoluble protein from the cell extracts between strains and media were 
examined. Good protein expression was observed by BL21 (DE3) in both auto-induction 
media but expression was observed to be higher in TYE auto-induction (Figure 4.12). 
Furthermore, the protein expressed by BL21 (DE3) had an increased soluble fraction 
compared to the insoluble fraction. In the case of C41 (DE3), there was little amount of 
protein expressed and most of the protein was truncated in both induction media. Some 
truncation of the protein was also observed in the BL21 (DE3) lane but this was not as 
severe. 
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Figure 4.10: The inoculated of E. coli strain (A) BL21 (DE3) and (B) C41 (DE3) colonies 
transformed with pET24a-HLTEV hLtn variants wild type on 2×TYE agar plate with 
kanamycin.  
(A) BL21 (DE3) 
(B) C41 (DE3) 
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Figure 4.11: Comparison between fusion protein expression in different E. coli strains 
and induction schemes. pET24a-(IEGR) and pET24a-(TEV) hLtn constructs were 
expressed using E. coli strain BL21 (DE3) monitored by Coomassie blue dye-stained 
SDS-PAGE (10% polyacrylamide gel). M: molecular weight standard (kDa). Lane 1: Total 
intracellular protein before induction. Lane 1&3: Total intracellular protein without 
induction in TYE media. Lane 2&4: Total intracellular protein after IPTG induction in TYE 
media. Lane 5&7: Total intracellular protein after TB auto-induction. Lane 6&8: Total 
intracellular protein after TYE auto-induction. The arrow ◄ is the expected fusion protein 
size (~26 kDa).  
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Figure 4.12: Comparison between the soluble and insoluble fusion protein expression 
in different E. coli strain and auto-induction media. pET24a-(TEV) hLtn constructs was 
expressed using E. coli strain BL21 (DE3) and C41 (DE3) monitored by Coomassie blue 
dye-stained SDS-PAGE (15% polyacrylamide gel). M: molecular weight standard (kDa). 
Lane 1: Total intracellular protein without induction. Lane 2-5: Soluble and insoluble cell 
extract from BL21 (DE3) and C41 (DE3) expression using tryptone-yeast extract (TYE) 
auto induction media. Lane 6-9: Soluble and insoluble cell extract from BL21 (DE3) and 
C41 (DE3) expression using terrific broth (TB) auto induction media. The arrow ◄ is the 
fusion protein size (~26 kDa). Protein truncation at arrow  was also observed.   
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4.3.4 TEV Protease Protein Purification 
TEV protease is an enzyme widely used to remove an affinity tag from 
recombinant proteins by site-specific endoproteolysis (Tropea, Cherry and Waugh, 
2009) through recognition of the ENFLYQ↓X sequence. The TEV protease construct 
used in this experiment contained a polyhistidine tag to accommodate affinity purification 
followed by a lipoyl domain to increase protein quantity and solubility in a pRSET vector 
to obtain a high-copy number of expression (Ramos et al., 2004). Two of the constructs 
were tested and both were engineered to have a high yield. The TEV protease containing 
the lipoyl domain has a total molecular weight of ~36 kDa. The colony size of BL21 (DE3) 
with the TEV A Protease construct is smaller compared to TEV S Protease (Figure 4.13). 
For the protease purification, the result showed a good profile for TEV A protease 
(Figure 4.14) while not for TEV S Protease (Figure 4.15).  
 
Figure 4.13: Inoculated of E. coli strain BL21 (DE3) colonies transformed with pRSET-
His.Lipoyl TEV proteases on 2×TYE agar plate with ampicillin.  
TEV A Protease 
TEV S Protease 
Vehicle control 
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Figure 4.14: Purification of TEV A protease using the FPLC ÄKTA Pure system. The 
product was monitored by Coomassie blue dye-stained SDS-PAGE (10% 
polyacrylamide gel). M: molecular weight standard (kDa). Lane 1: Total intracellular 
protein after induction. Lane 2: Soluble cell extract. Lane 3: Flow-through. Lane 4: 
Washing residual. Lane 5: Elute fraction 8. Lane 6: Elute fraction 10. Lane 7: Elute 
fraction 14. Lane 8: Elute fraction 15. Lane 9: Elute fraction 16. The arrow ◄ is the 
expected MW of the His.Lipoyl TEV Protease (~36 kDa).  
66.4 – 
55.6 – 
42.7 – 
27.0 – 
20.0 – 
34.6 – 
Protein 
Ladder 
Chapter 4(b): Production of the Recombinant hLtn Variants 
 
Functional Role of the Chemokine Receptor XCR1 and Its Bioengineered Ligand in Oral 
Squamous Cell Carcinoma 165 
 
Figure 4.15: Purification of TEV S protease using the FPLC ÄKTA Pure system. The 
product was monitored by Coomassie blue dye-stained SDS-PAGE (10% 
polyacrylamide gel). M: molecular weight standards (kDa). Lane 1: Total intracellular 
protein before induction. Lane 2: Total intracellular protein after induction. Lane 3: 
Soluble cell extract. Lane 4: Flow-through. Lane 5: Washing residual. Lane 6: Elute 
fraction 7. Lane 7: Elute fraction 8. Lane 8: Elute fraction 9. Lane 9: Elute fraction 13-19. 
The arrow ◄ is the expected protein band of the TEV Protease.  
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4.3.5 Protein Purification of hLtn Variants  
4.3.5.1 Wild type Recombinant hLtn 
Initial expression of the fusion protein was performed on the wild type construct. 
The expected size of the fusion protein is ~26 kDa (as discussed in Chapter 4(a)). 
Results showed that the protein expressed is highly soluble (Figure 4.16) by comparing 
the soluble (refer Lane 3) and insoluble fraction (refer Lane 4). This indicates that the 
fusion protein construct with the lipoyl domain has improved the protein solubility. 
Treatment with the nickel resin highly purifies the fusion protein, although there are still 
some impurities observed and a noticeable truncated form of the protein. 
The next step was to obtain the mature hLtn peptide by digestion the TEV 
protease cleavage site of the fusion protein. Before the digestion and re-introducing the 
fusion protein to the nickel resin, the protein was treated beforehand in a size exclusion 
chromatography column to remove excess imidazole salt. The presence of the salt can 
interfere with binding of polyhistidine tag to the nickel affinity resin. The result shows that 
the recovery of the mature hLtn peptide very low as most of it remains bound to the nickel 
beads (Figure 4.17 (a)). Moreover, the cleaved protein size for the His-Lipoyl domain 
and mature hLtn protein was at ~15 kDa and ~13 kDa respectively, with a total size 
higher than the undigested fusion protein (only ~26 kDa). The observed recombinant 
hLtn had a higher molecular weight (~13 kDa) than the theoretical (~10 kDa). Therefore, 
we ran the commercially available hLtn on the gel to clarify the result. The recombinant 
hLtn gel migration was slightly slower than expected which was comparable to the 
commercial hLtn (refer Figure 4.17 (b)). The recombinant hLtn produced had a slightly 
higher molecular weight compared to the commercial as it contains two extra amino acids 
on the N-terminal. The lipoyl domain corresponds to the correct theoretical molecular 
weight at ~16 kDa. Interestingly, the mature recombinant hLtn peptide gel migration 
shows a higher molecular weight <10 kDa (Figure 4.12 (a) Lane 3) compared to the 
expected theoretical molecular weight generated using Expasy ProtParam analysis 
(refer Chapter 4 (a)).   
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Figure 4.16: First-step of Ni-NTA purification of recombinant HLTEV-hLtn WT. The 
product was monitored by Coomassie blue dye-stained SDS-PAGE (15% 
polyacrylamide gel). M: molecular weight standards (kDa). Lane 1: Total intracellular 
protein without induction. Lane 2: Total intracellular protein after induction. Lane 3: 
Soluble cell extract. Lane 4: Insoluble cell extract. Lane 5: Flow-through. Lane 6: 
Washing residual. Lane 7: First elution. Lane 8: Second elution. Lane 9: Third elution. 
The arrow  is the fusion protein (theorectical MW ~26 kDa)  
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Figure 4.17: Second-step of Ni-NTA purification of recombinant HLTEV-hLtn WT. The 
product was monitored by Coomassie blue dye-stained SDS-PAGE (15% 
polyacrylamide gel). On the left (a): M: molecular weight standards (kDa). Lane 1: Elution 
from first-step purification. Lane 2: Digestion of desalted fusion protein with His.Lipoyl-
TEV protease. Lane 3: Purified recombinant hLtn. On the right (b): M: molecular weight 
standards (kDa). Lane 1: Digestion of desalted first elution fusion protein with His.Lipoyl-
TEV protease. Lane 2: Commercial hLtn (Peprotech®) diluted in 1% (w/v) BSA (arrow 
). Lane 3: Purified recombinant wild type hLtn. The arrow  is the His.Lipoyl-TEV 
Protease (theoretical MW ~36 kDa); is the fusion protein (theoretical MW ~26 kDa) 
and ◄ is the recombinant hLtn (theoretical MW ~10 kDa).  
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4.3.5.2 Recombinant CC3 and W55D Mutants of hLtn 
Purification of the hLtn mutant variants was carried on once the purification profile 
has been established with the recombinant wild type hLtn. Similar profile in the mutant 
protein purification was observed compared to the wild type, as there are no differences 
in the hLtn variants sequence only replacement of strategic amino acids. Both CC3 
(Figure 4.18) and W55D (Figure 4.20) mutant fusion protein expressed at ~26 kDa. 
Noticeably, the W55D mutant fusion protein has more truncation of the fusion protein 
(cleaved of the fusion protein before treatment with protease) compared to CC3.  
The second-step in the purification of the mutants revealed that while the 
digestion of the TEV linker site was successful, there was some residual fusion protein 
which was not cleaved by the protease. The purified recombinant CC3 (Figure 4.19 Lane 
4) and W55D (Figure 4.21 Lane 4) mutants contained less impurities than in the wild 
type. Unfortunately, more than half of the protein was lost due to non-specific binding to 
the nickel resin was observed (refer Figure 4.19 and 4.21 Lane 6).  
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Figure 4.18: First-step of Ni-NTA purification of recombinant HLTEV-hLtn CC3 (rCC3) 
mutant. The product was monitored by Coomassie blue dye-stained SDS-PAGE (15% 
polyacrylamide gel). M: molecular weight standards (kDa). Lane 1: Total intracellular 
protein without induction. Lane 2: Total intracellular protein after induction. Lane 3: 
Soluble cell extract. Lane 4: Insoluble of cell extract. Lane 5: Flow-through. Lane 6: 
Washing residual. Lane 7: First elution. Lane 8: Second elution. Lane 9: Third elution. 
The arrow ◄ is the His.Lipoyl.TEV-hLtn CC3 (theoretical MW 26 kDa).  
250 – 
150 – 
100 – 
70 – 
50 – 
40 – 
30 – 
20 – 
10 – 
15 – 
Protein 
Ladder 
Chapter 4(b): Production of the Recombinant hLtn Variants 
 
Functional Role of the Chemokine Receptor XCR1 and Its Bioengineered Ligand in Oral 
Squamous Cell Carcinoma 171 
 
Figure 4.19: Second-step of Ni-NTA purification of recombinant HLTEV-hLtn CC3 
(rCC3) mutant. The product was monitored by Coomassie blue dye-stained SDS-PAGE 
(15% polyacrylamide gel). M: molecular weight standards (kDa). Lane 1: Elution from 
first-step purification. Lane 2: Desalted first-step elution. Lane 3: Digestion of desalted 
first elution fusion protein with His.Lipoyl-TEV protease. Lane 4: Purified recombinant 
CC3 mutant hLtn. Lane 5: Washing residual. Lane 6: First elution. Lane 7: Second 
elution. The arrow  is the His.Lipoyl-TEV Protease (~36 kDa);  is the CC3 (theoretical 
MW ~26 kDa); ◄ is the lipoyl domain of the fusion protein (~16 kDa); and  is the rCC3 
hLtn (~10 kDa).  
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Figure 4.20: First-step Ni-NTA purification of recombinant HLTEV-hLtn W55D (rW55D) 
mutant. The product was monitored by Coomassie blue dye-stained SDS-PAGE (15% 
polyacrylamide gel). M: molecular weight standards (kDa). Lane 1: Total intracellular 
protein without induction. Lane 2: Total intracellular protein after induction. Lane 3: 
Soluble cell extract. Lane 4: Insoluble body of cell extract. Lane 5: Flow-through. Lane 
6: Washing residual. Lane 7: First elution. Lane 8: Second elution. Lane 9: Third elution. 
The arrow  is the His.Lipoyl.TEV-hLtn W55D (theoretical MW 26 kDa) and arrow ◄ is 
the truncated protein.  
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Figure 4.21: Second-step Ni-NTA purification of recombinant HLTEV-hLtn W55D 
(rW55D) mutant. The product was monitored by Coomassie blue dye-stained SDS-
PAGE (15% polyacrylamide gel). M: molecular weight standards (kDa). Lane 1: Elution 
from first-step purification. Lane 2: Desalted first-step elution. Lane 3: Digestion of 
desalted first elution fusion protein with His.Lipoyl-TEV protease. Lane 4: Purified 
recombinant CC3 mutant hLtn. Lane 5: Washing residual. Lane 6: First elution. Lane 7: 
Second elution. The arrow  is the His.Lipoyl-TEV Protease (~36 kDa);  is the rW55D 
(theoretical MW ~26 kDa); ◄ is the lipoyl domain of the fusion protein (~16 kDa); and  
is the rW55D hLtn (~10 kDa).  
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4.3.5.3 Concentration of Recombinant Protein Produced 
The concentration of recombinant hLtn variants produced were measured and 
concentration assumption correction was re-calculated based on the extinction co-
efficient provided in Chapter 4(a) (refer Table 4.3). 
Table 4.9: Recombinant hLtn variants protein concentration. 
hLtn variants 
Optical Density [Protein] 
(mg/mL) A260 A280 A340 
Wild type 0.615 0.578 0.387 0.843 
CC3 mutant 0.271 0.246 0.105 0.360 
W55D mutant 0.133 0.115 0.055 0.782 
 
 
 
4.3.6 Analysis of the Functional Activity of Recombinant hLtn Variants using 
Calcium Flux Assay 
The functional activity of recombinant protein is important to investigate whether 
the produced protein behave and function similarly to its native protein. Calcium flux 
assay was performed to determine the protein activity due to chemokine ability to activate 
calcium flux signalling in cells through their receptor. Previous publications had shown 
behaviour of hLtn variants in calcium signalling [hLtn WT, CC3 and W55D mutant 
(Tuinstra et al., 2007, 2008)]. The results (Figure 4.22) show that the recombinant hLtn 
variants produced were functional. Both canonical fold hLtn, hLtn WT and CC3 displayed 
the ability to promote calcium flux whilst this was not the case for W55D.    
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Figure 4.22: Calcium flux assay of SCC4 cells using Indo-1 dye. (A) Ionomycin and (B) 
EGTA was used as positive and negative controls respectively. The cells were treated 
with 100 mg/mL hLtn (C) WT, (D) CC3 and (E) W55D. The dotted line (- - - -) is the base 
line of the unbound Indo-1 SCC4 cells before stimulation.  
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4.4 DISCUSSION 
There are number of challenges in producing and purifying large number of 
protein in high-throughput manner (Jia and Jeon, 2016). Small proteins are especially 
difficult such as the protein being easily degraded by the expressing organism, usually 
in E. coli or problems with purification. Chemokines are categorised as small proteins 
due to its molecular weight being around 10 – 12 kDa. To facilitate purification, tag 
vectors or fusion protein partners can assist in the expression. Continuation of the work 
from Chapter 4(a), this sub-chapter was to produce and purify the designed protein using 
all the information obtained from the in-silico analysis. 
 
4.4.1 Molecular Cloning of Plasmid pET24a-His.Lipoyl-TEV hLtn Variants 
Two different constructs were produced to study hLtn protein expression in E. 
coli. The pET24a-(IEGR) construct was designed and generated using GenScript 
services. The sequence was codon-optimised to accommodate expression in E. coli. 
Meanwhile, pET24a-(TEV) was constructed from pCMV6-Entry hLtn where the 
hLtn/XCL1 DNA sequence is from human. Distinct differences between the two 
constructs were the use of different linkers and the cleavage site.  
The OneClick tool was used to generate the mutagenesis primers and the 
experimental conditions (Warburton et al., 2015). The whole-plasmid amplification was 
successful, and the PCR product corresponded to the expected size of the DNA and 
desired amino acid mutation. Expression in E. coli requires a different vector, therefore 
the hLtn variant DNA sequences were required to be transferred into pET24a-HLTEV 
plasmid cassette. 
 
4.4.2 Comparative Study of pET24a-(IEGR) and pET24a-(TEV) hLtn Expressing 
Plasmid Constructs 
There are different ways to induce the plasmid promoter. The operon ‘substrate’ 
is highly dependent on the nature of the promoter. IPTG is a synthetic molecule that 
mimics allolactose, a structural analogue which triggers the transcription of lac operon to 
induce recombinant protein expression. In contrast auto-induction recipe uses lactose in 
the media (Studier, 2014) which drives the protein expression after depletion of glucose.  
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The protein was not expressed as highly with IPTG induction as for auto-
induction. One of the possible explanations for this is that IPTG can provide stress to the 
E. coli system as due to its synthetic nature and is unable to be metabolised by the cell. 
It was found that IPTG exacerbates haloalkene substrate induced toxicity that can 
causes a metabolic burden to E. coli as well as stimulating expression of exogenous 
genes (Dvorak et al., 2015). Lactose is a natural inducer of lac operon and can effectively 
reduce the negative influence on the metabolic pathways, making it a better inducer than 
IPTG for heterologous protein expression in BL21 (DE3) (Dvorak et al., 2015). Moreover, 
the induction is highly dependent on the binding and dissociation rates of IPTG and 
lactose to the lac repressor (Daber et al., 2007). However, some issues of induction with 
IPTG can be rectified by adjusting the concentration. 
The fusion protein migration in SDS-PAGE runs slower than expected and 
therefore appears to have a higher molecular weight compared to theoretical analysis 
generated by the Expasy ProtParam tool (refer Chapter 4(a) Table 4.2). This is not 
unusual as aberrations in protein migration in SDS-PAGE can be due to the process, 
where the separation is by charge rather than mass. Additional protein domains or 
abundance of particular amino acids can affect the process. Moreover high content of 
basic or acidic amino acids (Guan et al., 2015), and partial reduction of the protein thus 
retaining its disulphide bonds (Okamoto et al., 2014) can also contribute to why the 
molecular weight results in protein migration 3-4 kDa above the expected size. Further 
examination using western blot for the His-tag confirmed the SDS-PAGE protein size at 
26 kDa. 
The codon-optimised IEGR construct showed lower expression than the TEV 
construct, in contrast to expectations. Usually codon-optimisation allows a higher 
expression of recombinant protein as codon frequency is different in each organism. 
Furthermore, this juxtaposition may due to the addition of a fusion partner at the N-
terminus which often results in high level expression of the fusion protein (Steinmetz and 
Auldridge, 2017) which facilitates the expression of TEV construct. Further contributions 
to the disparity may come from the content of the amino acids in the linker region. In 
conclusion, pET24a-(TEV) construct was selected in further experimentation. 
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4.4.3 Comparative Study of pET24a-(TEV) hLtn Expression in Different E. coli 
Strains and Induction Scheme 
Two E. coli strains BL21 (DE3) and C41 (DE3) were used to study their ability to 
express the novel fusion protein. C41 (DE3) is a mutant strain of BL21 (DE3) that can 
overcome the toxicity associated when overexpressing recombinant proteins (Dumon-
Seignovert, Cariot and Vuillard, 2004). Induction with IPTG resulted in similar problems 
as previously explained for both strains, although TB and TYE auto-induction has 
positive total protein expression. While there is little difference in the expression, C41 
(DE3) was shown to express slightly more protein compared to BL21 (DE3). This is 
probably due to the differences between the two strains, where C41 (DE3) has a higher 
transformation success rate and expression of heterologous protein compared to its 
parental strain, BL21 (DE3) (Dumon-Seignovert, Cariot and Vuillard, 2004). Also, TB 
media is a highly enriched compared to TYE media with increased concentration of 
peptone, yeast extract and glycerol as carbon source. 
Additional investigations of the protein expression between the strains and auto-
induction recipe were performed by comparing their soluble and insoluble protein 
fractions. Interestingly, C41 (DE3) had a poor expression in this analysis making BL21 
(DE3) the suitable vehicle for the fusion protein expression. The content of soluble 
protein was higher compared to the insoluble, which was expected due to the 
incorporation of the lipoyl domain in the fusion protein. Truncation of protein was 
observed, highly in C41 (DE3). As C41 (DE3) is a mutated strain of BL21 (DE3), it 
behaves differently and is not compatible with the fusion protein. Presence of 
endogenous proteases is a possible cause of the truncation as their function is to remove 
abnormal and misfolded proteins (Gottesman, 1996) although BL21 (DE3) has a 
knockout of OmpT and Lon proteases. This can be remedied by introducing a sufficient 
concentration of exogenous protease inhibitor. 
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4.4.4 Protein Purification of Functionally Active hLtn Variants 
After rigorous examination of the expressing conditions, the hLtn variants were 
expressed and purified. SDS-PAGE analysis was performed to observe the recombinant 
protein purification profile. A similar protein size was observed between the fusion protein 
of hLtn WT, CC3 and W55D fusion proteins.  
The first-step of purification was performed to isolate protein using the affinity tag. 
Non-specific proteins were detected to bind to the resin and eluted along with the fusion 
protein. BL21 (DE3) has shown to produce small number of native proteins that has a 
high affinity to nickel ions even in presence of a high concentration of imidazole (Bartlow 
et al., 2011; Robichon et al., 2011), allowing some amount of unwanted proteins bind to 
the nickel resin.  
A size exclusion chromatography step was sandwiched between the first and 
second purification steps for removal of imidazole salt before re-introducing the fusion 
protein to a nickel resin. Imidazole can interfere with the binding resulting in poor protein 
purity. A second IMAC purification was used to capture the residual ‘nickel-loving’ 
protein, including both the His-Lipoyl TEV protease and the His-Lipoyl domain of the 
fusion protein after digestion. The intention was to release the mature hLtn protein in to 
the solution. Unfortunately, when executing the ‘negative nickel’ attachment, a high 
amount of the purified hLtn variants still bound to the nickel resin even though the 
polyhistidine tag was removed. Some possible explanations for this behaviour are: 1) the 
abundance of free electron pair amino acids (His, Cys, Met, Arg, Lys), and 2) the buffer 
conditions such as pH, salt content, addition of reducing agent or stabilising elements. 
There is some report shown that high content of glutamine (Gln), aspartic acid (Asp) and 
can contribute to non-specific binding to the nickel resin. The enrichment of electron pair 
amino acids potentially sufficient to interact with sequestered Ni2+ ion. Untagged protein 
has natural affinity to for Ni-NTA and is dependent on the proximity of histidine including 
the previously described amino acid residues on its surface. The amino acids will 
deprotonate in pH higher than 7 and readily bind to metals. Nevertheless, this still does 
not explain low recovery of the purified hLtn. Besides, the overall positively charged 
residues of the hLtn protein, increasing the likelihood that the protein feebly adsorbs to 
Ni2+ resin, reducing its capability to be released into the solution.  
The observed pattern of the protein migration in the SDS=PAGE for hLtn WT, 
CC3 and W55D mutant after TEV cleavage were interesting. The mature hLtn protein 
ran slightly higher on the gel suggesting its molecular weight was larger than the 
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theoretical value. This aberrant mobility may be contributed by the overall charge of the 
protein. hLtn protein contains high number of positively charge amino acids and has the 
possibility to be saturated with SDS (Dolnik and Gurske, 2011). SDS-PAGE protein 
migration is highly dependent on charge, therefore this ‘gel-shifting’ phenomenon is to 
be expected. Similar behaviour was observed by using the commercially available hLtn 
(refer Figure 4.17), where documented the molecular weight is documented at 10 kDa 
when measured by mass spectrometry.   
Calcium flux assay was performed to test the functional activity of the purified 
recombinant hLtn. The results obtained were contrast to those of Tuinstra et al. (2007), 
where they showed that any modification at the hLtn N-terminal did not stimulate the 
calcium flux. Our commercially bought XCL1 from Peprotech did activate the calcium 
signalling (contains 2-93 AA of native XCL1 V2GSE) and our in-house recombinant hLtn 
variants has additional glycine ‘leftover’ due to an artefact of TEV protease cleavage (G-
1VGSE). The difference in calcium signalling is probably due to the use of XCR1+ oral 
cancer cell line expressing native chemokine receptor whilst other studies have used 
stably expressing XCR1 human embryonic kidney (HEK) cells. Also, the calcium flux 
assay method in the literature was different where spectrofluometer was used to detect 
Fluo-2 fluorescence. Alternatively, high-throughput flow cytometer quantification using 
Indo-1 dye were used in this experiment. Comparatively, Indo-1 is more sensitive than 
Fluo-2 in detecting intracellular calcium flux (Bailey and Macardle, 2006). In conclusion, 
the recombinant hLtn WT, CC3 and W55D can be produced using the method described 
in this chapter. 
 
4.5 SUMMARY 
This chapter demonstrates that the production and purification methods used are 
applicable for small sized proteins (≤ 10 kDa) such as chemokines. The incorporation of 
the lipoyl domain, a hyper acidic fusion tag at the N-terminus of the fusion protein further 
facilitated the solubility of the protein domain in E. coli. This technique can be generally 
applied to improve production of chemokines although additional optimisation should 
further refine the process on case-by-case basis. The produced chemokine was 
functionally active as observed by its ability to induce calcium flux activity. All the 
recombinant hLtn variants in this chapter will be used in Chapter 5 to study their influence 
on the behaviour of oral cancer cells. 
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CHAPTER 5: THE EFFECT OF RECOMBINANT hLtn ON THE BEHAVIOUR OF 
ORAL CANCER CELL LINES  
5.1 INTRODUCTION 
Previous chapters covered the design, development and production of 
recombinant hLtn variants and expression of XCR1 in oral cancer cell lines (OCCLs). 
hLtn has been shown to mediate cell proliferation, adhesion, migration and invasion in 
cancer cells but the studies have been limited to the wild type variant. hLtn is a 
metamorphic protein that can interconvert between two different protein conformations, 
one that activates the chemokine receptor (hLtn10) while the other does not (hLtn40). 
To date, there have been no studies investigating the effect of the hLtn variants on 
epithelial cells. Therefore, this chapter explores the effect of these variants on oral cancer 
cell lines (OCCL). 
Several functional assays were used to investigate the behaviour of oral cancer 
cell lines (OCCL) after treatment with the hLtn variants. Characteristics such as 
proliferation, adhesion to extracellular matrix (ECM) components, and migration towards 
the variants was studied. 
Proliferation is a key cell characteristic with an upregulation in case of cancer. It 
has been shown previously that hLtn mediates cell proliferation in OCCL through its 
receptor XCR1 (Khurram et al., 2010). However, it is not known whether this interaction 
is associated with the canonical chemokine fold only.  
For the adhesion study, several ECM components abundant in oral connective 
tissue were selected including collagen I and fibronectin. Collagen I is the most abundant 
main structural component in the ECM and expressed in all connective tissues 
(Shoulders and Raines, 2009; Ricard-Blum, 2011). Fibronectin is an ECM glycoprotein 
that is involved in cell growth, differentiation, adhesion and migration (Pankov and 
Yamada, 2002; Singh, Carraher and Schwarzbauer, 2010). Fibronectin is secreted by 
various cells, primarily as a soluble protein dimer, which is then assembled into an 
insoluble matrix, providing a structural support and signal for cells through integrin 
binding. Similarly, fibronectin binds to other ECM structures such as collagen, fibrin and 
heparin sulphate proteoglycans. Collagen IV is a basement membrane component in 
primarily found in the basal lamina epithelial and endothelial cells to separate tissue 
compartments (Lu, Weaver and Werb, 2012). Interaction with collagen IV is key in cancer 
progression as invasion through the basement membrane (predominantly comprising of 
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collagen IV) is the first step in OSCC invasion. These ECM components are important in 
cancer invasion providing anchorage to cancer cells and facilitating spread. 
While it has been previously reported that hLtn is a chemokine with a canonical 
fold able to activate the receptor and mediate calcium flux signalling, the exact 
contribution of different hLtn conformations in cancer is still unknown. Different cell types 
behave differently towards a certain stimulus and in cancer cell, this is often aberrant. 
Therefore, this chapter further investigate the role of hLtn variants on oral cancer cell 
behaviour. 
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5.2 MATERIALS AND METHODS 
5.2.1 Materials 
List of detailed information of the materials (reagents, kits, equipment, software 
and miscellaneous) used in the chapter can be found in Appendix 1-5. 
 
5.2.2 Basic cell culture 
Methods performed in this chapter can be referred in Chapter 3 Section 3.22. 
 
5.2.3 Proliferation assay 
Principle: The proliferation assay was conducted utilising a tetrazolium compound, ([3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt; MTS]) to determine the number of living cells. The dye reaction is 
dependent on the availability of NAD(P)H flux because of cellular metabolic activity and 
indirect method to quantify cell number. 
Procedure: Cells were prepared and seeded at a density of 2×103 cells per 100 µL in 
96-well plates. Overnight incubation at 37°C was performed allowing the cells to adhere 
to the plate. Several wells were pre-treated with anti-human XCR1 antibody for an hour 
to block the receptor activity. Treatment with hLtn variants (wild type, CC3 and W55D 
mutants) was performed at a concentration 100 ng/mL (or ~10 nM) in serum-free media 
(SFM). For positive and negative controls, full-serum media and SFM were used 
respectively. In addition, mitomycin C (concentration 1 µg/mL) was used to arrest cell 
proliferation, serving as baseline for the cell proliferation. The plate was incubated at 
37°C in 5% CO2 incubator. After 48 h and 72 h, 20 µL of MTS was added into each well 
and further incubated for another hour before absorbance measurements were taken. 
Absorbance was quantified using an Infinite® M200 Pro Series (Tecan UK Ltd) at 492 
nm accompanied by MagellanTM Data Analysis Software (Tecan UK Ltd). 
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5.2.4 Adhesion Assay 
96-well tissue culture plates were coated with collagen type I, solution from rat 
tail (Sigma-Aldrich), collagen IV from human cell culture (Sigma-Aldrich) or plasma 
fibronectin (Sigma-Aldrich) (concentration: 0.1 – 10 µg/mL) for an hour in an incubator at 
37°C. Control wells were not coated but left in phosphate buffed saline (PBS) (Sigma-
Aldrich). Non-specific binding sites were blocked using serum free medium (SFM) with 
1% (w/v) BSA for one hour at 37°C. Cells were prepared by detaching the cells using 
0.05% (v/v) Trypsin-EDTA solution (Sigma Aldrich) in PBS. For cell treatment, cells were 
incubated with 100 ng/mL (~10 nM) of recombinant human lymphotactin (XCL1) 
(Peprotech, London, UK) for 24 hours at 37°C with serum-free medium in a T75 flask. 
Using centrifugation (1000×g, 5 min, 28oC), cell pellets were collected, re-suspended 
and counted. 4 × 104 cells in 100 µL were seeded in each well (number of cells was 
determined after optimisation assays). Cells were left to adhere for another 1 hour in the 
incubator. Unattached cells were removed by washing twice using serum free medium. 
100 µL of fresh medium was added to each well followed by addition of 20 µL of CellTiter 
96® Aqueous One Solution Cell Proliferation Reagent in the dark (Promega, 
Southampton, UK). The reagent contains a tetrazolium compound, 3-(4, 5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, 
inner salt (MTS) which is metabolically cleaved by viable cells. After 1 hour, absorbance 
was recorded at 492 nm using an Infinite® M200 Pro Series (Tecan UK Ltd) 
accompanied by MagellanTM Data Analysis Software (Tecan UK Ltd). All assays were 
performed in triplicate and a standard curve for each assay used to determine the cell 
numbers. Data analysis was performed, and graphs prepared using GraphPad Prism 
(GraphPad Software, CA, USA). Statistical analysis using paired Student’s t-test and 
one-way ANOVA were also analysed using GraphPad Prism). A p-value < 0.05 was 
considered significant. 
 
  
total number of adhered cells = 
absorbance value (OD at 492 nm) - c
m
 
% of cell adhesion = 
total number of adhered cells
40,000 cells (initial seed count )
 
Where; c is the intercept value at y-axis, and m is the value of gradient (refer Appendix 14) 
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5.2.5 Migration assay 
Procedure: Chemotaxis/migration assay was performed using Corning® Transwell® 
polycarbonate membrane cell culture inserts with 8.0 µm pores (Cat#: CLS3422-48EA; 
Sigma-Aldrich, UK). The under-side of the membrane was coated with 10 µg/mL of 
fibronectin for an hour in incubator at 37°C and blocked by 1% (w/v) BSA for another one 
hour. 1×105 cells in 100 µL were seeded on the top chamber and 500 µL of chemokine 
solution to the bottom well (as Figure 5.1). Four hours of incubation at 37°C incubator 
allowed the migration to occur. After this incubation, the residual cells and media on the 
top chamber was removed and membrane was fixed in formalin at least for 20 min. 0.5% 
(w/v) crystal violet (in 10% ethanol) was used to stain the cells for 5 to 10 minutes for 
quantification. Cells on the top chamber were removed with a cotton bud and the inserts 
washed with distilled water to remove residual crystal violet stain. The formalin-fixed 
membrane was cut and mounted on a microscope slide for analysis. The migrated cells 
were counted in five random field of views at magnification 100× using FIJI software. 
 
2) Place upper chamber into new well 
8 µM membrane pore size 
Fibronectin (10 µg/mL) 
1) Coat the membrane with fibronectin 
Incubate for 1 hour at 37
o
C in 5% CO
2
 incubator 
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4) Migration assay incubation 
Test substance Lower: Chemokine 
Upper: Seed cells (1×10
5
) 
Seed cells 
Incubate for 1 hour at 37
o
C in 5% CO
2
 incubator 
3) Block non-specific binding site with 1% BSA 
5) Fix the membrane with formalin for at least 20 
minutes 
Formalin 
Incubate for 4 hours at 37
o
C in 5% CO
2
 incubator 
Chapter 5: The Effect of Recombinant hLtn Variants on the Behaviour of Oral Cancer Cell Lines 
Functional Role of the Chemokine Receptor XCR1 and Its Bioengineered Ligand in Oral 
Squamous Cell Carcinoma 188 
 
Figure 5.1: Overview of migration assay steps using Transwell Boyden chamber.  
6) Stain the cells with 0.5% (w/v) of crystal violet 
(diluted in 20% (v/v) EtOH) for 5-10 minutes. 
Crystal violet 
7) Remove excess cells from the upper chamber. 
Clean the membrane gently using cotton bud. 
8) Cut the membrane and mount on microscope 
slide. 
9) Migrated cells were analysed using light microscope and the picture 
was taken for number of cell migrated per 100× view. 
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5.2.6 Statistical Analysis 
All experiments were performed in triplicate with at least three independent 
repeats. The mean average and standard deviation for each sample were calculated, 
and the significance value was calculated using paired Student’s t-test and ANOVA. A 
p-value less than 0.05 was considered significant. 
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5.3 RESULTS 
5.3.1 Proliferation of OCCL on hLtn variants 
Exposure to media with 10% (v/v) FCS significantly increased the proliferation of 
H357 and SCC4 cells after 48h (p=0.0003 and p=0.0022 respectively) (see Figure 5.2 
A-B). OCCLs also showed proliferation in SFM alone compared to cells treated with 
mitomycin C. The proliferation further increased when exposed to hLtn variants. For 
H357 cells, WT, rCC3, and rW55D significantly increased proliferation (p=0.016, 
p=0.0015, and p=0.0101 respectively). There was no significant difference between the 
different hLtn variants treatments. Exposure to all hLtn variants also significantly 
increased the proliferation of SCC4 cells after 48 hours for WT (p=0.0258), rWT 
(p=0.0326), rCC3 (p=0.0088), and rW55D (p=0.0301). Analysis of variance (ANOVA) 
was performed and the proliferation for both H357 and SCC4 was significant compared 
to control (p<0.0001 and p=0.0024 respectively). No significant increase of observed 
after 72 hours for H357 cells but the SCC4 cells retained the same proliferation profile 
as after 48 hours.   
The data demonstrates that SCC4 cells (with higher XCR1 expression) were 
more proliferative and in response for longer duration to hLtn variants compared to H357 
(Figure 5.3). This suggests that cell proliferation mediated through hLtn/XCR1 is 
correlated to XCR1 expression.  
Table 5.1: Rate of proliferation of H357 and SCC4 cells. 
Cell 
line 
Treatment 
duration 
Proliferation rate (normalised to initial seeding) 
Mitomycin C Negative control Positive control 
H357 
48 h 0.85 ± 0.0633 2.95 ± 0.3249 7.47 ± 0.5210 
72 h 0.30 ± 0.1525 5.33 ± 1.1450 9.66 ± 1.5080 
SCC4 
48 h 1.13 ± 0.2024 1.72 ± 0.2083 4.89 ± 0.5830 
72 h 0.34 ± 0.0186 2.17 ± 0.4337 5.50 ± 0.1406 
Mitomycin C was used to arrest the cell proliferation, the negative control well only 
contained serum-free media, while the positive control was treated with 10% (v/v) FCS.  
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Figure 5.2: Proliferation of H357 and SCC4 cells after treatment with hLtn variants for 
(A & C) 48h and (B & D) 72h. Positive controls were grown in medium with 10% (v/v) 
FCS and negative control in SFM only. Mitomycin C (mitoC) was used to stop cell growth. 
All the treatments were prepared in SFM with respective hLtn variants where WT is 
commercial wild type from Peprotech, rWT is recombinant wild type, rCC3 is recombinant 
CC3 mutant, and rW55D is recombinant W55D mutant. The dashed line (- - -) indicates 
the initial seeding baseline. The number of cells were calculated using equation from the 
linear regression graph (see Appendix 14). Data are from three independent repeats 
(n=3), mean ± SEM. (* p-value<0.05, ** p-value<0.01, *** p-value<0.001, **** p-
value<0.0001, NS indicates not significant). 
  
(A) (B) 
(C) (D) 
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Figure 5.3: The proliferation fold change compared to control (SFM) for H357 and SCC4 
after exposure to hLtn variants for 48 h and 72 h. The annotation used above is as 
follows: the positive control (+) (10% (v/v FCS)), the vehicle control (C) (SFM only), and 
the hLtn variants are arranged as follows - position 1: commercial hLtn (WT), position 2: 
recombinant WT (rWT), position 3: recombinant CC3 mutant (rCC3), and position 4: 
recombinant W55D (rW55D). Data are from three independent repeats (n=3), mean ± 
SEM. (* p-value<0.05, ** p-value<0.01). 
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5.3.2 Adhesion of OCCL after exposure to hLtn variants 
The results (see Figure 5.4 A-B) shows increased adhesion of oral cancer cells 
to Collagen I with the highest adhesion at 10 µg/mL concentration. SCC4 cells showed 
higher adhesion than H357 at 10 µg/mL (p<0.0001 and p=0.0008 respectively) 
compared to control. Compared between the two OCCL, more SCC4 cells attached to 
Collagen I than H357 cells. SCC4 cells showed significant adhesion to Collagen I at most 
concentrations (Figure 5.4 B) while H357 cells only showed significantly higher 
attachment at higher concentrations, 3 µg/mL (p=0.0022) and 10 µg/mL (p=0.0008) 
(Figure 5.4 A). ANOVA for H357 and SCC4 adhesion to the different concentration of 
Collagen I was statistically significant (p=0.0022 and p<0.0001 respectively). 
For Collagen IV, OCCL adhesion was relatively low at lower concentration (see 
Figure 5.4 C-D). The highest percentage of cell adhesion was approximately 15% for 
both cell lines on 10 µg/mL of Collagen IV. The adhesion at concentration 10 µg/mL was 
significant to control for SCC4 (p=0.0005) and H357 (p=0.0016). ANOVA to different 
concentrations of Collagen IV for H357 was significant (p<0.0001) but not for SCC4. This 
was considerably different to Collagen I where the same concentration showed 50% or 
more cell adhesion. Thus, OCCLs showed more attachment to Collagen I (significant 
difference from controls at most concentrations) than Collagen IV (significant difference 
to control only at high concentrations). 
Low adherence to fibronectin was observed for H357 compared to SCC4. The 
highest adhesion for both was at 10 µg/mL concentration with 11.96% for H357 cells 
(p=0.0008) and 45.69% for SCC4 cells (p=0.0014) (Figure 5.4 E-F). Both cell lines show 
increased adhesion with increasing concentration of fibronectin. ANOVA for both H357 
and SCC4 adhesion to fibronectin was significant with p<0.0001 and p=0.0055 
respectively. 
The results show that OCCL adhesion to ECM proteins follows a similar general 
trend where adherence to collagen I > fibronectin > collagen IV, although in H357 (with 
lower XCR1 expression), the adhesion to fibronectin and collagen IV were somewhat 
similar. SCC4 cells had more than twice the adherence compared to H357 for both 
collagen I and fibronectin. Similar adherence to collagen IV was observed in both cell 
lines.  
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Figure 5.4: Adhesion of OCCL to collagen I (A-B), collagen IV (C-D), and fibronectin (E-
F). The concentration range used was 0-10 µg/mL. Data are from three independent 
repeats (n=3), mean ± S.E.M. Statistical analysis with Student’s t-test and ANOVA 
analysis were performed. (* p-value<0.05, ** p-value<0.01, *** p-value<0.001, **** p-
value<0.0001).  
(A) (B) 
(C) (D) 
(F) (E) 
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To study the effect of hLtn on OCCL adhesion, cells were incubated for 24 hours 
with the commercial hLtn wild type (WT). There was an approximately 10% for H357 cell 
line (p=0.0159) (see Figure 5.5) and ~20% increase in adhesion for SCC4 cell line 
(p=0.0174) (Figure 5.6) at 10 µg/mL concentration of collagen I after treatment. 
However, the increase in adhesion to collagen IV was relatively low compare to collagen 
I (see Figure 5.5 B). For H357 cells, the increased adhesion was ~5% (p=0.0149) as 
well as for SCC4 cells (p=0.0183) at concentration 10 µg/mL 
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Figure 5.5: Adhesion of H357 cells after 24-hours hLtn stimulation (100 ng/mL) to (A) 
Collagen I and (B) Collagen IV (concentration range: 0-10 µg/mL). All assays were 
performed for three independent repeats (n=3) with error bar represents SEM. (* p-
value<0.05).  
  
(A) 
(B) 
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Figure 5.6: Adhesion of SCC4 cells after 24-hours hLtn stimulation (100 ng/mL) to (A) 
Collagen I and (B) Collagen IV (concentration range: 0-10 µg/mL). All assays were 
performed for three independent repeats (n=3) with error bar represents SEM. (* p-
value<0.05, ** p-value<0.01). 
  
(B) 
(A) 
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5.3.3 Migration of OCCL towards hLtn variants 
SCC4 cells were used for the chemotaxis/migration assays, as nearly 80% of the 
cell population are XCR1-positive (as described in Chapter 3). Also, the number of cells 
migrating towards the positive control was the highest (p<0.01) compared to control 
(Figure 5.7). All the canonical chemokine fold hLtn variants, including commercial hLtn 
wild type (WT), and recombinant hLtn wild type (rWT) and CC3 mutant (rCC3) caused a 
significant increase in migration compared to control (p=0.0404, p=0.0181 and p=0.004 
respectively). The highest migration was observed towards rCC3, followed by rWT and 
Comm. rCC3 induces higher migration compared to the WT and rWT (p=0.0015 and 
p=0.0101 respectively). Interestingly, we found that the rWT causes significantly more 
migration than the commercially available WT (p=0.0357). No significance difference in 
migration towards the recombinant W55D mutant (rW55D) was seen. However, some 
migration was seen towards rW55D and the level was higher than to WT, although this 
was inconsistent.   
Additionally, the recombinant hLtn variants were also compared to cells that were 
treated with XCR1 antibody prior to migration to ensure specificity of migration. All the 
cells with antibody treatment showed minimal migration comparable to the negative 
control. 
. 
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Figure 5.7: Migration of SCC4 cells towards hLtn variants. The assay was carried out 
using Transwell® Boyden chambers. The legend describes the experimental condition 
for each well. Treatment with XCR1 antibody 30 mins prior to exposure to hLtn variants 
was performed to ensure the chemokine migration was XCR1-specific. Annotation: WT 
is the commercially available hLtn (Peprotech); rWT is the recombinant hLtn wild type; 
rCC3 is the recombinant hLtn CC3 mutant; rW55D is the recombinant hLtn W55D 
mutant; and Ab indicates treatment with XCR1 antibody. Data are representative of three 
independent experiments (n=3) with SEM. (* p-value<0.05, ** p-value<0.01, and NS is 
not significant).   
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5.4 DISCUSSION 
The aim of this part of the study was to investigate the functional effect of hLtn 
variants on the behaviour of OCCLs. Previously, hLtn has been shown to induce 
proliferation, migration and invasion in oral cancer as well as in other types of cancer. 
Due to unique nature of hLtn, it exists in two distinct conformations in physiological 
conditions, a canonical chemokine fold and a dimer. To date, there is no information 
about the role of these conformations in disease processes. Therefore, these different 
conformations were studied including a locked structure (CC3 and W55D mutants) to 
understand their contribution to cancer pathology. 
 
5.4.1 Proliferation profile of OCCL after exposure to hLtn variants 
Proliferation is integral for tissue biology to maintain a balance between cell loss 
and cell division. This process is tightly regulated in normal cells. However, cancer cells 
proliferation is dysregulated leading to uncontrolled growth or failure of the cells to 
undergo apoptosis. 
Chemokines have been shown to induce cell proliferation by acting through their 
receptors on immune cells (Badr et al., 2012; Dirice et al., 2014), mesangial cells (Wörnle 
et al., 2004) and cancers (Balkwill, 2004a, 2012). In periodontal disease and oral cancer, 
chemokine-chemokine receptor interaction has been shown to promote cell growth 
(Sahingur and Yeudall, 2015; Panda, Padhiary and Routray, 2016) through CXCR1 
(ligand CXCL8 or IL-8), CXCR2 (ligand or CXCL1 or GROα) (Khurram et al., 2014), and 
XCR1 (ligand XCL1 or hLtn). Although XCR1, has been shown to play a role in cell 
proliferation, the role of each hLtn conformation in this process is not known. 
As expected, the commercial and recombinant wild type hLtn (rWT) increased 
proliferation of both H357 and SCC4 cells after 48 h. The fold increase in proliferation of 
SCC4 cells compared to controls was higher than H357. This is probably due to the 
abundance of XCR1-expressing cells in SCC4 compared to H357, allowing more 
receptor activation and downstream signalling (Khurram et al., 2010). The recombinant 
hLtn was designed with a different amino acids in the N-terminal compared to the nature 
and chemokine N-terminus which have been shown to be important in receptor activation 
by recognizing the grooves of the chemokine surface (Szpakowska et al., 2012). This 
has been shown in CCR2 where the N-terminal region interact with minor sub-pockets 
of the receptor to trigger distinct interactions (Huma et al., 2017). The modified N-
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terminus of the recombinant hLtn may bind with a higher affinity to the conserved 
sulfotyrosine-binding pocket by stabilizing the interaction. 
The recombinant CC3 mutant induced higher proliferation in both H357 and 
SCC4 compared to the wild type. This is because its structure is locked in the active 
chemokine fold, while the wild type exists in two different conformations in physiological 
conditions (active chemokine fold and dimer). Both the wild type and CC3 mutant have 
the canonical chemokine fold, but the W55D mutant was designed to exist in the dimer 
conformational state. The result show that the mutant also induces proliferation in both 
OCCLs but to a lesser extent.  The mutant usually exists in dimer, where it binds strongly 
to heparin (Tuinstra et al., 2008), blocking HIV viral infection (Fox, Tyler, et al., 2015; 
Guzzo et al., 2015), and has potent antimicrobial properties (Nevins et al., 2016) but its 
role in inducing proliferation has not been reported so far. There are also no published 
reports of the W55D mutant activating the XCR1 receptor. Previous reports, show that 
the CXCL2 dimer has an agonistic properties and is a potent activator of CXCR2 receptor 
(Ravindran et al., 2013). Small-molecule agonist can also activate the receptor by 
binding to allosteric sites such as in CCR3 (Wise et al., 2007; Jensen and Rosenkilde, 
2009) and CXCR3 (Scholten et al., 2012), suggesting that the signalling activation does 
not require the whole chemokine to trigger the process but only important amino acids 
residues.   
Proliferation after exposure to the hLtn variants (excluding rW55D) was similar to 
treatment with 10% (v/v) serum in SCC4 cells. Proteomic profiling of serum compared to 
plasma has previously shown that amongst the growth factors, 11 chemokines level was 
elevated including lymphotactin (Ayache et al., 2006). This explains the similar fold 
increase to the hLtn variants. The fold difference to serum was not profound in H357 
cells. The result indicates that hLtn/XCR1 highly influences the cell growth in SCC4 cells 
and partially in H357 cells. SCC4 cells express more XCR1 than H357 cells resulting in 
greater influence in cell proliferation through the hLtn/XCR1 axis. 
The proliferation of OCCLs relative to control was higher at 48 hours than 72 
hours. Previously, stimulation of OCCL proliferation through the hLtn/XCR1 axis has 
been shown after 72 hours (Khurram et al., 2010) but not after 48 hours. This discrepancy 
may be partially due to the protein half-life and stability, as small proteins such as 
cytokines and chemokines have a short half-life (Panicker et al., 2007; Zhou et al., 2010). 
The estimated half-life for hLtn in vitro is 30 hours as determined using Expasy 
ProtParam (ExPASy Bioinformatics Resource Portal, Swiss Institute of Bioinformatics).  
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5.4.2 Adhesion profile of OCCL to extracellular matrix (ECM) components 
The interaction between cancer cells and the ECM components are fundamental 
for each stage of cancer progression. This ranges from involvement in local invasion of 
cancer cells to facilitating intravasation/extravasation of primary tumour through 
basement membrane of vessels. Additionally, adherence of cancer cell to ECM 
components is essential in tumour progression and metastatic spread (Todd et al., 2016). 
SCC4 cells showed higher adhesion to collagen I and fibronectin compared to 
H357 cells. The data is comparable to the findings of Khurram et al. (2010) who showed 
similar results for both collagen I and fibronectin but did not study adhesion to collagen 
IV. Interestingly the trends for adhesion to collagen I and IV for both H357 and SCC4 
cells were different. This is probably due to the different structural arrangement and 
components that make up the collagen, thus presenting a different surface for cell 
adhesion. Fibronectin provides glycoprotein anchor between the cell and collagen 
primarily type 1, giving an intermediate adherence towards it. Collagen I structure is 
fibrillar (Lu, Weaver and Werb, 2012) while collagen IV structure resembles an 
interconnected network (Kalluri, 2003) explaining the differences in cell attachment. It 
also suggests that the OCCL used probably have different expression or activation of 
integrins responsible in collagen IV associated attachment. Concurrently, SCC4 cells 
has highest adherence collagen I, followed by fibronectin and collagen IV suggesting 
different distribution of integrins that responsible for attachment. In H357 cells, 
attachment to Collagen I was the highest, whereas adherence for both collagen IV and 
fibronectin was similar suggesting the distribution level of the responsible integrins are 
the same. Several integrins are related closely to basal membrane such as α2β1, α3β1 
and α6β4 (Janes and Watt, 2006). Some evidence suggests that focal loss of α2, α3, α6 
and β4 subunits is observed when normal oral epithelium undergoes malignant 
transformation (Jones et al., 1993). In addition, α6 and β4 integrin subunit loss is related 
to loss of basal membrane protein (Downer, Watt and Speight, 1993; Jones, Watt and 
Speight, 1997). β1 subunit is important in basal membrane as it is expressed higher than 
basal stem cells (Liang et al., 2014). Furthermore, β1 subunit heterodimerises with α2 
for receptor to Collagen IV, and with α3 to laminin (Alonso and Fuchs, 2003). Additionally, 
in cancer, integrin-related signalling can promote the production of MMP that facilitate 
cancer migration and invasion (Koistinen and Heino, 2013).  
Integrins are heterodimers of two protein subunits: an α subunit and a β subunit. 
They mediate interactions either between cells or to ECM proteins by activating 
MAPK/ERK (mitogen-activated protein kinases/extracellular signal-regulated kinases) 
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pathway within the cell. Integrins bind to a number of extracellular ligands, with the 
highest number binding to fibronectin (12 integrins), followed by laminin (6 integrins), and 
collagens (4 integrins) (Plow et al., 2000).  Integrin subunit αv expression has identified 
in OSCC (Jones, Watt and Speight, 1997) has been shown to be involved in invasion as 
its overexpression allows rapid phosphorylation of focal adhesion kinase (FAK) 
(Hayashido et al., 2014). Furthermore, introduction of the α9 subunit results in an 
increase in OSCC cell adhesion to collagen I (Roy et al., 2011). Others report that high 
expression of integrin α2β1 and α3β1 facilitates metastasis in OSCC (Soares et al., 
2015). Modulation of integrin activity or expression is a possible explanation for the 
increased adherence of OCCL to ECM after exposure to hLtn (Figure 5.8). 
Previous reports have shown that H357 cells express α2, α3, α5, α6, β1 and β4 
integrins (Thomas et al., 2001). Additionally, increased expression of α9 integrin 
mediates adhesion and migration towards tenascin-C but not proliferation (Roy et al., 
2011). Reports have also shown expression of α9 integrin subunit in oral epithelium, 
specifically in suprabasal and prickle layer and upregulation in their cancer counterpart. 
Furthermore, hLtn  had shown to enhance α9 integrin-dependent cell migration in vivo 
and in vitro in autoimmune disease (Matsumoto et al., 2017).  
Inside-out signalling of integrin is regulated by talin and kindlin in the cytoplasmic 
domain of the cell (Calderwood, Campbell and Critchley, 2013) with assistance of G-
protein activation (Das et al., 2014). Integrin signalling requires recruitment of both 
monomeric small G-proteins and heterotrimeric G-proteins, where the G-protein subunit 
Gα13 binds to the β subunit (Shen, Delaney and Du, 2012) such as in integrin αIIbβ3 
(Gong et al., 2010). Chemokine receptors are G-protein coupled and their activation is 
tightly associated to integrin upregulation in cancer such as in CXCR4 and α4β1 integrin 
(Sosa-Costa et al., 2016).  
Previous reports have shown a correlation between increased adhesion and 
XCR1 receptor expression on the cell surface (Khurram et al., 2010). The result here 
also shows that SCC4 has higher adhesion to Collagen I. Adhesion to Collagen I is 
mediated through the interaction of α1β1 and α2β1 integrin (Jokinen et al., 2004).  
Khurram et al. (2010) also showed an increase in OCCL adhesion to Collagen I 
after 2 hours of hLtn treatment. This effect can still be seen after 24 hours (see Figure 
5.5 and 5.6) suggesting that the mechanism through which hLtn mediates cell adhesion 
is quickly initiated and manifests itself for a long period. It is possible that this increase 
in adhesion is related to an increase in integrin expression, or increased activity avidity 
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of already expressed integrins. However, further work is required to establish the 
relationship between XCR1 and integrin expression/avidity. As OSCC is derived from 
oral epithelial cells, most of the integrins: α6β4, α6β1, α2β1 and α3β1 are expressed in 
cancer but at different levels (Desgrosellier and Cheresh, 2010). Integrins such as αvβ6 
have been shown to be upregulated in OSCC but loss of certain integrins has also been 
reported. However, the precise set of integrins involved in oral cancer progression 
remains unknown. In ovarian cancer, β1 integrin is overexpressed which increases the 
metastasis of ovarian carcinoma cells (Shen et al., 2012). Further work is required to 
establish the expression of these integrins on H357 and SCC4 cells and their interaction 
with hLtn and XCR1. 
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Figure 5.8: Diagram for possible interaction for hLtn/XCR1 mediated integrins 
attachment to ECM. The signalling cascade activates G-protein followed by downstream 
signalling through possible MAPK/ERK pathway. This signal amplifies the gene 
expression to recruit integrin attachment.  
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5.4.3 Migration profile of OCCL after exposure to recombinant hLtn variants 
Migration assays were performed to understand the extent to which the hLtn 
conformational state contributes to OSCC chemotaxis.  Recombinant hLtn has been 
previously shown to promote migration of XCR1+ oral cancer cells (Khurram et al., 2010). 
SCC4 cell line was chosen for the assay as it highly expresses XCR1 (~80% positive 
expression). The results suggest that migration is significantly enhanced by hLtn variants 
with canonical chemokine fold.  
Recombinant hLtn wild type facilitated greater migration compared to the 
commercial hLtn. As explained earlier in the discussion (Section 5.4.1), the additional 
amino acids at the N-terminal may increase the triggered binding interaction (Huma et 
al., 2017) resulting in higher downstream signalling that could influence cell migration. 
Furthermore, the recombinant CC3 mutant stimulated higher migration than other hLtn 
variants due to its locked fold, allowing it to remain in the canonical chemokine fold 
(Tuinstra et al., 2007). This differs from hLtn WT that interconverts between two 
conformations and has a slightly lower migration index.  
By blocking the XCR1 receptor, the migration of SCC4 cells was significantly 
reduced and comparable to the controls, indicating the specificity of the migration. While 
there are numerous reports of hLtn inducing migration in cancer cells, none have studied 
the contribution of the variants in the process. 
 
5.5 SUMMARY 
To summarize, the results for the first time show that the OCCLs respond to hLtn 
variants. The recombinant variants with the canonical fold promote greater chemotaxis 
compared to the commercial hLtn showing that the recombinant chemokines are 
functional. The initial hypothesis was that the dimer can act as a natural inhibitor. A 
preliminary study showed that the dimer form can either attach or blocking the receptor 
in some sort of manner (refer Appendix 15). The only known antagonist for XCR1 
receptor is vCCL2 (or vMIP-II), a viral chemokine produced by herpes-virus. Original 
assumption was that the dimer has no agonistic properties due to its non-canonical 
chemokine fold. This finding showed that it influences the oral cancer cells proliferation 
while not inducing chemotaxis. This adds to the complexity and dynamic of chemokine-
chemokine receptor interaction. Probing more on this idea can potentially be used for 
drug development. 
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CHAPTER 6: GENERAL DISCUSSION & FUTURE PERSPECTIVES 
6.1 Thesis Overview 
Our results show the expression of XCR1 in normal epithelium, and oral 
squamous cell carcinoma and its metastatic counterpart. Furthermore, stromal 
components such as fibroblasts and endothelial cells also express both XCR1 and hLtn 
with significant differences between normal and cancerous tissue, which is a novel 
finding and suggest that hLtn and XCR1 can influence the tumour as well as the 
microenvironment in OSCC. This is evident as hLtn/XCR1 axis can regulate expression 
of XCR1 with significant increase in expression after indirect co-culture with cancer-
associated fibroblasts. Furthermore, for the first time an alternative technique was 
employed to produce and purify hLtn variants and tested them on epithelial cells in a 
working condition. Previously, the protein produced was highly insoluble, using our fusion 
protein construct, improved the protein solubility. By using the variants, we identified the 
proliferation, adhesion and migration of oral cancer cell lines in association with XCR1 
expression. These findings suggest that the hLtn/XCR1 system may play an important 
role in oral cancer progression. Researching the behaviour of metamorphic protein can 
be vital to provide more insight in developing future treatments 
 
6.2 General Discussion 
In Chapter 2, chemokines particularly hLtn and its receptor XCR1 were discussed 
not to only be involved in localisation and trafficking of lymphocytes but also play a pivotal 
role in cancer growth and dissemination. Mainly in oral epithelial cells and carcinoma 
where they mediated various effects such as cell migration and invasion, as well as 
influencing their behaviour. These implications are thought to facilitate tumour invasion 
and metastasis to lymph nodes in vivo. 
The first ever study of XCR1 and hLtn in oral squamous cell carcinoma was by 
Khurram et al. (2010). Their study showed expression of chemokine receptor (XCR1) in 
oral epithelial cells for the first time. Prior to this study, it was only reported to be 
expressed on lymphocytes, neutrophils and NK cells (Huang et al., 2001), rheumatoid 
synovium by mononuclear cells (Wang et al., 2004) and by fibroblast-like synoviocytes 
(Blaschke et al., 2003). Since then more studies have shown expression of XCR1 in 
dendritic cells as part of antigen-presentation (Ohta et al., 2016) and overexpression in 
cancer such as in breast (Yang et al., 2017), lung (T. Wang et al., 2015), and ovary (Kim 
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et al., 2012). Yet none of them reported positive XCR1 expression in normal epithelial 
cells. 
Immunohistochemistry showed XCR1 expression in the basal normal oral 
epithelium, oral squamous cell carcinoma (OSCC) and its metastatic counterparts (refer 
Chapter 2). Fibroblasts, endothelial cells and lymphocytes were also demonstrated to 
express XCR1 receptor in normal and diseased tissue, with greater expression in the 
latter, and similar to what was reported by Khurram et al. (2010). Additionally, it was 
observed that XCR1 and hLtn were strongly expressed in the cervical lymph in the 
peripheral cortex, subcapsular sinus and germinal centre. Others have reported dendritic 
cells (DC)-expressing XCR1 in spleen localizing in the T cell zone, marginal zone and 
the red pulp in mouse (Bachem et al., 2012). One report has stated sparse XCR1 
expression in DCs in T-cell zone proximal to B-cell follicles or medullary regions with 
enriched high endothelial venules (HEV) (Kitano et al., 2016).   
Strong and diffuse expression of XCR1 and hLtn was observed in metastatic 
tumour as well as lymphocytes in cervical lymph nodes, although the sample size was 
minimal (n=5). The presence of strong XCR1 and hLtn staining by fibroblasts in the 
reactive stroma of the metastatic node also supports this idea. Results confirms similar 
to those informed by Khurram et al. (2010) although it extends this significantly by using 
of paired metastatic tissue from the same patient. This suggests a correlation between 
the modulation of hLtn/XCR1 axis with the spread of metastatic OSCC in the lymph node. 
Chapter 3 showed the regulation of XCR1 in various oral cancer cell lines (OCCL) 
through its activation by hLtn. This can be either mediated through autocrine or paracrine 
signalling as the same cells i.e. epithelial and stromal cells expressed both the ligand 
and receptor. Autocrine regulation has been seen by other chemokine receptors in skin 
after wounding (Kroeze et al., 2012) and in systemic sclerosis by dermal fibroblasts 
(Carulli et al., 2005). Conditioned media (CM) influences the expression of XCR1 and 
hLtn mRNA in OCCLs, where cancer-associated fibroblast (CAF) to increase their level 
of expression. Moreover, their expression was downregulated by myofibroblast and 
senescence-induced NOF CM. These are novel and interesting findings suggesting a 
role for hLtn/XCR1 in the tumour microenvironment although further investigations are 
required to determine the significance of these findings (Figure 6.1). 
The hLtn variants (WT, CC3 and W55D mutant) were observed to modulate the 
behaviour of OCCLs in the final experimental chapter. The key difference between the 
CC3 and W55D mutant is that the former is the monomer form while the latter is the 
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dimer form of hLtn. Functionally, the dimer has no ability to induce chemotaxis and 
calcium flux in XCR1-transfected (human embryonic kidney) HEK cells. The function of 
each variants was first demonstrated in cancer here by the oral cancer cell lines 
expressing XCR1. These are novel experiments and findings in cancer as previous 
studies more focus on the structural biology of the variants instead of its physiological or 
pathological consequences. Understanding its effect in cancer will enable better 
understanding of its function, thus can be used a tool of drug discovery.  
Almost all the previous published work has been performed on either Jurkat cells, 
immortalized T cell lymphocytes or XCR1-transfected HEK cells. The initial assumption, 
at the start of the project, was that the dimeric form of hLtn does not activate XCR1, 
hence acting as antagonist of the receptor. Proliferation assays showed hLtn/XCR1 
involvement in the process, where the canonical fold (WT and CC3 mutant) appeared to 
influence OCCL growth as previously described by Khurram et al. (2010). However, the 
dimeric form still induces proliferation of OCCLs comparable to other variant forms. Due 
to complexity of chemokine receptors mechanism, there are several possible 
explanations, such as 1) tissue bias where the hLtn/XCR1 activation and transduction is 
different from other tissue (Steen et al., 2014); 2) the homo-dimerization or hetero-
dimerization of chemokine receptor allows receptor activation by the dimeric ligand such 
as seen by CXCR4 (Rodríguez-Frade, Mellado and Martínez-A, 2001; Springael, Urizar 
and Parmentier, 2005; Rodríguez-Frade et al., 2009; Salanga, O’Hayre and Handel, 
2009; Kleist et al., 2016); or 3) the W55D hLtn dimer populates the unfolding form, the 
transitional state between the monomer and dimer as mentioned by Fox et al. (2016), 
thus having some activity on the XCR1 receptor. 
Biomarkers can be defined as distinct quantifiable characteristics to indicate 
biological processes describing normal or pathological state, pathogen process, or 
pharmacological responses to predict the outcome of incidence, leading to therapeutic 
intervention (Goossens et al., 2015).  Salivary biomarkers have been used as an early-
stage detection biomarker for several types cancer such as lung, pancreatic, breast and 
stomach using transcriptome, proteomic biomarkers, miRNA microarray and exosomes 
(Wang, Kaczor-Urbanowicz and Wong, 2017). Chemokines such as CCL2, CCL3, CCL4, 
CXCL1, CXCL8 and CXCL12 have been shown as strong candidates as biomarkers for 
pre-cancerous cervical lesions based on analysing the protein sample extracted by liquid 
based cytology using proteomic array technology with high sensitivity and specificity 
(Bhatia et al., 2018). ELISA data for analysis of CXCL8, CXCL10, and CXCL14 levels in 
oral fluid indicated their elevation in cancer patients. The levels was not affected by 
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periodontitis thus indicating their potential as cancer biomarkers (Michiels et al., 2009). 
Unfortunately, there is less research focusing on salivary biomarker for oral cancer 
compared to other types of cancer.  
Preclinically, the data suggest that XCR1 and hLtn can be used as diagnostic 
biomarkers for oral cancer detection. High expression of hLtn can be seen in the tissue 
samples. It would be interesting to investigate if there any differences in the content of 
hLtn in the serum, saliva or ascitic fluid in normal compared to disease in terms of 
developing a non-invasive clinical test. Moreover, XCR1 can also be a prognostic 
biomarker for as it can be a good indicator of OSCC progression.  
In clinical sense, XCR1 can be used as target as a diagnostic biomarker as it is 
highly expressed by OSCC. Currently, there is no drug targeting specifically for oral 
cancer. All of them are chemotherapy drugs where targeting highly proliferative cells 
such as cisplatin and carboplatin. Antibody-based drug for cancer therapy has been 
introduced for clinical trials in human where it is targeting CXCR4, CCR2 and CCR4 
(Vela et al., 2015). This review paper stated that most of the studies on CCR2 were in 
Phase II clinical trial while only in Phase I for CXCR4. Treatment for lymphoma targeting 
CCR4 was in Phase III clinical trial. Additionally, other chemokine receptors such as 
CXCR2, CXCR5, CCR7, CCR9 and ACKR3 are still in pre-clinical assay for cancer 
treatment (Vela et al., 2015). More study on XCR1 and hLtn on its behaviour in in vivo 
metastasis is required to proceed to the next step, where the XCR1 receptor can be used 
as a target in oral cancer.  
The ligand, hLtn can be used for tool development for drug discovery. hLtn dimer has 
the capability to prevent early HIV infection. Due to uniqueness of hLtn, being able to 
metamorphose into two distinct protein fold. By using protein engineering, this capability 
can be exploit on improving future drug treatment. Our understanding on its capability in 
cancer perspective is still in its infancy. There are discrepancies in the literature how the 
ligand behaves as well as lack of understanding on the variants behaviour (chemokine 
or chemokine receptor dimerization interaction) especially in disease.   
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Figure 6.1: Summary of main thesis findings and their significance. Annotation: Cancer-
associated fibroblast (CAF), oral fibroblast (OF); endothelial-mesenchymal transition 
(EMT). 
  
Pre-clinical or 
Clinical Approach 
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6.3 Future Perspectives 
Our findings addressed several research questions to understand XCR1 and 
hLtn role, regulation and mechanism precisely in the OSCC pathogenesis. Additionally, 
the metamorphic ligand adds another layer of complexity to the receptor activation. 
Several future investigations should be performed to improve our understanding in the 
role of hLtn and XCR1 in OSCC progression. 
1) Further immunohistochemistry 
It would be useful to perform immunohistochemistry on a bigger cohort to 
establish the findings (XCR1 and hLtn role in OSCC metastasis) and correlate it 
with clinicopathological variables such as tumour size, depth, recurrence and 
survival. 
 
2) Invasion assays using 3D model or tissue-engineered oral mucosa (TEOM). 
Although monolayer or 2D assay are widely used for studying invasion, it does 
not really give a similar indication due to its minimal interaction and lack of tissue 
complexity. Using a 3D model or TEOM will give a better understanding OSCC 
invasion into the underlying connective tissue in response to chemokine 
(particularly hLtn) to mimic in vivo conditions. 
 
3) siRNA or CRISPR knockdown of XCR1 and hLtn in OCCLs. 
XCR1 gene knockdown in cancer cells can be performed using siRNA or CRISPR 
technique. Functional assays (migration, proliferation, adhesion etc.) can be 
repeated to better understand the role of XCR1 in cancer cell regulation. More 
functional assay can also be included such as invasion assay etc. 
 
4) Contribution of tumour microenvironment to OCCLs behaviour through 
hLtn/XCR1 axis. 
Investigate the effect of hLtn on endothelial cell (lymphatic and vascular) by 
studying proliferation and tubule formation by using hLtn variants. The expression 
in stroma and role in epithelial-mesenchymal transition (EMT), such as 
expression of E- and N-cadherin, ZEB-1, SLUG, SNAIL etc. by OCCL could be 
studied after exposure of hLtn variants. 
  
Chapter 6: General Discussion & Future Perspectives 
Functional Role of the Chemokine Receptor XCR1 and Its Bioengineered Ligand in Oral 
Squamous Cell Carcinoma 214 
5) Post-translational modification (PTM) identification of XCR1 receptor using 
mass spectrometry (LC-MS/MS). 
Glycosylation of protein is important especially in mammalian system. Some of 
the interaction between receptor/ligand axis is highly influenced by protein 
glycosylation. Therefore, it is interesting to investigate whether the glycosylation 
of XCR1 receptor in normal and OSCC has different glycosylation profile. The 
result might allow us to better understand the importance of (PTM) in cancer. 
 
6) Signalling pathway and transduction of hLtn/XCR1 activation (in context of 
hLtn different conformations). 
ERK1/2 pathway has been demonstrated to be involved in hLtn/XCR1 axis 
(Khurram et al., 2010). Since, hLtn/XCR1 activation increases adhesion, it will be 
in interesting to study involvement of focal adhesion kinase (FAK), as well as 
integrins molecules. α9β1 has been shown to modulate epithelial behaviour and 
its expression pattern is somewhat similar to what we found by XCR1 ex vivo 
(Roy et al., 2011). Also, hLtn has been shown to enhance α9 integrin-dependent 
cell migration in vitro and in vivo in autoimmune disease, which is interesting to 
investigate similar fashion in OSCC. Furthermore, as migration appeared to be 
correlated to hLtn variant conformation, F-actin polymerisation could be 
investigated as XCR1 was observed to be synonymous with OSCC metastasis. 
Similarly, adhesion to other extracellular matrix molecules could be investigated 
as well. Additionally, pertussis toxin (PTX) can be used in the assay as to 
understand XCR1 relation with its G-protein coupled receptor (GPCR) as the 
toxin abrogates its activity. 
 
7) New and stable dimeric hLtn conformation. 
Creating the restricted dimeric four-stranded β-sheet fold (CC5 mutant) can 
further understand the full function of the dimer state of hLtn function in cancer 
pathology. This engineered mutant forms a stable form compared to XCL1dim than 
WT-XCL1 or W55D as determined by hydrogen-deuterium exchange (HDX) 
(Fox, Tyler, et al., 2015). This can further improve our understanding of the role 
of each conformation better in cancer pathogenesis. 
 
8) In vivo study using orthotropic xenograft mouse models. 
It will be interesting to study the effect of hLtn and its variants in vivo using 
orthotropic xenograft mouse models and compare primary tumour cells as well 
as lymph node metastases. 
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APPENDICES 
Appendix 1: List of reagents 
List of Reagent Catalogue #; Manufacturer details 
1 kb DNA Ladder Cat#: N3232L; New England Biolabs, Hitchin, 
UK 
Adenine Cat#: A8626; Sigma-Aldrich, Dorset, UK  
Amphotericin B solution Cat#: A2942; Sigma-Aldrich, Dorset, UK 
Anti-alpha smooth muscle actin (α-SMA) 
[1A4] (FITC-conjugated) 
Cat#: ab8211; Abcam, Cambridge, UK 
Anti-XCR1 human antibody (extracellular 
domain) IHC-plusTM LS-A158 (human anti-
rabbit) 
Cat#: LS-A158-50; LifeSpan Bioscience Inc., 
WA, USA 
Anti-XCL1/Lymphotactin antibody (clone 
1E1) IHC-plusTM LS-B5938 (human anti-
mouse) 
Cat#: LS-B5938-50; LifeSpan Bioscience Inc., 
WA, USA 
B2M probe (TaqMan Gene Expression 
Assays) [sequence not available] 
Cat#:4331182; Life Technologies, Paisley, UK 
CellTiter 96® Aqueous One Solution Cell 
Proliferation Reagent 
Cat#: G3582; Promega, South Hampton, UK 
Cholera toxin Cat#: C8052; Sigma-Aldrich, Dorset, UK 
Collagen Type IV from human cell culture Cat#: C6745; Sigma-Aldrich®, Dorset, UK 
Collagen, Type I solution from rat tail Cat#: C3867; Sigma-Aldrich®, Dorset, UK 
Dimethyl sulfoxide Cat#: D8418; Sigma-Aldrich, Dorset, UK 
Dulbecco’s Modified Eagle Media (DMEM) Cat#: D5546; Sigma-Aldrich, Dorset, UK 
Dulbecco’s Phosphate Buffered Saline with 
MgCl2 and CaCl2 
Cat#: D8552; Sigma-Aldrich, Dorset, UK 
Fibronectin bovine plasma Cat#: F1141; Sigma-Aldrich®, Dorset, UK 
Foetal Bovine Serum (FBS) Cat#: F9665, Sigma-Aldrich, Dorset, UK 
Goat anti-rabbit IgG (H+L) secondary 
antibody, Alexa Fluor® 488 conjugate 
Cat#: A-11008; Life Technologies Ltd, Paisley, 
UK 
Goat serum donor herd Cat#:G6767; Sigma-Aldrich, Dorset, UK 
Ham’s Nutrient Mixture F12 (HAMS-F12) Cat#: N6013, Sigma-Aldrich, Dorset, UK) 
His-PurTM Ni-NTA Resin Cat#: 88221; ThermoFisher Scientific, Paisley, 
UK 
Horse serum donor herd Cat#:H1270; Sigma-Aldrich, Dorset, UK 
Human epidermal growth factor (hEGF) Cat#: E9644; Sigma-Aldrich, Dorset, UK 
Hydrocortisone Cat#: H4001; Sigma-Aldrich, Dorset, UK 
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Hydrogen peroxide 30% (w/v) (100 
volumes), Extra Pure SLR 
Cat#: 10687022; Fisher Chemical, 
Loughborough, UK 
Hydrogen peroxide 30% (w/v) (100 
volumes), Extra Pure SLR 
Cat#: 10687022; Fisher Chemical, 
Loughborough, UK 
Indo-1, AM Cat#: 21030, AAT Bioquest (by Stratech), 
Suffolk 
Insulin Cat#: 91077C; Sigma-Aldrich, Dorset, UK 
Isopropanol Cat#: 10674732; Fisher Chemical, 
Loughborough, UK 
L-Glutamine Cat#: G7513; Sigma-Aldrich, Dorset, UK 
Methanol Cat#: 10598240; Fisher Chemical, 
Loughborough, UK 
Minimum Essential Medium Eagle (EMEM) Cat#: M2279; Sigma-Aldrich, Dorset, UK 
Mitomycin C Cat#: ab120797; Abcam, Cambridge, UK 
Nuclease-free water  
Nuclease-free water Cat#:AM9914G; Life Technologies, Paisley, 
UK 
Penicillin-Streptomycin Cat#: P4333; Sigma-Aldrich, Dorset, UK 
Penta.His HRP Conjugate Kit  Cat#: 34460; QIAGEN, Manchester, UK 
Phosphate Buffered Saline (PBS) Cat#: D8537; Sigma-Aldrich, Dorset, UK 
PierceTM Protease Inhibitor Mini Tablets Cat#: 88665; Thermo Fisher Scientific, Paisley, 
UK 
Propan-2-ol Cat#: 11428782; Fisher Chemical, 
Loughborough, UK 
QIAprep Spin Miniprep Kit Cat#: 27106; Qiagen, Manchester, UK 
Recombinant human lymphotactin (XCL1) Cat#:300-20; Peprotech, London, UK 
Recombinant Transforming Growth Factor-
beta 1(TGF-β1) Protein 
Cat#: 240-B-010; R&D System, Abingdon, UK 
Senescence Detection Kit Cat#: ab65351; Abcam, Cambridge, UK 
SYBRTM Green PCR Master Mix Cat#: 4309155; ThermoFisher Scientific, 
Paisley, UK 
TaqMan Gene Expression Master Mix Cat#:4369016; Life Technologies, Paisley, UK 
Trypan blue solution 0.4% Cat#: T8154; Sigma-Aldrich, Dorset, UK 
Trypsin-EDTA solution Cat#: T3924; Sigma-Aldrich, Dorset, UK 
VECTASTAIN® Elite® ABC-HRP kit 
(peroxidase, Mouse IgM) 
Cat#: PK-6102; Vector Laboratories Ltd, 
Peterborough, UK 
VECTASTAIN® Elite® ABC-HRP kit 
(peroxidase, Rabbit IgG) 
Cat#: PK-6101; Vector Laboratories Ltd, 
Peterborough, UK 
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VECTOR NovaRED peroxidase substrate 
kit 
Cat#: SK-4800; Vector Laboratories Ltd, 
Peterborough, UK 
XCR1 probe (TaqMan Gene Expression 
Assays) 
Cat#:4331182; Life Technologies, Paisley, UK 
XCL1 probe (TaqMan Gene Expression 
Assays) 
Cat#:4331182; Life Technologies, Paisley, UK 
Xylene, Extra Pure, SLR Cat#: 10784001; Fisher Chemical, 
Loughborough, UK 
 
 
Appendix 2: List of kit 
List of Kit Catalogue #; Manufacturer details 
High Capacity cDNA Reverse Transcription 
Kit 
Cat#: 4368814; Life Technologies Ltd, Paisley, 
UK 
ISOLATE II RNA Mini Kit Cat#: BIO-52072; Bioline Reagents Limited, 
London, UK 
PierceTM BCA Protein Assay Kit Cat#: 23225; ThermoFisher Scientific, Paisley, 
UK 
QIAprep Spin Miniprep Kit Cat #: 27106, QIAGEN, Manchester, UK. 
QIAquick Gel Extraction Kit Cat #: 28706, QIAGEN, Manchester, UK. 
QIAquick PCR Purification Kit Cat #: 28106, QIAGEN, Manchester, UK. 
 
 
Appendix 3: List of equipment 
List of Equipment Details 
BDTM FACSCalibur  BD Bioscience, Oxford, UK 
BDTM LSRII  BD Bioscience, Oxford, UK 
DNA Engine Dyad® Peltier Thermal Cycler Bio-Rad Laboratories Ltd., Hertfordshire, UK 
Infinite® M200 Pro Series Tecan UK Ltd, Reading, UK 
Olympus BX51-P polarising microscope KeyMed Ltd., Essex, UK 
SpectrafugeTM 24D Digital Microcentrifuge Labnet International Inc., NJ, USA 
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Appendix 4: List of software 
List of Software Details 
FlowJo v10 FlowJo, LCC, USA 
GraphPad Prism GraphPad Software, CA, USA 
MagellanTM Data Analysis Software Tecan UK Ltd, Reading, UK 
Mendeley Elsevier, Amsterdam, Netherlands 
Pymol Schrödinger, LLC, NY, USA 
 
 
Appendix 5: List of miscellaneous 
List of Miscellaneous Catalogue #; Manufacturer details 
96 well PCR plate, Semi-Skirted Cat#: 1402-9700; STARLAB (UK) Ltd, Milton 
Keynes, UK 
Advanced Polyolefin StarSeal Film Cat#: E2796-9795; STARLAB (UK) Ltd, Milton 
Keynes, UK 
Corning® 6.5 mm Transwell® with 8.0 µm 
polycarbonate membrane cell culture inserts, 
TC-treated, sterile, 48/cs 
Cat#: CLS3422-48EA; Sigma-Aldrich, Dorset, 
UK 
Corning® Costar® tissue-culture treated 
multiple well plates 
Cat#: CL3516; Sigma-Aldrich, Dorset, UK 
SuperFrost® Plus microscope slide Cat#: 4951PLUS4, ThermoFisher Scientific, 
Paisley, UK 
T25 suspension culture flask with filter cap Cat#: 658190; Greiner Bio-One Ltd, UK 
T75 suspension culture flask with filter cap Cat#: 690195; Greiner Bio-One Ltd, UK 
X-cell II Blot Module Cat#: EI9051; ThermoFisher Scientific, 
Paisley, UK 
 
  
Appendices 
Functional Role of the Chemokine Receptor XCR1 and Its Bioengineered Ligand in Oral 
Squamous Cell Carcinoma 252 
Appendix 6: HistoQuest settings 
Haematoxylin settings 
Various Shape 2.0 
Nuclei size 5 
Remove small-sized objects 1 
Remove weakly stained objects 1 
Automatic background threshold Yes 
Threshold range [5, 255] 
Use Merging rules: 
Max combined area 10,000 µm2 
Max involved compactness 0.9 
Group max 6 
Min resulted compactness 0.6 
  
  
NovaRed settings 
Various Shape 2.0 
Ring mask Yes 
Interior radius -0.28 µM 
Exterior radius +0.28 µM 
Use identified cell mask Outside 
Max growing steps 2.2 µM 
Use nuclei mask No 
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Fibroblast 
Lymphocytes 
Metastasis in 
the lymph node 
(A) H&E (100×) 
(C) XCR1 (400×) 
(B) XCR1 (100×) 
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Appendix 7: Metastatic OSCC in a lymph node (representative photomicrograph).  
(A) H&E staining at 100× magnification, (B, C) XCR1 staining at 100× and 400× 
magnification respectively, and (D, E) hLtn staining at 100× and 400× magnification 
respectively. XCR1 staining is seen throughout the tumour cells and in lymphocytes. 
Scattered fibroblasts are also positive. In contrast, hLtn stain is weaker but still seen in 
the metastatic carcinoma, lymphocytes and fibroblasts in the reactive stroma. 
 
 
  
(E) hLtn (400×) 
Fibroblast 
Lymphocytes 
Metastasis in 
the lymph node 
(D) hLtn (100×) 
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Appendix 8: Keratinocytes grown (KGM) media preparation 
Keratinocytes Growth Media (KGM) 
Material: 335mL Dulbecco’s Modified Eagle Medium (DMEM), 115mL F12, 50mL Serum 
(either fetal calf serum (FCS) or fetal bovine serum (FBS)), 5mL Penicillin/Streptomycin 
(P/S), 5mL Antifungal, 5mL L-Glutamine, 5mL Adenine, 2mL Hydrocortisone, 500µL 
Cholera Toxin, 250µL Insulin and 500µL epithelial growth factor (EGF). 
 
EGF: 0.2mg Vial adds 10mL DMEM containing 10% FCS aliquot into 0.5mL (10µg/mL) 
and store at -20oC. 
Final concentration 10ng/mL 
 
Hydrocortisone: Make 10X concentrate first. Weigh out 40mg and add 4mL 100% 
ethanol and agitate. Add 36mL DMEM. This 10X concentrate is filtered and can be stored 
in 5mL aliquots at-20oC 0- label well. Each aliquot can be added to 45mL DMEM and 
2mL aliquots stored at -20oC (100µg/mL) 
Final Concentration 0.5µg/mL 
 
Insulin: 10mL sterile water add 100µL glacial acetic acid add to vial of insulin (100mg) 
resulting in 10mg/mL conc. Aliquot into 250µL and store at 4oC 
Final concentration 5µg/mL 
 
Adenine: Weigh out 330mg add 100 mL 0.1HCl, agitate to mix well, filter and aliquot into 
5mLs store at -20oC (1.8 × 10-2M stock) 
Final Concentration 1.8 × 10-4  
 
Cholera toxin: Add 1.67mL distilled sterile water into vial (0.5mg) half of this into 50mL 
sterile water (10-7M stock). Keep at 4oC 
Final Concentration 10-10  
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Appendix 9: Melting curve of α-SMA and U6-snRNA primers. 
 
  
α-SMA 
U6 snRNA 
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Appendix 10: Example for XCR1 surface receptor analysis of SCC4 cell using FlowJo 
software.  
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Combined Histogram  
Control +XCR1 
Step 1:  
Determine the 
distribution of 
cells 
Step 2:  
Discriminate 
the dead cells 
population 
(FL-3 
channel). 
Dead cells can 
give false 
positive 
expression 
Step 3:  
Select the 
positively 
expressing 
cells 
(population 
right of the 
control). 
Step 4:  
Compare the 
expression 
using 
histogram. 
Step 5:  
Combined 
histogram. 
Shift to the 
right indicating 
expression of 
the target 
protein. 
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CATATG 
 NdeI 
 
        10        20        30        40        50        60 
CATCATCATCATCATCACTCGGGTGCTTTTGAATTTAAACTGCCGGACATTGGCGAAGGT 
 H  H  H  H  H  H  S  G  A  F  E  F  K  L  P  D  I  G  E  G.  
 
        70        80        90       100       110       120 
ATCCACGAAGGCGAAATTGTGAAATGGTTTGTGAAACCGGGTGATGAAGTTAACGAAGAT 
 I  H  E  G  E  I  V  K  W  F  V  K  P  G  D  E  V  N  E  D. 
 
       130       140       150       160       170       180 
GACGTGCTGTGCGAAGTTCAGAATGACAAAGCGGTGGTTGAAATTCCGAGTCCGGTCAAG 
 D  V  L  C  E  V  Q  N  D  K  A  V  V  E  I  P  S  P  V  K. 
 
       190       200       210       220       230       240 
GGTAAAGTGCTGGAAATCCTGGTGCCGGAGGGTACGGTTGCAACCGTCGGCCAAACGCTG 
 G  K  V  L  E  I  L  V  P  E  G  T  V  A  T  V  G  Q  T  L. 
 
       250       260       270       280       290       300 
ATTACCCTGGATGCTCCGGGCTATGAAAACATGACGTTTGGCGGTGGCAGTGGTGGCGGT 
 I  T  L  D  A  P  G  Y  E  N  M  T  F  G  G  G  S  G  G  G. 
 
       310       320       330       340       350       360 
TCCGGCGGTGGCACCGGTGGCGGATCCGGCGGTGGCATTGAAGGTCGTGTTGGCAGCGAA 
 S  G  G  G  T  G  G  G  S  G  G  G  I  E  G  R  V  G  S  E. 
 
       370       380       390       400       410       420 
GTCTCTGACAAACGTACCTGTGTCAGCCTGACCACCCAGCGTCTGCCGGTTTCTCGTATT 
 V  S  D  K  R  T  C  V  S  L  T  T  Q  R  L  P  V  S  R  I. 
 
       430       440       450       460       470       480 
AAAACCTACACGATCACCGAAGGTAGCCTGCGCGCAGTGATTTTCATCACGAAACGTGGC 
 K  T  Y  T  I  T  E  G  S  L  R  A  V  I  F  I  T  K  R  G. 
 
       490       500       510       520       530       540 
CTGAAAGTGTGTGCCGATCCGCAGGCCACCTGGGTTCGTGATGTCGTGCGCTCAATGGAC 
 L  K  V  C  A  D  P  Q  A  T  W  V  R  D  V  V  R  S  M  D. 
 
       550       560       570       580       590       600 
CGTAAATCGAATACCCGCAACAATATGATCCAAACGAAACCGACGGGCACGCAACAATCC 
 R  K  S  N  T  R  N  N  M  I  Q  T  K  P  T  G  T  Q  Q  S. 
 
       610       620        
ACCAACACCGCAGTGACGCTGACGGGT 
 T  N  T  A  V  T  L  T  G. 
 
TAATGAATTC 
    EcoRI 
 
START CODON; HIS-TAG; PROTEIN LINKER; LIPOYL DOMAIN; FACTOR XA; 
MATURE LYMPHOTACTIN SEQUENCE; STOP CODON;  
 
Appendix 11: Optimized codon sequence of the designed recombinant fusion protein 
HL-IEGR.hLtn (WT). 
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Appendix 12: Flow cytometer settings and preparation. 
Instrument settings: The BD LSRII (BD Bioscience, Oxford, UK) was used to measure 
to emission of bound or unbound Indo-1 dye. The violet laser was turned off by using the 
in-line rocker-type switch. This is critical as stray violet laser light may cause interference 
in the violet channel of the UV trigon for Indo-1. Importantly, the waste tank was ensured 
to be empty and the sheath tank was filled to the maximum level allowed. The filter 
configuration on the UV trigon was verified as follows: “B” PMT: the 450 /50 filter was 
removed and replaced with 405 /20 for Indo-1 violet (calcium-bound); and “A” PMT: the 
505 DLP was removed and replaced with 450 DLP filter for Indo-1 blue (calcium-
unbound).  
Instrument setting optimization: 1) It is critical that the cells should be acquired on 
“LO” setting with the flow rate adjusted to approximately 200 – 300 cells/seconds; 2) 
Ensure the Indo-1 only sample was installed; 3) The FSC and SSC voltages, and FSC 
threshold were adjusted; 4) A linear bivariate dot blot of blue and violet was created, 
ensuring the ‘blue’ on the y-axis and ‘violet’ on the x-axis; 5) The voltages and gains on 
the blue and violet parameters were adjusted so that the population that appears forms 
along an imaginary line from the vertex at 0/0 and 70° from the x-axis; and 6) A ‘time vs 
ratio’ dot plot was created. During the run, unbound loaded cells should fill the bottom 
part of the plot and when the Indo-1 dye binds to the calcium (violet) due to stimulation, 
it causes a shift in the ratio resulting in the changes of the observed histogram due to 
shift in population ratio. 
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Appendix 13: DNA sequence identification for W55D site-directed mutagenesis from 
pCMV6-Entry-hLtn (WT) DNA sequence. 
Original sequence: 
 
After mutagenesis: 
  
atcagtaccgaggagatctgcgccgcgatcgccatgagacttctcatcctggccctcctt 
 I  S  T  E  E  I  C  A  A  I  A  M  R  L  L  I  L  A  L  L  
ggcatctgctctctcactgcatacattgtggaaggtgtagggagtgaagtctcagataag 
 G  I  C  S  L  T  A  Y  I  V  E  G  V  G  S  E  V  S  D  K  
aggacctgtgtgagcctcactacccagcgactgccggttagcagaatcaagacctacacc 
 R  T  C  V  S  L  T  T  Q  R  L  P  V  S  R  I  K  T  Y  T  
atcacggaaggctccttgagagcagtaatttttattaccaaacgtggcctaaaagtctgt 
 I  T  E  G  S  L  R  A  V  I  F  I  T  K  R  G  L  K  V  C  
gctgatccacaagccacatgggtgagagacgtggtcaggagcatggacaggaaatccaac 
 A  D  P  Q  A  T  W  V  R  D  V  V  R  S  M  D  R  K  S  N  
accagaaataacatgatccagaccaagccaacaggaacccagcaatcgaccaatacagct 
 T  R  N  N  M  I  Q  T  K  P  T  G  T  Q  Q  S  T  N  T  A  
gtgactctgactggctagacgcgtacgcggccgctcgagcagaaactcatctcagaagag 
 V  T  L  T  G  -  T  R  T  R  P  L  E  Q  K  L  I  S  E  E  
gatctggcagcaaatgatatcctggattacaaggatgacgacgataaggtttaaacggcc 
 D  L  A  A  N  D  I  L  D  Y  K  D  D  D  D  K  V  -  T  A  
ggccgcggtcatagctgtttcctgaacagatcccgggtggcatccctgtgacccctcccc 
 G  R  G  H  S  C  F  L  N  R  S  R  V  A  S  L  -  P  L  P  
agtgcctctcctggccctggaagttgccactccagtgcccaccagccttgtcctaataaa 
 S  A  S  P  G  P  G  S  C  H  S  S  A  H  Q  P  C  P  N  K  
attaagttgcatcattttgtctgactaggtgtccttctataatattatggggtggaaggg 
 I  K  L  H  H  F  V  -  L  G  V  L  L  -  Y  Y  G  V  E  G  
ggggtgggt 
 G  V  G 
atcagtaccgaggagatctgcgccgcgatcgccatgagacttctcatcctggccctcctt 
 I  S  T  E  E  I  C  A  A  I  A  M  R  L  L  I  L  A  L  L  
ggcatctgctctctcactgcatacattgtggaaggtgtagggagtgaagtctcagataag 
 G  I  C  S  L  T  A  Y  I  V  E  G  V  G  S  E  V  S  D  K  
aggacctgtgtgagcctcactacccagcgactgccggttagcagaatcaagacctacacc 
 R  T  C  V  S  L  T  T  Q  R  L  P  V  S  R  I  K  T  Y  T  
atcacggaaggctccttgagagcagtaatttttattaccaaacgtggcctaaaagtctgt 
 I  T  E  G  S  L  R  A  V  I  F  I  T  K  R  G  L  K  V  C  
gctgatccacaagccacagacgtgagagacgtggtcaggagcatggacaggaaatccaac 
 A  D  P  Q  A  T  D  V  R  D  V  V  R  S  M  D  R  K  S  N  
accagaaataacatgatccagaccaagccaacaggaacccagcaatcgaccaatacagct 
 T  R  N  N  M  I  Q  T  K  P  T  G  T  Q  Q  S  T  N  T  A  
gtgactctgactggctagacgcgtacgcggccgctcgagcagaaactcatctcagaagag 
 V  T  L  T  G  -  T  R  T  R  P  L  E  Q  K  L  I  S  E  E  
gatctggcagcaaatgatatcctggattacaaggatgacgacgataaggtttaaacggcc 
 D  L  A  A  N  D  I  L  D  Y  K  D  D  D  D  K  V  -  T  A  
ggccgcggtcatagctgtttcctgaacagatcccgggtggcatccctgtgacccctcccc 
 G  R  G  H  S  C  F  L  N  R  S  R  V  A  S  L  -  P  L  P  
agtgcctctcctggccctggaagttgccactccagtgcccaccagccttgtcctaataaa 
 S  A  S  P  G  P  G  S  C  H  S  S  A  H  Q  P  C  P  N  K  
attaagttgcatcattttgtctgactaggtgtccttctataatattatggggtggagggg 
 I  K  L  H  H  F  V  -  L  G  V  L  L  -  Y  Y  G  V  E  G  
ggggtgggtttg 
 G  V  G  L   
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Appendix 14: Linear regression of OCCLs 
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Appendix 15: XCR1 dimer form (hLtn W55D mutant) capable of binding to the XCR1 
receptor or blocking the antibody attachment. Similar trend observed amongst the 
variables (temperature, duration and washing) suggesting that the W55D dimer variant 
able to attach to the receptor by blocking the anti-XCR1 antibody, impairing its capability 
to bind to the third extracellular loop of the receptor. 
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Appendix 16: List of amino acids and its abbreviation 
 Amino Acid 3-Letter 1-Letter  Amino Acid 3-Letter 1-Letter 
 Alanine Ala A  Leucine Leu L 
 Arginine Arg R  Lysine Lys K 
 Asparagine Asn N  Methionine Met M 
 Aspartic acid Asp D  Phenylalanine Phe F 
 Cysteine Cys C  Proline Pro P 
 Glutamic acid Glu E  Serine Ser S 
 Glutamine Gln Q  Threonine Thr T 
 Glycine Gly G  Tryptophan Trp W 
 Histidine His H  Tyrosine Tyr Y 
 Isoleucine Ile I  Valine Val V 
 Selenocysteine Sec U     
 
Side chain properties: 
 Basic (positively charged)   
 Acidic (negatively charged)   
 Polar (uncharged)   
 Hydrophobic    
 Special cases   
 
 
